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ABSTRACT 
Non-alcoholic fatty liver disease (NAFLD) is a major metabolic liver disease worldwide, 
which is developed from fatty liver or simple hepatic steatosis (accumulation of excessive 
triglyceride fat in liver). The prevalence of NAFLD is 20-30% of the general population of 
Western countries and about 10-20% in Asian countries. Approximately 2-3% of the general 
population with NAFLD is estimated to progress to non-alcoholic steatohepatitis (NASH), 
which may further progress to liver cirrhosis and hepatocarcinoma. Type 2 diabetes (T2D), 
the most common form of diabetes, is a well-known metabolic disease. T2D is characterized 
by high blood glucose levels resulting from inuslin resistance and insufficient insulin 
productions. Both NAFLD and T2D are associated with or share the same pathology of 
metabolic syndrome, insulin resistance, obesity and excessive lipid accumulation.  
Excessive energy stored in our body results in an accumulation of lipid which can impair 
action of insulin in metabolic tissues such as liver and muscle in both animals and humans by 
interfering with insulin signal transduction, molecular mechanisms and pathways. Insulin as a 
major hormone regulates blood glucose levels by promoting glucose utilization in muscle 
while blocking glucose production in the liver. These tissues become less responsive to 
insulin’s action due to a defect in insulin signal transduction, becoming insulin resistant. 
Liver is a major tissue for the metabolism of glucose, lipids and proteins. It is susceptible to 
developing insulin resistance with triglyceride fat/lipid accumulation at an early stage.  
This thesis investigated whether alterations to a process for degrading cellular debris for 
recycling (so called autophagy) can impact on liver lipid metabolism and if so, the possible 
mechanism involved. The thesis focused on the molecular metabolic pathway in relation to 
lipid metabolism, leading to the pathogenesis of hepatic steatosis and insulin resistance, 
 21 
 
especially in the context of over consumption of a lipogenic fat, and stimulation of protein 
receptors. 
Peroxisome proliferator activated receptors (PPARs) are nuclear protein receptors that 
function as transcriptional factors to regulate lipid metabolism. PPARα and PPARγ are two 
isoforms of the subfamily of PPARs. Both PPARα and PPARγ play important roles directly 
or indirectly in the process of lipid metabolism in the liver. PPARα, highly expressed in liver, 
directly regulates genes involved in fatty acids uptake, β-oxidation and ω-oxidation during 
fasting or pharmacological stimulation with a fibrate ligand. In comparison, PPARγ is 
predominantly expressed in adipose tissue where it potentiates adipogenesis to maintain lipid 
storage to modulate the distribution of fatty acids to various organs. Pharmacological 
activation of the PPARγ receptor with the glitazone ligand improves insulin sensitivity and 
influences lipid metabolism in liver. 
Autophagy is a defensive catabolic mechanism that promotes normal physiological function 
by regulation or degradation of proteins/lipids. This process is essential in the removal of 
damaged cellular components, misfolded proteins due to endoplasmic reticulum (ER) stress 
of unfolded protein resonse (UPR) and accumulated lipid droplets to maintain protein and 
energy homeostasis in the cell under physiological conditions. Destruction of autophagy 
function promotes lipid accumulation as lipid droplets resulting in liver steatosis.  
Therefore, this thesis aimed to investigate 1) the effect/role of PPARγ and/or PPARα in 
pharmacological regulation on autophagy in coordination with lipid metabolism in the liver 
after consumption of a high fat diet; 2) whether the autophagy pathway is altered along with 
nuclear protein receptors, PPARγ and/or PPARα, in relation to lipid metabolism; 3) the 
possible molecular mechanism associated with alteration of autophagy which can impact on 
the above metabolic disorders. 
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Firstly, in Chapter 3, I investigated the effect/role of PPARγ in a rat model of insulin 
resistance (IR) accompanied with hepatic steatosis produced by a high fat diet (HF), to mimic 
the over-consumption of fat commonly occurring in humans, on the autophagy pathway. 
Stimulation of PPARγ activation with the pharmacological activator, rosiglitazone (RG; 
15mg/kg/day), restored insulin sensitivity and lowered lipid content in the liver. PPARγ 
activation by RG showed moderate effects on certain lipogenic enzymes and autophagy 
proteins in the liver, however, there was no clear indication of an increase or decrease in 
lipogenesis and autophagy activity. I further examined ER stress in the UPR pathway, which 
is a protective mechanism to inhibit protein synthesis, to promote protein folding and 
degradation, and to maintain protein homeostasis in the cell under physiological conditions. 
Findings from this study revealed that there was no involvement of ER stress in PPARγ 
activation by RG in liver. Therefore, the results led to the conclusion that PPARγ activation 
by RG has no overall effect or role on autophagy in relation to lipid metabolism and ER 
stress in the liver despite increased insulin sensitivity and lowered lipid accumulation in the 
liver via fatty acids re-distribution.  
In Chapter 4, I examined the effect/role of PPARα on autophagy in the liver. In this study, 
stimulated PPARα activation by fenofibrate (FB; 100mg/kg/day) showed a significant 
decrease in multiple autophagy proteins irrespective of diets. PPARα activation by FB also 
revealed a significant ER stress inhibition along with upregulation of lipogenic enzymes, 
indicating an intrinsic causal relationship among autophagy, ER stress and lipid metabolism. 
My results highlight a crucial role of autophagy in the context of PPARα activation by FB 
and provide a proof-of-concept to target the autophagy pathway, possibly for the treatment of 
metabolic disorders. 
In order to obtain the evidence for the definitive role of PPARα, Chapter 5 examined these 
effects of PPARα action in PPARα knockout (PPARα-/-) mice treated with or without FB 
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(50mg/kg/day). My results clearly indicated that PPARα activation is required for FB to up-
regulate peroxisomal fatty acid oxidation, lipogenesis and to suppress the multiple autophagy 
proteins in the liver. For PPARα-induced suppression of autophagy, I further investigated the 
reported possible upstream mechanism. These included mammalian target of rapamycin 
(mTOR), AMP-activated protein kinase (AMPK), Akt, ER stress and fibroblast growth factor 
21 (FGF21) hepatokine induced by PPARα activation.  Interestingly, PPARα-induced 
suppression of autophagy was found to occur independent of mTOR inhibition, activation of 
AMPK, Akt, ER stress, and FGF21 stimulation in the liver.  
PPARα activation by pharmacological or physiological effect, such as starvation, has been 
suggested to alleviate autophagy induction through cytosolic forkhead box protein O1 
(FoxO1) function. My results revealed a reduction in the level of FoxO1, which is a key 
transcriptional factor controlling the expression of multiple autophagy proteins in the 
presence of suppressed autophagy by prolonged activation of PPARα with FB. Collectively, 
these findings suggest that PPARα induced suppression of autophagy may play an important 
role in regulating liver metabolism which may impact on the future treatment of metabolic 
disorders.  
In summary, my findings in PPARγ activation by RG revealed no correction of dysregulated 
multiple autophagy proteins in HF fed rats, despite improved insulin sensitivity and lowered 
triglyceride/lipid content in the liver. More importantly, the results from studies in this thesis 
provided strong evidence that autophagy is likely suppressed in prolonged PPARα activation 
with FB, which is independent of FGF21 and accompanied with enhancement of lipogenic 
enzymes for upregulation of de novo lipogenesis (DNL). PPARα induced suppression of 
autophagy is via FoxO1 inhibition in the presence of disarrayed signalling pathways of the 
mTOR, AMPK, Akt and ER stress. The discoveries from this thesis have identified the 
interactions of these pathways with autophagy beyond their previously recognised roles in 
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liver metabolism. My studies are also believed to provide a potential rationale for further 
investigation of the possible role of autophagy in PPARα-induced adapted response in the 
liver.   
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Chapter 1- Introduction and Literature Review 
1.1 Metabolic diseases and liver 
Metabolic disease refers to any of the diseases or disorders that disrupt normal metabolism, 
the process of converting food to energy on a cellular level [1-3]. It affects the ability of the 
cell to perform critical biochemical reactions involving the processing or transport of organic 
compounds and proteins such as amino acids, carbohydrates including sugar and starches, 
and/or lipids such as fatty acids [4, 5]. These functions play essential roles of the liver, and as 
such metabolic diseases in relation to liver metabolism are of great importance. 
Liver is the second largest internal metabolic glandular organ in the digestive system, located 
in the right upper quadrant of the abdomen, under the diaphragm [6]. The liver is a vital 
organ for supporting every other organ metabolism to some capacity in the body. As little as 
one quarter of its 1.5 kilogram lump of pinkish brown tissue containing several bile ducts is 
required to recover from injury, but the organ has its limitation [7]. The liver has a complex 
role in our body in functions essentially related to metabolism (including regulation of 
glycogen storage), immunity, detoxification, hormone regulation, protein synthesis, digestion 
and nutrient storage. Failure of these important roles causes development of not only certain 
liver diseases such as alcoholic or non-alcoholic fatty liver disease, hepatitis and cirrhosis or 
cancer but also contributes to metabolic syndromes with metabolic diseases including insulin 
resistance, obesity and Type 2 diabetes.  
1.1.1 Fatty liver 
The liver stores and breaks down fats needed for hormone production, vitamin transport and 
insulation in a tightly regulated process [7]. Large vacuoles of triglyceride fat accumulates in 
liver cells or hepatocytes via the process of steatosis (abnormal retention of lipids within a 
cell), a reversible condition of fatty liver so called fatty liver disease [8, 9] as illustrated in 
Fig. 1.1. Fatty liver is considered a metabolic disorder that occurs in those not only with 
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excessive alcohol intake and the obese, with or without effects of insulin resistance, but is 
also associated with other diseases that influence lipid metabolism [10]. Disrupted fat/lipid 
metabolism process is likely to cause accumulation of triglyceride/fat in excessive amounts in 
the liver, thus resulting in a fatty liver. Fat accumulation is a risk factor for a progressive 
inflammation of the liver termed hepatitis, so called steatohepatitis [9, 11].  
Pathogenesis of fatty liver diseases depends on defects in fatty acid metabolism that may be 
due to imbalanced energy consumption and its combustion, resulting in lipid storage, insulin 
resistance or increased fatty acids transport from adipose tissue to the liver [12]. The 
contribution of fat accumulation can be due to impairment or inhibition of molecule receptors 
such as peroxisome proliferator activated receptor α, γ (PPARα, PPARγ) and sterol 
regulatory element binding protein 1 (SREBP1) which control the enzymes responsible for 
fatty acids synthesis [11]. While damaged mitochondria, endoplasmic reticulum (ER), 
cellular structures and energy mechanism further contribute to the inhibition of fatty acid 
oxidation in the fatty liver alcoholics [13], non-alcoholic fatty liver disease (NAFLD) is due 
to excessively un-metabolised energy in hepatocytes [14].  
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 Figure 1.1 A schematic diagram of fatty liver (hepatic steatosis).  Adapted from Cohen, 
J.C. et al. 2011 & Reddy, J.K. et al. 2006 [9, 10]. Compared with a healthy liver, fatty liver 
appears enlarged and discoloured. Large vacuoles of triglyceride accumulating in the liver via 
the process of steatosis such as abnormal retention of lipids within a cell is considered a 
single disease that occurs worldwide with excessive alcohol intake termed alcoholic fatty 
liver disease (AFLD), and the obese with or without insulin resistance effect, termed non-
alcoholic fatty liver disease (NAFLD). Fatty liver is also associated with other diseases 
influencing lipid metabolism, resulting in fatty liver due to excessive amounts of fat 
accumulated in the liver.  
1.1.2 Non-alcoholic fatty liver disease 
The fatty liver, so called hepatic steatosis, with or without devloping to insulin resistance, 
progresses to non-alcoholic fatty liver disease (NAFLD), and if the condition persists the 
more severe non-alcoholic steatohepatitis (NASH). 20-30% of the general population is 
estimated to have NAFLD [9, 15]. NAFLD is a liver disease with hepatic steatosis that is not 
caused by alcohol consumption or other medical symptoms like hepatitis C [16]. NAFLD 
likely comprises a range of liver abnomalties from simple steatosis to NASH and even 
cirrhosis (Fig. 1.2). Due to consumption of high calorie nutrients and reduced physical 
exercise, low energy expenditure exists, leading to the deposition of unburnt energy in the 
cytoplasm of hepatocytes in the form of triglycerides (TG), inducing hepatic steatosis as a 
simple steatosis at the early stage of NAFLD [9, 16, 17]. Clinically, steatosis is regarded as a 
TG level in liver greater than 5.6% or equivalents in diagnostic measurements such as 
ultrasound, computed tomography, magnetic resonance spectroscopy and liver biopsy.  
NAFLD has become a worldwide health problem [18] and is closely associated with obesity. 
The proportion of NAFLD is over 20% in Western countries and over 15% in Asian region 
[19, 20]. Increased prevalence of NAFLD in the general population is likely due to changes 
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in the quantity and composition of food over the past 30 years [9]. Nearly 50% of people with 
diabetes, 76% with obesity, and almost 100% of obese individuals with diabetes are reported 
to suffer from NAFLD [21]. NAFLD increases the susceptibility of the liver to acute liver 
injury and can possibly lead to cirrhosis and hepatocellular cancer, where changes in insulin 
response, β-oxidation, lipid storage and transport, autophagy and an imbalance of nuclear 
receptor signalling are held responsible for NAFLD proceeding to more severe diseases [8]. 
 
Figure 1.2 A schematic diagram of the fatty liver diseases. Adapted from Cohen, J.C. et al. 
2011 [9]. TG accumulation causes fatty liver or so called hepatic steatosis, which is the early 
stage of NAFLD. Imbalanced liver fat decomposition from low energy expenditure and over 
nutrient consumption, causes NAFLD and in some cases development of insulin resistance 
which is a major characteristic of Type 2 diabetes. From simple steatosis to NAFLD, NASH 
is characterized by accumulation of TG in the liver, inflammation and liver injury, with or 
without, fibrosis. 
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1.1.3 Type 2 diabetes and metabolic syndrome 
Diabetes is a major metabolic disease characterized by hyperglycaemia (high blood glucose 
level) resulting from insufficient insulin secretion and/or ineffective use of insulin by the 
body [22, 23]. There are two major types of diabetes, known as Type 1 and Type 2 diabetes 
[22]. Type 1 diabetes (T1D) is also termed insulin dependent diabetes, characterized by 
absolute insulin deficiency, and diagnosed relatively more in children or young adults under 
the age of 30 [24]. Type 2 diabetes (T2D) is described as non-insulin dependent diabetes, 
which is characterized by insulin resistance and β-cell failure [22]. T2D is the most common 
type of diabetes and accounts for about 95% of all diabetic patients [22].  
The development of T2D is suggested to be the net result of an imbalance between insulin 
action and secretion, where a decreased responsiveness of the tissues to insulin action 
commonly occurs due to excessive lipid accumulation in non-adipose tissues [25]. Impaired 
glucose tolerance and/or impaired fasting glucose are regarded as pre-diabetes, an early stage 
of T2D [26], and it has been suggested that impaired glucose tolerance is primarily caused by 
insulin resistance in peripheral tissues where fasting hyperglycemia is predominantly due to 
the failure of insulin’s suppression of glucose production in the liver [27, 28]. One of the 
important mechanisms for this is hepatic insulin resistance, which can be a result of fatty liver, 
thus NAFLD and T2D are closely associated.  
At the early stage, β-cells in the pancreas secrete more insulin to compensate for the 
decreased insulin action in such tissues involving the regulation of blood glucose levels. 
However, the ability of β-cells to secrete adequate levels of insulin deteriorates over time 
resulting in failure of β-cell functions to express and secrete insulin, resulting in overt T2D 
[29]. Insulin is a hormone secreted by pancreatic β-cells in the islets of Langerhans and 
released into the blood stream upon a rise of blood glucose for glucose lowering [30]. Insulin 
promotes glucose uptake in muscle and adipose tissue while it also inhibits glucose 
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production in the liver at the same time, thus insulin secretion is negatively correlated with 
insulin sensitivity and is elevated with insulin resistance [31, 32]. Insulin resistance is a 
condition where the body becomes less responsive to insulin, and to compensate for insulin 
resistance more insulin is produced, thus leading to hyperinsulinaemia [3, 31]. When the 
insulin secretion from the β-cells is inadequate to compensate for insulin resistance, 
hyperglycaemia, the characteristic of T2D, likely occurrs [33]. Damage to blood vessels and 
organs from chronic hyperglycaemia is a major cause of morbidity and mortality in diabetic 
patients, and the diabetes also causes metabolic disorder. As illustrated in Fig. 1.3 Obesity 
and metabolic syndrome promotes physiological changes that cause NAFLD and Type 2 
diabetes [8]. Metabolic syndrome or so called insulin resistance syndrome includes 
dyslipidaemia, hyperglycaemia, hypertension, coronary heart disease, central obesity and 
insulin resistance [34]. These are risk factors of diabetes, NAFLD and cardiovascular disease. 
 
Figure 1.3 A schematic diagram of natural history of T2D in relation to NAFLD. 
Adapted from Henry R.R. 1998 [25]. Obesity promotes ectopic lipid accumulation in 
different metabolic tissues, such as liver, muscle and pancreas. Accumulated ectopic lipid in 
liver develops a non-alcoholic fatty liver disease (NAFLD), which progresses to insulin 
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resistance occurring in muscle due to ectoplic lipid accumulation, while β-cell dysfunction is 
acquired in the pancreas. T2D is a progressive disease with insulin resistance and β-cell 
failure as two major defects. During the pre-diabetes stage, the body is able to produce 
insulin but due to different insults to the insulin signalling pathway, the body is unable to 
respond to the effect of insulin effectively, a condition known as insulin resistance. To 
compensate for insulin resistance, the β-cells in the pancreas secrete more insulin to maintain 
a normal blood glucose level, however, the β-cells are exhausted and fail to secrete enough 
insulin to maintain normal blood glucose levels and lead to the onset of T2D at a later stage.     
1.1.4 Insulin resistance 
As previously described, insulin resistance is a primary disorder of metabolic syndrome or 
insulin resistance syndrome which includes dyslipidaemia, hypertension and coronary heart 
disease [34]. The body is required to have higher levels of insulin to maintain normal blood 
glucose during insulin resistance due to less sensitivity to insulin action, thus elevated fasting 
insulin levels is used as diagnostic measurement [35]. In addition, a glucose tolerance test 
(GTT) can facilitate diagnosis of insulin resistance by measuring blood glucose levels after 2 
hours of glucose administration to the subject, to estimate the efficacy of glucose clearance. 
High levels of insulin is capable of compensating for reduced glucose clearance, as such the 
hyperinsulinemic euglycemic clamp technique is suggested as the gold standard method for 
measuring insulin sensitivity or resistance [36, 37]. Insulin is infused at a constant rate to 
achieve a steady state hyperinsulinemia while glucose is infused to maintain blood glucose at 
a normal level, between 5mM and 5.5mM in this particular clamp technique method [38]. 
The difference in glucose infusion rate indicates insulin sensitivity at the whole-body level 
[39].  
Insulin signalling pathway The secretion of insulin is stimulated in response to increased 
level of glucose, fatty acids, and/or to a less extent of amino acids in the bloodstream. The 
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physiological role of insulin in glucose and lipid metabolism at the tissue level includes 1) 
stimulation of glucose uptake into muscle and adipose tissue by facilitating the translocation 
of glucose transporter (GLUT4) to the plasma membrane; 2) inhibition of glucose production 
from liver by suppressing glycogenolysis and gluconeogenesis; 3) promotion of glycogen 
synthesis largely in liver and muscle; and 4) stimulation of glucose incorporation into lipids 
in liver and adipose tissue [40]. These functions of insulin are carried out by the insulin 
signalling pathway in the cell.  
As shown in Fig. 1.4, the insulin signalling cascade begins firstly with the binding of insulin 
to a transmembrane protein that belongs to the family of tyrosine kinase receptors, the so 
called insulin receptor (IR) [41]. This binding leads IR to stimulate autophosphorylation at 
tyrosine sites and to activate intrinsic tyrosine kinase [41]. The activated IR recruits insulin 
receptor substrate (IRS) proteins and promotes their binding to a Src homology 2 (SH2) 
domain on the p85 regulatory subunit of phosphoinositol 3-kinase (PI3K) [30, 40]. This is 
followed by the recruitment of the catalytic p110 subunit and activation of PI3K [42, 43] to 
catalyse the phosphorylation of the 3-position hydroxyl group of the inositol ring of 
phosphatidylinositol (PI), converting phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) on the plasma membrane [44]. Subsequently 
PIP3 recruits cytosolic protein kinase Akt or other named protein kinase B (PKB) to the 
plasma membrane [45],  forming a complex with constitutive membrane threonine kinase 
phosphoinositide-dependent kinase 1 (PDK1), where PDK1 phosphorylates Akt at Thr308 in 
its activation loop [41, 46]. Akt is also phosphorylated at Ser473 in the hydrophobic C-
terminal regulatory domain, likely by mTOR [47]. Phosphorylation of both Thr308 and 
Ser473 is essential for the complete activation of Akt [48]. 
The insulin-mediated phosphorylation of Akt plays an important role in glucose metabolism 
through the effector molecules [41]. In muscle and fat cells, activated Akt phosphorylates 
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TBC1 domain family member 4 (TBC1D4, also known as AS160) stimulating the 
translocation of GLUT4 vesicles to the plasma membrane [49]. While fused with the plasma 
membrane, GLUT4 transporters are inserted to serve as channels for the entry of glucose into 
these cells. In liver and muscle cells Akt phosphorylates and inhibits glycogen synthase 
kinase 3 (GSK3) [50], regulating glycogen synthesis negatively through the suppression of 
glycogen synthase (GS). GS is a key enzyme in glycogenesis, a process converting glucose 
into glycogen [50, 51]. Akt promotes glycogen synthesis and glucose utilization by 
diminishing the inhibitory effects of GSK3, also mediating the phosphorylation and inhibition 
of transcriptional protein, forkhead box protein O1 (FoxO1) in liver [52-54]. Activated 
FoxO1, apart from its phosphorylation is localized in the nucleus, binding to the promoter of 
its target genes to regulate their expression. Once phosphorylated by Akt, FoxO1 is 
transported out of the nucleus and degraded in the cytosol. FoxO1 degradation leads to a 
decrease in its transcriptional activity and a downregulation of glucose 6-phosphatase 
(G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), two rate-limiting enzymes in 
gluconeogenesis [52, 53]. Gluconeogenesis is the de novo synthesis of glucose from the 
three-carbon substrates such as lactate and alanine, and is a major metabolic pathway for 
hepatic glucose output [8, 41, 55]. Insulin suppresses gluconeogenesis through Akt-FoxO1 
signalling cascade while glycogenolysis [8], a process for the breakdown of glycogen into 
glucose, which is also inhibited by Akt through the activation of mTOR and subsequent 
inhibition of glycogen phosphorylase in both liver and muscle [47].  
Akt is further considered in regulation of lipid metabolism through a link of sterol regulatory 
element binding protein (SREBP), transcriptional factor mainly regulating lipid metabolism.  
The potential mechanisms by which Akt influences SREBPs could be through GSK3 by 
preventing the mature SREBP degradation [56]. Another possible mechanism is related to the 
 35 
 
Chapter 1- Introduction and Literature Review 
mammalian target of rapamycin (mTOR). The effects of mTOR on modulating SREBPs 
cleavage is through Akt activation [57, 58]. 
 
Figure 1.4 A schematic diagram of a simplistic insulin signalling cascades. Adapted from 
Pessin et al. 2000. & Saltiel et al. 2001 [40, 41]. The binding of insulin to the insulin receptor 
(IR) recruits and phosphorylates tyrosine phosphorylation for insulin receptor substrate (IRS) 
proteins. IRS proteins activate phosphoinositol 3-kinase (PI3K), catalysing the converion of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate 
(PIP3). PIP3 triggers Akt which is activated by phosphoinositide-dependent kinase 1 (PDK1) 
to the plasma membrane. In muscle cells and adipocytes, activated Akt promotes glucose 
transport by facilitating the translocation of GLUT4 vesicles to the plasma membrane; while 
it promotes glycogen synthesis by inhibiting glycogen synthase kinase 3 (GSK3) and relieves 
the repression of GSK3 on glycogen synthase (GS) in liver and muscle cells. In liver cells, 
the activated Akt suppresses gluconeogenesis by inhibiting forkhead box protein O1 (FoxO1), 
a transcriptional regulator for two key enzymes for gluconeogenesis, namely glucose 6-
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phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK). Akt further 
regulates lipid metabolism via sterol regulatory element binding protein (SREBP), a 
transcriptional factor regulating lipid metabolism while the effects of mammalian target of 
rapamycin (mTOR) on modulating SREBPs cleavage is through Akt activation. 
Hepatic insulin resistance It is well known that liver is important for insulin-mediated 
glucose homeostasis while the glucose is utilised in response to insulin action in muscle and 
fat. Blood glucose levels are maintained by increased glucose production from the liver 
through glycogenolysis and gluconeogenesis during nutrient deficiency [8, 59]. Hepatic 
insulin sensitivity is reported to have a strong association with the area under the curve (AUC) 
during the first 30 min of the oral glucose tolerance test (OGTT) in humans [60]. Under 
normal conditions, glucose production from liver is also suppressed by insulin to counteract 
the rise of blood glucose [61, 62]. Defects in hepatic insulin signalling by liver-specific 
insulin receptor knockout led to systemic insulin resistance in mice [63]. In addition to this, 
insulin resistance is suggested to occur in the liver at first under both high fat and high 
fructose feeding conditions [64, 65], likely due to the disruption of insulin signalling by 
metabolites derived from both carbohydrate/glucose and lipid metabolism.  
Moreover, the liver is also heavily involved in the catabolism of dietary lipids. The majority 
of dietary lipids appear in the form of triglycerides (TG), which are required to be broken 
down into fatty acids and glycerol before being absorbed by the intestine [9, 66]. TGs are 
resynthesized and assembled into chylomicrons to enter the systemic circulation from the 
lymphatic system in the intestine [8, 54, 66]. Further, TGs within the chylomicrons is 
hydrolysed by lipoprotein lipase in the endothelium of liver, muscle, and adipose tissue [10, 
66]. The resultant fatty acids can be taken up by these tissues for utilization [67] while 
chylomicron remnants are formed where liver is responsible for the removal of these remnant 
particles from the circulation [68]. It is believed that the multifunctional role of liver makes it 
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susceptible to environmental challenges including overloaded nutrients, impaired insulin 
action, deregulated glucose/lipid metabolism and ER stress, due to the dietary fat and 
carbohydrate induced molecular mechanisms that will be reviewed in Sections 1.2, 1.3 and 
1.4 respectively. 
1.2 Fuel metabolism in the liver 
Liver is a key metabolic organ playing a major role in body energy metabolism, and after 
food is digested in the gastrointestinal tract, glucose, fatty acids and amino acids are absorbed 
into the bloodstream and transported to the liver [54]. Regulation of liver metabolism is 
important to maintain normal physiological functions of our body as such nutrients and 
hormones including neuronal signals are required to regulate metabolism of amino acid, 
glucose and lipids in the liver. Failure of liver metabolism may cause metabolic syndrome 
leading to NAFLD and Type 2 diabetes. 
1.2.1 Carbohydrate metabolism 
Glucose metabolism Glucose is a carbohydrate and an important simple sugar or 
monosaccharide, a major source of energy for cells in our body. In liver, glucose metabolism 
plays a critical role. About 80% of liver cells are hepatocytes, where blood glucose enters via 
a glucose transporter type 2 (GLUT2) in the postprandial state [8, 54]. GLUT2 is a membrane 
bound transporter with high capacity and low affinity for glucose, and its expression or 
activity is independent of insulin signalling in contrast to the glucose transporter type 4 
(GLUT4), which is expressed primarily in muscle and adipose tissue [8, 69]. Additional 
transporters such as glucose transporter type 1 (GLUT1) are involved in the process of 
glucose release from the hepatocyte [70]. The glucose taken up by hepatocytes is 
phosphorylated to glucose-6-phosphate by liver glucokinase, an enzyme acting as a glucose 
sensor which is transcriptionally regulated by SREBP1c, hepatic nuclear factor 4 α (HNF4α), 
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HNF6, forkhead box O1 (FoxO1) and upstream stimulatory factor 1 [71], leading to enzyme 
limitation for glucose utilization [8] such as reducing glucose concentration that further 
increases glucose uptake in muscle [54]. As simply illustrated in Fig 1.5, glycogen is 
carbohydrate energy stored in liver and muscles. Glucose is converted to glycogen by the 
process called glycogenesis, for glycogen to be hydrolysed by glycogen phosphorylase to 
generate glucose in the fasted state [54]. On the other hand, glycogen stored in the liver and 
muscles is converted back to glucose in a process called glycogenolysis. Glycogen is also 
hydrolysed to generate glucose through autophagy during fasting [72]. An allosteric inhibitor 
of glycogen phosphorylase and an activator of glycogen synthase, glucose-6-phosphate is the 
precursor for glycogen synthesis which is catalysed by glycogen synthase after conversion of 
glucose-6-phosphate to uridine diphosphate glucose (UDP-glucose) [55, 73] and/or glycolysis 
by glucokinase that metabolises glucose to pyruvate which is further decarboxylized to 
acetyl-CoA and processed in the tricarbocylic acid cycle (TCA) or utilized for de novo 
lipogenesis (DNL) during the systemic metabolic rate such as fasting [8]. Phosphorylation of 
glycogen synthase, mainly by glycogen synthase kinase 3 (GSK3), a downstream target of 
Akt/Phosphoinositide 3-kinase (PI3K) and thus insulin signalling [54, 74], inhibits activity of 
glycogen synthase where phosphorylation of glycogen phosphorylase increases its activity 
[74]. A multifunctional kinase GSK3 is involved in cell senescence, apoptosis and lipid 
metabolism via phosphorylation of SREBP1c [75]. In addition to this, other protein kinases 
phosphorylating glycogen synthase are AMP-activated protein kinase (AMPK) and protein 
kinase A (PKA), where insulin activates glycogen synthesis via repression of PKA [8]. 
The liver releases glucose mainly through glycogenolysis during short term periods of fasting, 
while prolonged fasting in the liver leads to glycogen depletion and hepatocytes synthesizing 
glucose through gluconeogenesis using lactate, pyruvate, glycerol, and amino acids [54, 76]. 
These substrates are either generated in the liver or delivered to the liver through the 
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circulation from other tissues. Hepatic gluconeogenesis occurs by the induction of pyruvate 
carboxylase in the presence of acetyl-CoA, and is further regulated via allosteric and 
transcriptional activation of phosphoenolypyruvate carboxykinase (PEPCK), fructose-1, 6-
bisphosphatase, and glucose-6-phosphatase (G6Pase) [77]. PEPCK expression via Akt-
mediated FoxO1 phosphorylation is suppressed by insulin action, and the over expression of 
PEPCK is reported to promote insulin resistance in mice [78]. For example, it has been 
suggested that PEPCK knockout mice decreased gluconeogenesis and removal of TCA 
anions [79] causing triglyceride accumulation and steatosis in the liver [80]. Moreover, 
PPARα signalling-mediated induction of the pseudokinase tribbles-homologue 3 (TRB3), its 
expression associated with insulin resistance in humans [81, 82], suppresses PEPCK 
expression via Akt-mediated FoxO1 phosphorylation pathway [8, 52, 83]. Expression of 
PEPCK and G6Pase are also mediated by other nuclear receptors such as FoxO1, PPARγ co-
activator 1α (PGC1α), farnesoid X receptor (FXR), glucagon and glucocorticoids [59, 84]. 
Fructose metabolism Glucose production from liver is suppressed to counteract the rise of 
blood glucose [61, 62]. This contribution from liver is believed to be even higher after 
fructose ingestion compared to glucose. Following intestinal absorption via glucose 
transporter 5 (GLUT5), fructose is transported through the portal vein to the liver where 
GLUT2 facilitates its entry [69, 85, 86]. Unlike glucose, fructose catabolism is primarily 
initiated by fructokinase (Fig. 1.5), which converts fructose to fructose-1-phosphate, and liver 
is the major metabolic tissue expressing this enzyme [85]. Hexokinase, which can be found in 
most metabolic tissues including skeletal muscle and heart, can also catalyse fructose 
phosphorylation, converting fructose to fructose-1-phosphate [86]. There is less chance for 
this reaction to occur in vivo due to a substantially low affinity, thus fructose is suggested to 
be metabolised almost entirely in the liver. The resultant fructose-1-phosphate is further 
hydrolysed by fructose-1-phosphate aldolase to yield glyceraldehyde-3-phosphate, which can 
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be further utilized in glycolysis to generate energy; alternatively, it is also used as a substrate 
to produce glucose or triglycerides [85, 86].  
 
Figure 1.5 A schematic diagram of carbohydrate metabolism in liver. Adapted from 
Lyssiotis et al. 2013 [86]. Dietary carbohydrate largely from sucrose breaks down to two 
different forms of sugar, so called glucose and fructose respectively. Glucose is mainly 
metabolized by glycolysis and regulated through feedback inhibition by ATP or citrate, 
which redirects glucose towards storage as glycogen. Glucose also converts into fructose 
through the polyol pathway, which involves the action of the enzyme aldose reductase (AR). 
Additionally, glucose metabolites are used to generate FA and TG. By expressing the enzyme 
ketohexokinase (KHK), fructose is metabolized to fatty acids (FA), glycerol, and 
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triglycerides (TG), which is the biosynthetic pathway that is not regulated by the ATP or 
citrate feedback mechanisms. PFK: phosphofructokinase. 
1.2.2 Lipid metabolism 
As important as glucose metabolism, the liver is also a key player in lipid metabolism. An 
important biological process, lipid metabolism in the liver maintains energy homeostasis 
within the fatty acid synthesis and lipid circulation through lipoprotein synthesis [66].  
Hepatic lipid induced insulin resistance An oversupply of nutrients converts to excessive 
energy stored, primarily in the form of TGs/fats, while under nutrient deficit, TGs are likely 
catabolised and used as a source for energy in the body. The major site for lipid storage is 
adipose tissue but when the net energy exceeds the storage capacity, the excessive lipids may 
overflow to metabolic tissues containing less TGs, such as liver and muscle, so called ectopic 
lipid accumulation, which is a determinant of tissue specific insulin resistance [87]. It has 
been suggested that the site-specific overexpression of lipoprotein lipase in liver or muscle 
induced lipid accumulation is associated with insulin resistance in transgenic mice [88, 89]. 
Also, reductions in ectopic lipids are accompanied with the reversal of insulin resistance, as 
seen when weight loss by a hypo-caloric diet dramatically reduces TG and normalizes insulin 
sensitivity in the liver of diabetic patients [90].  
Insulin-stimulated tyrosine phosphorylation of IRS and downstream PI3K activation are 
believed to be crucial for insulin action. These signalling cascades have been shown to be 
impaired in association with insulin resistance after lipid infusion in both humans [91] and 
animals [92], suggesting defective insulin signalling can be responsible for lipid-induced 
insulin resistance. Also, it has been further determined that the impairment in insulin 
signalling can be regulated by diacylglycerol/ceramide-mediated protein kinase C (PKC) 
activation (Fig. 1.6) [93]. Insulin resistance is a complex metabolic disorder, which is known 
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to be induced by a wide range of physiological insults including ectopic lipid accumulation 
which is the accumulation of lipid in non-adipose tissues and endoplasmic reticulum (ER) 
stress. A number of lipid intermediates have been identified to have detrimental effects on the 
insulin signalling cascade. 
Fatty acids (FAs) The excess FAs oxidation promotes increased levels of acetyl CoA 
stimulating pyruvate dehydrogenase kinase (PDK) [94], which in turn induces the inhibitory 
phosphorylation of pyruvate dehydrogenase (PDH) [95]. PDH is a key enzyme regulating the 
conversion of pyruvate which is a product of glycolysis, to acetyl CoA, thus excess FAs 
inhibits insulin-stimulated glycolysis [94, 95]. Furthermore, oxidation of excess FAs also 
increase the level of citrate, which inhibits PFK1 and blocks the formation of fructose 1,6-
phosphate in glycolysis [96].  
Long Chain Acyl-CoAs (LCACoAs) LCACoAs are the esterification product of FAs with 
CoA catalysed by acyl-CoA synthetase [94]. LCACoA enter mitochondria through CPT-1 for 
β-oxidation, which generates acetyl-CoA for the tricarboxylic acid cycle (TCA cycle, or citric 
acid cycle), or be used as the substrate for the production of triglyceride [79, 97]. The 
accumulation of LCACoA has been shown to be associated with decreased insulin-mediated 
glucose uptake in soleus muscle ex vivo [98], impaired glycogen synthesis in the muscle of 
rats infused with intralipid [99] and a reduction of whole-body insulin action in both rats and 
human [97]. Additionally, the increase of intracellular C18:2 CoA level is associated with the 
activation of protein kinase C (PKC) θ and inhibition of insulin-stimulated IRS-1 and PI3K 
activation [92]. The impairment of insulin signalling transduction by LCACoA is attributed 
to its ability to activate novel PKCs directly or indirectly [100]. 
Diacylglycerols (DAGs) DAGs are intermediate lipid species during the synthesis or lipolysis 
of triglyceride or phospholipids [101, 102]. Also they are known as the precursor of TG 
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consisting of two fatty acid chains and a glycerol molecule, which is a lipid intermediate 
derived from the hydrolysis of TG or de novo synthesis from glycerol-3-phosphate and 
LCCoA [94, 101].  Accumulation of DAGs has been suggested to link to insulin resistance 
with the involvement of PKCs activation [93], where insulin resistance is associated with the 
activation of PKC ε and θ in high fat-fed rats [103], and PKC θ/δ in both rats and humans 
with lipid infusion [92, 104].  
Ceramides Ceramides are another class of lipid intermediates, composed of sphingosine and 
FAs [94, 105]. It has been shown that ceramides stimulate protein phosphatase 2A (PP2A) 
[105] leading to subsequent dephosphorylation and inhibition of Akt, impairing the insulin 
signalling transduction [106, 107]. Also, it has been reported that inhibition of ceramide 
synthesis can improve insulin resistance induced by different insults including glucocorticoid, 
saturated-fat and obesity [108].  
Triglycerides (TGs) TGs are composed of one glycerol molecule and three FAs [102, 109]. 
They are the major storage form of lipids, and commonly used as an indicator of ectopic lipid 
accumulation [102]. Indeed, while triglycerides per se are generally considered benign to 
insulin resistance, it has been shown that the intracellular level of triglyceride in the muscle is 
inversely associated with whole-body insulin action in humans [110]. 
In addition to these lipid intermediates, other insults to the insulin signalling, such as ER 
stress and autophagy are tightly intertwined with lipid metabolism including fatty acid uptake, 
lipogenesis and fatty acid oxidation, and often lead to ectopic lipid accumulation. It has been 
suggested that during ER stress, activation of IRE1 leads to the splicing of X-box-binding 
protein 1, which can promote lipogenesis by up-regulating the transcription of a number of 
lipogenic proteins [111]. Also, autophagy has been reported to regulate lipid content with co-
localising TGs, lipid droplets and autophagic compartments [112]. These findings suggest 
 44 
 
Chapter 1- Introduction and Literature Review 
ectopic lipid accumulation might be a convergence of several pathogenetic mechanisms, at 
least partly involved in these physiological insults to the insulin signalling pathway. 
In summary, accumulation of ectopic lipids from dysregulated lipid metabolism is a major 
cause of insulin resistance and it mainly comes from two sources: increased lipid synthesis 
and/or reduced fatty acid oxidation [113].  
 
Figure 1.6 A schematic diagram of disrupted lipids on insulin pathway in the liver. 
Adapted from Savage et al. 2007 [114]. In liver, LCCoAs are obtained from plasma or de 
novo synthesis. Diacyglycerol (DAG) activates the  form of protein kinase C (PKC) in the 
liver. Activated PKC directly inhibits insulin receptor (IR) while DAG and ceramides-
mediated suppression of Akt also inhibits glycogen synthase kinase (GSK) phosphorylation 
and glycogen synthesis in the liver. Further, suppression of Akt activates forkhead box 
protein O 1 (FoxO1), leading to the upregulation of glucose 6 phosphatase (G6Pase) and 
phosphoenolpyruvate carboxykinase (PEPCK) and gluconeogenesis. 
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As shown in Fig. 1.7, ectopic lipid accumulation might result from different metabolic 
perturbations in lipid metabolism such as regulation of lipid synthesis and fatty acid oxidation. 
Also, biosynthesis of TG, predominantly occurring in liver and adipose tissue, involves the 
generation of fatty acids and glycerol, and the esterification of these two moieties to produce 
TGs [115]. Through consumption of dietary fat, both fatty acids and glycerol can be obtained 
from the lipase-catalysed hydrolysis of TG (lipolysis) [54, 87]. Conversely, dietary 
carbohydrate cannot directly provide fatty acids or glycerol and both of them need to be de 
novo synthesized, mainly in the liver and adipose tissue [115].  
Triglyceride synthesis Two main biosynthetic pathways for TGs are the sn-glycerol-3-
phosphate pathway predominantly in liver and adipose tissue and the monoacylglycerol 
pathway in the intestines [66, 109]. The sn-glycerol-3-phosphate pathway is discussed in this 
thesis. The substrates for TG synthesis are monounsaturated FAs and glycerol 3-phosphate, 
which form the backbone of TG molecules during the sn-glycerol-3-phosphate pathway [102, 
109]. Glycerol 3-phosphate results from the reduction of the glycolytic intermediate 
dihydroxyacetone phosphate (DHAP) catalysed by glycerol-3-phosphate dehydrogenase 1 
(GPD1) or, to a lesser extent, ATP-dependent phosphorylation of glycerol catalysed by 
glycerol kinase [109]. Glycerol 3-phosphate is acylated with fatty acyl-CoAs to form 
lysophosphatidic acid (LPA, or 1-acylglycerol-3-phosphate) catalysed by sn-1-glycerol-3-
phosphate acyltransferase (GPAT) [116, 117]. LPA can also form from the acylation of 
DHAP catalysed by dihydroxyacetone-phosphate acyltransferase (DHAPAT) [117, 118], 
followed by reduction of acyl-DHAP catalysed by alkyl-DHAP reductase [119]. LPA is then 
further acylated by sn-1-acyl-glycerol-3-phosphate acyltransferase (AGPAT) to form 
phosphatidic acid (PA, or 1,2-diacylglycerol-3-phosphate) [120], while PA is hydrolysed by 
phosphatidic acid phosphohydrolase (PAP) to form DAG [121]. TG is synthesised by further 
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esterification of DAG with unsaturated FAs catalysed by diacylglycerol acyltransferase 
(DGAT) [102, 109, 121, 122].  
Ceramide synthesis In the ER, palmitoyl-CoA can also react with serine to form 3-
ketodihydrosphingosine, catalysed by palmitoyl transferase [106, 108]. 3-
ketodihydrosphingosine is then reduced to dihydrosphingosine via the action of 3-
ketodihydrosphingosine reductase, which is followed a dihydroceramide synthase-mediated 
acylation to produce dihydroceramide [105]. At the final step, dihydroceramide is unsaturated 
by the enzyme dihydroceramide desaturase 1 to form ceramides [123]. 
Lipid synthesis Regulation of lipid synthesis involves the expression of acetyl-CoA 
carboxylase (ACC), fatty acid synthase (FAS), and stearoyl-CoA desaturase 1(SCD1) from 
DNL [66] that are under the synergistic regulation of sterol regulatory element binding 
protein 1c (SREBP1c) and carbohydrate-responsive element-binding protein (ChREBP), 
which can  be activated by carbohydrate, fatty acids and insulin [124, 125]. Both SREBP-1 
and ChREBP are largely expressed in the liver and adipose tissue, which are the two major 
sites for lipogenesis [124]. SREBP1c is a member of the basic helix-loop-helix leucine zipper 
transcription factor family [126] that binds to the sterol regulatory element (SRE) in the 
promoter region of lipogenic genes [56, 127]. Inactive form of SREBP1c is synthesised as a 
full length precursor and resides in the ER membrane as SREBP cleavage activating protein 
(SCAP)/ insulin induced gene (Insig) complex [128, 129]. Once activated, SCAP dissociates 
from Insig and facilitates the translocation of SREBP1c to the Golgi apparatus, in which 
inactive SREBP1c undergoes proteolytic cleavage by site-1 protease (S1P) and site-2 
protease (S2P) [128] to release the N-terminal domain and turns into the mature form of 
SREPB1c (mSREBP1c) [130]. mSREBP1c translocates into the nucleus to regulate the 
expression of a series of key enzymes that involves DNL including ACC, FAS and SCD1 
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[125], as well as enzymes that regulate TG synthesis [131]. The activity of SREBP2 targets 
genes involved in cholesterol biosynthesis [128] and also is known to be stimulated by insulin, 
which can enhance the binding affinity of SREBP1c to the promoter region [132]. Complex 1 
of the mammalian target of rapamycin (mTORC1) has been suggested to play a critical role 
in this process [133]. Apart from insulin, simple carbohydrates, such as fructose, sucrose and 
glucose have also been shown to induce SREPB1c expression in an insulin-independent 
manner [134]. Dietary fatty acids such as polyunsaturated fatty acids (PUFAs) have been 
shown to suppress SREBP1c mRNA expression as well as its maturation [135, 136]. The 
transcriptional activity of SREBP1c is also under the regulation of a number of nuclear 
receptors. It has been reported that peroxisome proliferator-activated receptor α (PPARα) 
activation can directly enhance SREBP1c promoter activity [137]. This effect is additive to 
its capability of promoting SREBP1c cleavage and maturation [138]. Another important 
nuclear receptor Liver X receptor (LXR) has also been shown to activate SREBP1c via 
increasing its promoter activity [139], in addition to autoregulation [127]. Inhibition of 
SREBP1c by a pharmaceutical agent was shown to reduce hyperlipidaemia and improve 
insulin resistance in Western diet-fed C57BL/6J mice [140]. 
ChREBP is from the same protein family as SREBP1c. ChREBP binds to the carbohydrate 
response element (ChRE) and is known to be stimulated by glucose and cyclic adenosine 
monophosphate (cAMP) [141]. Similar to SREBP1c, ChREBP also directly binds to the 
promoter of lipogenic proteins ACC and FAS and regulates the expression of these genes 
[142]. A recent study suggested that the expression of SCD1 and GPAT as key enzymes in 
TG synthesis is also under the regulation of ChREBP [143]. Activity of ChREBP is believed 
to be coordinated by nutrients and other transcriptional factors. Glucose has been shown to 
upregulate ChREBP mRNA expression and facilitates its translocation from the cytosol to the 
nucleus [144, 145]. Dietary fatty acids like PUFAs can suppress ChREBP activity by 
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increasing ChREBP mRNA decay and inhibiting protein translocation [146]. Besides 
nutrients, activation of LXR can also enhance ChREBP gene expression and modulates 
ChREBP activity [147].  
It is believed that other lipogenic enzymes or transcriptional factors are also regulated at post- 
transcriptional levels. For example, AMPK has been reported to suppress ACC activity via an 
inhibitory phosphorylation [148]. AMPK also phosphorylates SREBP1c at Ser372 site to 
inhibit its proteolytic processing and transcriptional activity [149]. Regulation of FoxO1 is 
another critical topic in lipogenesis. Expression of FoxO1 drived by mTORC1 is reported to 
regulate a downstream target Akt, while promoting SREBP1c mediated lipogenesis [150]. 
Recently, it has been suggested that lipogenesis may be influenced by ER stress [151-153].  
 
Figure 1.7 A schematic diagram of hepatic lipid metabolism. Adapted from Rui L. 2014. 
& Nguyen, P. et al. 2008 [54, 66]. Detailed description is explained in Section 1.2.2. Figure 
explains the pathways involved in liver lipid metabolism. ACC: acetyl-CoA carboxylase; 
ACS: acyl-CoA synthetase; CPT-1: carnitine-palmitoyl transferase 1; DAG: diacylglycerol; 
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DGAT: diacylglycerol acyltransferase; DHAP: dihydroxyacetone phosphate; GPAT: sn-1-
glycerol-3-phosphate acyltransferase; GPD1: glycerol-3-phosphate dehydrogenase 1; 
LCACoAs: Long chain acyl-CoAs; LPA: lysophosphatidic acid; PA: phosphatidic acid; PAP: 
phosphatidic acid phosphohydrolase; PDH: pyruvate dehydrogenase; SCD1: stearoyl-CoA 
desaturase 1; TCA: tricarboxylic acid cycle; TG: triglyceride.  
 
1.2.3 Fatty acid metabolism in the liver 
Fatty acid synthesis Fatty acid is an essential substrate for the synthesis of triglycerides [10, 
66, 102]. In the liver, increased intracellular levels of FAs might be a result of increased 
dietary intake, lipolysis of adipose triglyceride, and/or hepatic de novo lipogenesis (DNL) [9]. 
The process of FA synthesis from simple carbohydrates is termed DNL [54]. The formation 
of malonyl-CoA is suggested to be the first step of the process for DNL [154]. Acetyl-CoA is 
generated from the dehydrogenation of pyruvate (product of glycolysis) or β-oxidation of 
fatty acid, and is carboxylated with a molecule of bicarbonate catalysed by acetyl-CoA 
carboxylase (ACC) to form malonyl-CoA [66, 95, 99]. Multiple acetyl-CoAs are added to 
malonyl-CoA by a highly structured multi-enzyme complex called fatty acid synthase (FAS) 
to form long-chain fatty acids, such as 16C palmitic acid and 18C stearic acid [66, 97]. 
Resulting from DNL and increased dietary intake or lipolysis of adipose triglyceride, the 
saturated FAs have to be esterified and activated with CoA by acyl-CoA synthetase such as 
forming LCACoAs, before participating in oxidation, elongation, desaturation, or synthesis of 
glycerolipids or cholesterol esters [115, 155]. Then, these activated saturated FAs are 
desaturated by stearoyl-CoA desaturase (SCD) and converted to monounsaturated FAs [155]. 
For example, overconsumption of lipogenic sugar, such as sucrose or fructose has been 
reported clearly to increase visceral fat in healthy adults and in animal models via oxidized 
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and appeared as free FAs in newly formed VLDL-TG in liver [156]. These effects align with 
the lipid dysregulation characteristic of fatty liver and hepatic insulin resistance.  
Fatty acid oxidation Fatty acid (FA) oxidation develops in three different forms known as α, 
β and ω oxidation [157]. β oxidation is the major process to oxidise FAs for energy 
generation [158] among those three forms of oxidation. β oxidation occurs in both the 
mitochondria and peroxisome, and the process is for the sequential removal of 2-carbon units 
by oxidation at the β-carbon position of fatty acyl-CoA molecules [157]. Mitochondrial β 
oxidation involves four steps, and these are: 1) two hydrogen atoms between carbon 2 and 3 
are removed by Acyl-CoA dehydrogenases, forming a double bond such as a trans enoyl-
CoA, and FADH2; 2) enoyl-CoA hydratase adds a water molecule to this double bond 
forming 3-L-hydroxyacyl-CoA; 3) 3-L-hydroxyacyl-CoA dehydrogenase removes hydrogen 
atoms on carbon 2 and 3 forming 3-ketoacyl CoA and NADH; 4) the terminal acetyl-CoA 
group on the 3-ketoacyl CoA molecule is cleaved by β ketothiolase forming a new acyl-CoA 
with two carbons shorter than the original one [11, 66, 159]. The removal of one 2-carbon 
unit like acetyl-CoA from a fatty acyl-CoA molecule in the mitochondria generates one 
NADH and one FADH2, which enter the electron transport chain in mitochondria for the 
generation of ATPs [158, 160]. The acetyl-CoA cleaved from the original fatty acyl-CoA can 
be converted to citrate, which enters the tricarboxylic acid cycle (TCA cycle, or Krebs cycle) 
for the generation of more NADH and FADH2 [10, 66, 79, 159].  
A major rate limiting step in β oxidation is the transportation of acyl-CoA across the 
mitochondrial membrane through the carnitine palmitoyltransferase system [157]. The 
carnitine palmitoyltransferase (CPT) system consists of CPT1 and CPT2. CPT1 is located on 
the outer mitochondrial membrane, and it has been shown to be inhibited by malonyl-CoA 
[157]. The removal of malonyl-CoA-mediated inhibition of CPT1, at least in part, accounts 
for the effect of AMP-activated protein kinase (AMPK) on FA oxidation. Activated AMPK 
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induces inhibitory phosphorylation of ACC, which converts acetyl-CoA to malonyl-CoA, and 
reduces the intracellular level of malonyl-CoA and facilitate the transportation of acyl-CoA 
into the mitochondria [161]. Furthermore, enzymes involved in the β oxidation are inhibited 
by fatty acyl-CoA intermediates produced during this process [162]. 
In addition to the regulation by substrates, FA oxidation is regulated at the transcriptional 
level. It is well known that peroxisome proliferator-activated receptor α (PPARα) and δ 
(PPARδ) [163] regulate the expression of a number of proteins involved in FA transportation 
and oxidation, such as CPT1, acetyl-CoA synthase and β-ketothiolase [164]. PPARγ is a 
master regulator of adipogenesis as well as a potent modulator of lipid metabolism by binding 
to fatty acids and their derivatives [165-167]. PPARγ co-activator 1α (PGC1α) protein at 
transcriptional level mediates the expression of a number of proteins involved in β oxidation, 
the TCA cycle and the mitochondrial electron transport chain [168]. 
 
Figure 1.8 A schematic diagram of fatty acid metabolism. Adapted from Wakil, S.J. et al. 
2009 [169]. Dietary high fat, carbohydrate and protein are digested, and the fatty acids (FA), 
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glucose and amino acids are transported to liver, adipose and muscle. FA metabolism with 
comparable reactions and appropriate modifications occurs in adipose and muscle tissues. 
This thesis is focused on liver. In liver, FAs are converted to acyl-CoA while glucose 
undergoes glycolysis and generates pyruvate, which is oxidized in the mitochondria through 
pyruvate dehydrogenase to acetyl-coenzyme A (acetyl-CoA). Acetyl-CoA is produced 
through amino acid metabolism, and transported into the mitochondria through 
carnitine/palmitoyl-transferase 1 (CPT1) for β-oxidation and generation of acetyl-CoA. The 
acetyl-CoA is oxidized through the citric acid cycle to yield energy, H2O and CO2 or it is 
converted [170] to citrate, which exits to the cytosol and generates acetyl-CoA through ATP 
citrate lyase (ACLY), or to [171] ketone bodies, through the hydroxymethylglutaryl-CoA 
(HMG-CoA) system, or to [172] carnitine/acetyl-CoA (CAT), which exits from the 
mitochondria to the cytosol. In the cytosol acetyl-CoA is carboxylated to malonyl-CoA by 
acetyl-coenzyme A carboxylase 1 (ACC1) and utilized through fatty acid synthase (FAS) 
reactions to generate palmitate, which is utilized in the synthesis of triglycerides (TG). Also, 
acetyl-CoA is carboxylated by acetyl-coenzyme A carboxylase 2 (ACC2) at the 
mitochondrial membrane to form malonyl-CoA, which inhibits the CPT1 and reduces acyl-
CoA transfer to mitochondria for β oxidation.  
 
1.2.4 Protein metabolism 
Proper physiological function is believed to rely on the expression of biological activation of 
molecules, and many of these molecules are proteins [173]. Protein metabolism in liver 
involves various biochemical processes which are for the synthesis/degradation of proteins, 
amino acids and urea to excrete ammonia [174], and the breakdown of proteins by catabolism 
[175]. One important function of the liver is the synthesis and secretion of a wide range of 
proteins into the bloodstream, including blood clotting factors and transporter proteins such 
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as lipoproteins and albumin [176]. Another important function is the synthesis and correct 
localization of integral membrane proteins of the plasma membrane and other compartments. 
These classes of proteins are determined during translation of the mRNAs in which they are 
encoded. The nascent chains of these proteins are targeted to the membrane of the 
endoplasmic reticulum (ER), a specialized intracellular compartment that initiates the 
synthesis by subsequent vesicle fission and fusion through the secretory pathway [176]. 
Under certain conditions, these irreversible regulatory steps for determining the amount, 
function and/or localization of the proteins are overcome by cellular machineries that degrade 
undesired proteins, and thereby end their action so called protein degradation [177]. 
In summary, a major protein regulation in liver comes from two sources: protein synthesis 
and degradation of protein. 
 
Protein/Amino acids synthesis Amino acids (AA) play an important role in energy supply 
[178]. Under normal nutritional and physiological conditions, proteins/AA are ingested in 
excess and are neither stored nor excreted but catabolized and used as an important source of 
energy that fuels the production of glucose and FA [178, 179]. During starvation, the use of 
AA degradation for energy supply is increased [174]. In the liver, carbon skeletons of the 
gluconeogenic AA, such as alanine and serine in the liver and glutamine in the kidney and the 
gut, are catabolized into pyruvate or into one of the metabolites of the citric cycle, which can 
then be converted into glucose [54, 174, 178]. The AA carbon skeleton used as the energy 
source results from an AA deamination process, which leads to the cytosolic accumulation of 
toxic free ammonia (NH4
+
) [178, 179]. NH4
+
 is transported as glutamate and/or glutamine to 
the liver and kidneys, where ammonia is freed and processed in the urea cycle [80, 178]. Urea 
is a diffusible molecule that is excreted through the urine in the kidney [80], and this process 
is also important during protein metabolism with AA regulation.  It is reported that regulation 
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of AA synthesis and degradation are mainly used in the short-term regulation of energy 
homeostasis [54, 174, 178].  
During and subsequent to translation and translocation of mRNA, the newly synthesized 
proteins are either degraded or further processed and matured in order to contribute to the 
protein’s physiological function [180]. Maturation involves non-covalent folding and 
covalent, post- and cotranslational modifications, as well as trafficking through the secretory 
pathway to the correct final destination [180]. These events may be interconnected, for some 
posttranslational modifications occurring in specialized compartments, such as sialylation of 
proteins in the trans-Golgi network. In other cases, a posttranslational modification is a 
requisite for a particular compartmental trafficking event, such as the role of mannose residue 
phosphorylation in directing lysosomal enzymes out of the secretory pathway and to those 
organelles [181]. 
Protein degradation The best understood function of proteasomes is in ER-associated 
degradation (ERAD) [182, 183]. It is generally believed that the ER is equipped with 
machinery for the selection of misfolded proteins that are recognized through exposure of 
disulphide bonds or posttranslational modifications, such as signal sequence cleavage and 
glycosylation [184]. These proteins are believed to be misfolded forms recognized by the ER 
molecular chaperones that exercise a ‘quality control’ function over protein products before 
they enter the later stages of the secretory pathway [182]. The journey of such misfolded 
molecules through the secretory pathway is blocked at the level of ER where they are instead 
targeted for return to the cytoplasm and destruction by the 26S proteasome complex [185-
187]. In some cases, unwanted proteins are selected for degradation at sites other than the ER, 
such as in the nucleus. A recent study has identified that the characteristics of nuclear 
degradation machinery resemble those of ERAD [188]. Apoptosis, cell development, cell 
cycle, antigen processing and lipid metabolism by the liver are cellular processes regulated by 
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degradation [177]. The half-life of normally short-lived proteins is thought to be determined 
by degradation through recognition of signals inherent in their amino acid sequence [187, 
189]. Among these signals, the best characterized is the N-degron of the N-end rule pathway, 
in which the half-life of a protein is determined by the identity of its N-terminal amino acid 
[190]. Lipid metabolism by the liver is a prime example of regulated degradation [190] . The 
liver enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) is an integral 
membrane protein of the ER, and it functions as a rate-limiting enzyme for the synthesis of 
cholesterol [191]. In addition to this, sterol regulation by the liver is subjected to regulated 
degradation at other levels, such as that apolipoprotein 100 (ApoB) is degraded by the ERAD 
if not assembled into very low-density lipoprotein particles in the liver secretory pathway 
[191, 192]. Therefore, proteolysis directs many cellular processes, primarily by controlling 
the levels of intracellular proteins, a function that was originally solely assigned to 
transcription and translational control [175, 193]. 
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Figure 1.9 A schematic diagram of protein/amino acid metabolism. Adapted from 
Desvergne, B. et al. 2006 [178]. In peripheral tissues such as muscles and lungs, amino acid 
(AA) deamination leads to the formation of glutamate, which is converted to glutamine, via 
glutamine synthase. Glutamine synthase expression is transcriptionally controlled by 
glucocorticoids, and directly used as an energy substrate by the gut. However, glutamine is 
also a major carrier of ammonia being delivered to the liver where it can be disposed of. It 
has a particularly important role in the kidneys during metabolic acidosis as seen upon fasting 
where the reverse reaction from glutamine to glutamate and α-ketoglutarate helps in excreting 
acid and provides a substrate for gluconeogenesis. In the liver, glutaminase activity under the 
control of cAMP releases NH3 for urea formation, which can be eliminated in the kidney 
through the urea cycle which is subjected to transcriptional control. 
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1.2.5 Hepatokines in liver metabolism 
The liver has a role in increased glucose production and dysregulated lipoprotein metabolism, 
conditions that are often found in patients with NAFLD and T2D [194]. Additionally, several 
proteins that are exclusively or predominantly secreted from the liver are known to directly 
affect glucose and lipid metabolism. These functional proteins released from adipose tissue 
and skeletal muscle are named adipokines and myokines respectively while liver derived 
proteins are called hepatokines [194]. At the present time, there are three major hepatokines: 
fetulin-A, the first to be described which correlates with increased inflammation and insulin 
resistance; recently identified selenoprotein P (SeP), which is associated with insulin 
resistance through serial analysis of gene expression [195]; and fibroblast growth factor 21 
(FGF21), an insulin sensitising hormone with beneficial metabolic actions [194-197] 
Fetuin-A The first identified liver-derived factor suggested to regulate metabolic balance 
through integrated organ crosstalk is fetuin-A, a 64 kDa phosphorylated glycoprotein that is 
primarily synthesized by hepatocytes [196, 198]. Circulating levels of fetuin-A are increased 
in obesity and related disorders such as the metabolic syndrome, T2D, fatty liver and NAFLD 
[194, 196]. It has been reported that fetuin-A is a natural inhibitor of the insulin receptor 
tyrosine kinase, leading to insulin resistance in rodents [199]. Fetuin-A concentrations are 
tightly correlated with insulin resistance and glucose intolerance as it directly inhibits the 
downstream phosphorylation events of the insulin signalling cascade and the translocation of 
the glucose transporter GLUT4 in insulin target tissues. Apart from its direct effects on the 
insulin receptor, fetuin-A promotes insulin resistance by propagating a pro-inflammatory 
state. It has been reported that palmitate-induced fetuin-A stimulates triacylglycerol 
accumulation in hepatocytes and that adiponectin inhibits palmitate-induced hepatic fetuin-A 
expression through the AMPK pathway [195, 200]. These findings suggest that fetuin-A is 
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causatively associated with insulin resistance and modulating inflammatory reactions, leading 
to various metabolic disturbances.  
Selenoprotein P (SeP) It is a 42-kDa glycoprotein, mainly produced in the liver and secreted 
into plasma [201]. SeP is identified as a hepatokine associated with insulin resistance in 
humans through serial analysis of gene expression, whereas in mice SeP inhibits insulin 
signalling in both liver and skeletal muscle [202]. It has been reported that patients with T2D 
and NAFLD had higher serum SeP levels than the healthy people [203, 204].  
Fibroblast growth factor 21 (FGF21) FGF21 is a 181 amino acid peptide hormone mediated 
by peroxisome proliferator activated receptor α (PPARα) that is primarily secreted by the 
liver and acts as a potent metabolic regulator [205, 206]. The expression of FGF21 is 
mediated by PPARα during starvation [206, 207] and regulated by peroxisome proliferator 
activated receptor γ (PPARγ) after feeding [208]. The role of FGF21 as a metabolic hormone 
during fasting or starvation [209] is well studied with circulating free fatty acids (FFA) and 
cellular stresses due to hepatic injury, chemical insult and diseases [210]. It has been reported 
that FGF21 has a promising pharmacological potential with its ability to reduce blood 
glucose independent of insulin by increasing the expression of glucose transporter GLUT1 in 
adipocytes [197, 211], and decreasing circulating triacylglycerol levels by reducing lipolysis 
and increasing β oxidation in the liver and adipose tissue [212]. A recent study has 
demonstrated that FGF21 is up-regulated in hepatocytes stimulated by high glucose and that 
its increased expression is directly induced by the glucose-sensitive transcription factor 
known as carbohydrate responsive element-binding protein (ChREBP) [213]. It is believed 
that a central role of FGF21 in metabolic regulation suggests beneficial effects on glucose 
metabolism and lipid homeostasis, in addition to promoting rapid body weight loss in rodents. 
FGF21 also benefits people with obese T2D and NAFLD [206, 212, 214-216]. 
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Figure 1.10 A schematic figure of functions of key hepatokines in metabolism. Adapted 
from Stefan N. et al. 2013 [194]. Both selenoprotein p (SeP) and fetuin-A have a role of 
promoting insulin resistance both in rodents and humans while fibroblast growth factor 21 
(FGF21) resolves insulin resistance in animals but promotes in humans.  
 
1.3 Peroxisome proliferator activated receptors (PPARS) in the liver 
Peroxisomes are subcellular organelles, found in most plant and animal cells, that perform 
diverse metabolic functions including H2O2 based respiration and β-oxidation of fatty acids 
metabolism [217]. The structurally diverse compounds that induce effects of increasing size 
and number of peroxisomes in liver and transcription of genes encoding peroxisomal 
enzymes are termed peroxisome proliferators [217]. In 1990, a nuclear receptor that was 
transcriptionally activated by peroxisome proliferators was identified and named peroxisome 
proliferator activated receptor (PPAR) as the peroxisome proliferators were activated, but did 
not directly bind to this receptor [218].  
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The peroxisome proliferator activated receptors (PPARs) are a subfamily of the nuclear 
receptor superfamily [164]. Three isoforms from PPARs encoded by separate genes are 
identified, and these are: peroxisome proliferator activated receptor α (PPARα), peroxisome 
proliferator activated receptor γ (PPARγ), and peroxisome proliferator activated receptor β/δ 
(PPARβ/δ) [164]. The PPARs are ligand-dependent transcription factors that regulate target 
gene expression by binding to specific peroxisome proliferator response elements (PPREs) in 
enhancer sites of regulated genes [164, 219]. Each receptor binds to its PPRE as a 
heterodimer with a retinoid X receptor (RXR) [164, 220]. Upon binding an agonist, the 
conformation of a PPAR is altered and stabilized such that a binding cleft is created and 
recruitment of transcriptional co-activators occurs [164]. Due to these changes, an increase in 
gene transcription is resulted.  
Recently, it has been demonstrated that the PPARs are the primary targets of numerous 
classes of synthetic compounds used in the successful treatment of diabetes and dyslipidemia 
[219]. Understanding of the molecular and physiological characteristics of these receptors is 
essential to those engaged in the development or utilization of drugs used to treat metabolic 
disorders. Despite their many similarities, each PPAR isoform has unique functions in vivo 
due to distinct tissue distributions, differential responses to divergent ligands and inherent 
differences in biochemical properties [166, 221]. As shown in Fig. 1.11, PPARα, the first 
PPAR to be identified, is expressed predominantly in the liver, heart and brown adipose 
tissue (BAT), where it is a major activator of fatty acid oxidation pathways and is the target 
of the hypolipidemic fibrate drugs [166, 221]. Although PPARδ or PPARβ commonly 
referred to as PPARδ/β shares similar functions with PPARα, it is ubiquitously expressed and 
has a crucial role in fatty acid oxidation in key metabolic tissues such as skeletal muscle, liver 
and heart [221, 222]. PPARγ is most highly expressed in white adipose tissue (WAT) and 
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BAT, where it is a master regulator of adipogenesis as well as a potent modulator of whole-
body lipid metabolism and insulin sensitivity [166, 167].  
Although all three PPARs are strongly implicated in the metabolic syndrome , the aim of this 
thesis focuses on two isoforms of PPARs namely PPARα and PPARγ associated signalling 
pathways, metabolism and therapeutic potential role for metabolic disorders such as T2D and 
NAFLD. 
 
Figure 1.11 A schematic figure of three isoforms of PPARs. Adapted from Evans R.M. et 
al. 2013 [166]. The three perosixome proliferator activated receptors (PPARs) isoforms are 
named peroxisome proliferator activated receptor α (PPARα), peroxisome proliferator 
activated receptor γ (PPARγ) and peroxisome proliferator activated receptor δ/β (PPARδ/β). 
They regulate lipid and glucose homeostasis through their coordinated activities in liver, 
muscle and adipose tissue.  
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1.3.1 PPARα  
PPARα was the first member of the PPARs family discovered in 1990s and since then has 
been identified as the master regulator of hepatic lipid metabolism [218]. PPARα is expressed 
highly in liver, hepatocytes, heart, enterocytes, muscle and kidney [163]. It governs the 
expression of genes involved in the β-oxidation of fatty acids, lipoprotein metabolism, 
glucose metabolism, liver inflammation, amino acid metabolism, and hepatocyte proliferation, 
specifically in rodents [223, 224]. Activation of PPARα occurs through a variety of natural 
agonists, including unsaturated fatty acids and eicosanoids whereas fibrate drugs including 
fenofibrate, gemfibrozil, bezafibrate, clofibrate and Wy14643 act as synthetic agonists [164, 
225].  
In liver, PPARα plays a pivotal role in fatty acid catabolism by upregulating the expression of 
numerous genes involved in mitochondrial fatty acid oxidation, peroxisomal fatty acid 
oxidation, and numerous other aspects of fatty acid metabolism in the cell [226]. As a 
consequence, activation of PPARα can prevent and decrease hepatic fat storage [227, 228]. A 
recent study of PPARα in high fat diet fed mice revealed that proper functioning of PPARα is 
essential to prevent the liver from storing large amounts of fat [229]. By inducing 
mitochondrial, peroxisomal, and microsomal fatty acid oxidation, PPARα reduces hepatic fat 
accumulation in the liver during the development of fatty liver disease, and thus prevents 
steatosis [10, 228, 230]. Also, PPARα has been shown to down regulate apolipoprotein C-III, 
inhibiting triglycerides hydrolysis lower density lipoprotein which further contributes to the 
lipid lowering effect by the activity of PPARα ligands [67, 231].  
Besides governing metabolic processes, PPARα also regulates inflammatory processes, 
mainly by inhibiting inflammatory gene expression [219], showing a potent anti-
inflammatory activity in liver, such that the progression of hepatic steatosis towards hepatic 
steatohepatitis might be counteracted by PPARα. Indeed, several studies have reported that 
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hepatic PPARα activation reduces hepatic inflammation elicited by acute exposure to 
cytokines and other compounds as a result of reversing steatohepatitis induced by feeding a 
methionine- and choline-deficient (MCD) diet [228, 230, 232]. In addition, specific PPARα 
activator, fenofibrate has been shown to decrease plasma levels of several acute phase 
proteins that are normally increased during inflammatory conditions in humans [233] while 
fenofibrate treatment showed prevented macrophage infiltration of the liver in vivo [219]. 
Moreover, dysregulation of all above functions of PPARα may result in severe 
hypoglycaemia, hypoketonemia, and elevated plasma levels of fatty acid indicating a defect 
in fatty acid uptake and oxidation via fasting [163, 227]. 
1.3.2 PPARγ  
PPARγ is characterized originally as a key regulator of adipocyte differentiation and lipid 
metabolism [234-237]. PPARγ expression is directed by different promoters, such as fatty 
acids and eicosanoid derivatives that bind and activate PPARγ at micromolar concentrations. 
PPARγ prefers polyunsaturated fatty acids, including the essential fatty acids linoleic acid, 
linolenic acid, arachidonic acid, and eicosapentaenoic acid [238]. Activation of PPARγ leads 
to two different PPARγ isoforms [239, 240], and these are 1) PPARγ1 isoform expression, 
which is restricted to liver, adipocytes, and a few other cell types while 2) PPARγ2 isoform is 
expressed predominantly in adipocytes [234, 235]. PPARγ is also found in other cell types 
including fibroblasts, myocytes, breast cells, the white and red pulp of rat spleen, human 
bone-marrow precursors, and macrophages/monocytes [241, 242]. In addition to this, PPARγ 
is shown in macrophage foam cells in atherosclerotic plaques [243, 244].  
PPARγ is identifed as an important player in metabolism of glucose and lipid, and well 
known for improving insulin sensitivity with high affinity PPARγ ligands known as a class of 
antidiabetic drugs called the thiazolidinediones (TZD), such as rosigliatzone (RG) and 
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pioglitazone [245]. The TZD is developed originally for the treatment of T2D on the basis of 
their ability to lower glucose levels and levels of circulating fatty acids in rodent models of 
insulin resistance [165, 246]. RG is a well known agonist of PPARγ and it helps promote 
insulin action [247, 248]. The findings of these PPARγ ligands show that they mediate their 
therapeutic effects through direct interactions with PPARγ, establishing PPARγ as a key 
regulator of glucose and lipid homeostasis [249]. PPARγ also has a role in cell proliferation 
and malignancy where from many recents studies, ligands for PPARγ are shown to mediate 
positive and negative effects on cell proliferation and malignancy [250-257]. 
Despite well known functions of PPARγ, the development of fatty liver is associated with 
increased hepatic expression of PPARγ in mouse models of steatosis [219]. In a non-fatty 
liver, the role of PPARγ appears to be limited and is probably restricted to stellate cell 
function during liver injury induced fibrogenesis [258]. However, during the development of 
steatosis, hepatocytes gain phenotypical characteristics of adipocytes which include the 
formation of large lipid droplets, where PPARγ plays a major role [219]. Expression of 
adipogenic and lipogenic genes such as sterol regulatory element binding protein (SREBP), 
adipose differentiation-related protein (ADRP) and PPARγ are strongly upregulated in 
steatotic livers [259]. 
1.3.3 The role of PPARα and PPARγ in lipid metabolism of liver 
PPARα in hepatic lipid metabolism Regulation of lipid metabolism is mainly coordinated by 
liver, which actively metabolizes fatty acids as fuel and continuously produces very low 
density lipoproteins (VLDLs) particles to provide a constant supply of fatty acids to 
peripheral tissues [219, 225]. Disturbances in these pathways are the basis for hepatic 
steatosis and alterations in plasma lipoprotein levels [67, 164]. Many aspects of hepatic lipid 
metabolism are under control of fatty acid uptake through membranes, fatty acid activation, 
intracellular fatty acid trafficking, fatty acid oxidation and ketogenesis, and triglyceride 
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storage and lipolysis [163, 219, 225]. PPARα is the molecular target for the fibrates, widely 
prescribed drugs for decreasing high circulating triglyceride levels and increasing high-
density lipoprotein (HDL) cholesterol levels [260]. It also has been suggested that the effect 
of PPARα on hepatic ketogenesis may be mediated by induction of the PPARα target 
fibroblast growth factor 21 (FGF21) [207, 214, 215]. PPARα activators exert their 
hypolipidemic effects by 1) regulating the uptake and metabolism of fatty acids in the liver 
and the resulting reduction of very low-density lipoprotein (VLDL) triglyceride production; 2) 
altering the genes governing intravascular hydrolysis of triglyceride and those governing 
HDL production; and 3) decreasing small dense low-density lipoproteins (LDLs) [261, 262]. 
PPARα regulates fatty acid transport and uptake into the cell by stimulating the genes 
encoding fatty acid transport protein, fatty acid translocase, and liver cytosolic fatty acid 
binding protein [263, 264]. After the passage across the plasma membrane, PPARα 
stimulated acyl-CoA synthetase esterifies the fatty acids to acyl-CoA esters, thereby 
preventing their efflux from the cell and activating the fatty acid for further metabolism [265]. 
PPARα also induces the entry of fatty acid into the mitochondria by stimulating 
mitochondrial carnitine palmitoyltransferase 1 (CPT1) and CPT2, which is a crucial step, 
especially in heart, skeletal muscle and liver [266, 267]. Activated acyl-CoA esters are 
oxidized by PPARα induced enzymes responsible for fatty acid oxidation in mitochondria, 
microsomes, and peroxisomes [164]. Peroxisomal enzymes for fatty acid β oxidation include 
ACOX, bifunctional enzyme, and thiolase [160, 268]. Mitochondrial enzymes for fatty acid β 
oxidation consists of four chain length-specific acyl-CoA dehydrogenases, such as medium 
chain acyl-CoA dehydrogenase [269]; microsomal enzymes for ω-hydroxylation, such as 
CYP4A1 and CYP4A6, which belong to the cytochrome P450 4A family [270]. 
PPARα ligands gemfibrozil and fenofibrate at low concentrations decreases the production of 
VLDL triglyceride by stimulating the oxidative metabolism of free fatty acids [271]. In 
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rodents, fibrate administration results in peroxisome proliferation and hepatomegaly, but this 
is not observed in humans [163]. The extracellular effects of PPARα on triglyceride 
metabolism are mediated by alterations in the expression of lipoprotein lipase (LPL) and 
apolipoprotein C III (apoCIII), major determinants of plasma triglyceride concentrations 
[272]. PPARα increases the expression of hepatic LPL, which has a PPRE responsive to 
PPARα activators [273]. In contrast to LPL, PPARα substantially decreases the expression of 
hepatic apoCIII, which inhibits clearance of plasma triglycerides. PPARα activators reduce 
the apoCIII synthetic rates, resulting in diminished secretion of apoCIII and lowered plasma 
triglyceride levels [274, 275].  
PPARγ in hepatic lipid metabolism As the expression level of PPARγ in liver is relatively 
low, the major role of PPARγ in hepatic lipid metabolism is believed to be influenced by its 
effects on adipose tissue. Activation of PPARγ stimulates the storage of fatty acids in mature 
adipocytes by acting at several steps [276] which are 1) release of fatty acids from the 
triglycerides contained in lipoprotein particles by stimulating lipoprotein lipase [273], 
intracellular fatty acid transport so called aP2, activation of fatty acids by acyl-CoA synthase, 
and 2) fatty acid esterification by stimulating the phosphoenolpyruvate carboxykinase 
(PEPCK) gene, which provides α glycerophosphate [277]. A stimulating effect on the insulin 
dependent glucose transporter GLUT4 has also been reported [278] to contribute an increased 
fatty acid synthesis from glucose [279]. PPARγ activation modulates the expression of 
products secreted by the adipocyte [280] which reduces leptin expression and activates 
adiponectin expression, a protein potentially involved in insulin sensitivity [281]. PPARγ also 
induces the expression of a secreted protein called PPARγ angiopoietin-related gene (PGAR) 
[282] from the angiopoietin family. These proteins usually serve as signaling molecules in 
vascular development [279]. PGAR expression is increased by hypoxia [283] and could 
indicate that PPARγ is able to modulate angiogenesis, a necessary component of adipose 
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tissue development [281]. PPARγ is a potent stimulator of fatty acid storage in adipose tissue 
because it increases both the storage capacity and the fatty acid flux into adipocytes [164-
166]. 
1.4 Endoplasmic reticulum stress in the liver 
A large number of studies have suggested a causative role of endoplasmic reticulum (ER) 
stress in metabolic disorders such as T2D and NAFLD [183, 284-286]. ER is a 
multifunctional organelle in all eukaryotic cells and categorized as smooth endoplasmic 
reticulum (SER) which is involved in lipid synthesis, carbohydrate metabolism and calcium 
homeostasis, whereas rough endoplasmic reticulum (RER) which is a major site for protein 
synthesis and folding with ribosomes attached onto its outer membrane [183]. At the 
translation level, newly synthesized polypeptide chains begin to fold into 3 dimensional 
structures in the ER lumen with the assistance of molecular chaperones, and are then 
transported to the Golgi apparatus for further modification [151]. During protein unfolding, 
the lectin-type chaperones calnexin and calreticulin can facilitate the refolding of immature 
glycoproteins to reach their native conformation [175]. Unfolded or misfolded proteins in the 
ER are retranslocated to the cytoplasm and disposed by ER associated degradation (ERAD) 
[287-289] which can be affected by changes in ER environment, such as temperature and 
calcium concentration, or protein overloading that exceeds the ER folding capacity. When the 
quality control mechanisms are overcome, unfolded/misfolded proteins and protein 
accumulation in the ER occur, and in turn cause ER stress [290].  
ER stress has been found in tissues that are active in protein and lipid synthesis, such as liver, 
pancreas, brain and adipose tissue [151, 182]. Chronic ER stress can lead to 
neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, as well as 
metabolic diseases including cardiovascular diseases, non-alcoholic fatty liver disease and 
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diabetes [291]. ER stress is believed to be an important mechanism underlying insulin 
resistance and ectopic lipid accumulation in the liver. In T2D, ER stress has emerged as an 
important factor that contributes to induce hepatic insulin resistance and is associated with -
cell dysfunction [292, 293]. In diet-induced and genetic animal models of insulin resistance, 
treatment of chemical chaperones 4-phenyl butyric acid (PBA) and taurine-conjugated 
derivative (TUDCA) has been reported to alleviate ER stress, normalize hyperglycemia and 
restore insulin action in liver, muscle and adipose tissue [286]. Similar effects can be 
achieved by overexpression of molecular chaperones such as 78-kDa glucose-regulated 
protein (GRP78) [294]. In obese humans, TUDCA or PBA therapy for 2-4 weeks results in 
marked increase in insulin sensitivity [295, 296] and improvement in -cell functions [295]. 
Also, activation of ER stress response triggered by its several unfolded protein response 
(UPR) components has been reported in livers of patients with NAFLD and NASH [297, 298] 
due to altered lipid metabolism and hepatic steatosis [299]. The induction of ER stress was 
firstly described in the livers of genetic and diet-induced animal models and a methionine 
choline deficient (MCD) diet fed mice [300, 301] demonstrating hepatic steatosis without 
obesity [302]. However, the contribution of ER stress associated with pathogenesis of 
NAFLD remains to be understood.  
1.4.1 Unfolded protein response 
ER stress triggers an adaptive mechanism called unfolded protein response (UPR) to alleviate 
ER stress and restore ER homeostasis. It is achieved by arresting protein translation, 
upregulating molecular chaperone expression and facilitating unfolded protein degradation 
[303]. These functions are mainly carried out through three canonical pathways initiated by 
dissociation of GRP78 to three ER resident transmembrane proteins, namely inositol-
requiring protein 1 (IRE1), PKP-like endoplasmic reticulum kinase (PERK), and activating 
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transcription factor 6 (ATF6) (Fig. 1.12) [304]. Consequently, this dissociation allows the 
activation of these three mediators.  
IRE1 IRE1 is composed of a luminal ER stress-sensing domain and a cytoplasmic domain 
that has both serine/threonine kinase activity and endoribonuclease activity [151]. There are 
two isoforms of IRE1 in mammalian cells, IRE1  and IRE1 [305]. Upon sensing ER stress, 
GRP78 is released from the binding site and the luminal domain of IRE1 undergoes 
dimerization, allowing the cytoplasmic domains to be close to the ER membrane [151]. This 
change facilitates transautophosphorylation of IRE1 kinase domain, which in turn activates 
the endoribonuclease domain [306]. The endoribonuclease activity of IRE1 is essential for 
the activation of X-box binding protein 1 (XBP1), which is a basic leucine zipper (bZIP) 
transcriptional factor that regulates a number of UPR genes [151]. Maturation of XPB1 
requires non-conventional mRNA splicing where IRE1 endoribonuclease initiates the 
removal of a 26 nucleotide intron from XBP1 mRNA, producing a larger form of XPB1 [111, 
307]. The unspliced form of XPB1 (uXPB1) is inactivate, whereas the spliced form (sXBP1) 
is able to translocate into the nucleus and bind to ER stress response element (ERSE) that 
contains UPR gene promoters [111, 307]. Known targets of sXBP1 include molecular 
chaperones, such as GRP78 and genes involved in ER associated protein degradation (ERAD) 
[308]. In addition, activated IRE1 binds the adaptor protein TNF receptor associated factor 2 
(TRAF2) to activate apoptosis signal-regulating kinase 1 (ASK1), which subsequently 
phosphorylates and activates c-Jun N-terminal kinase (JNK) [309]. 
PERK Similar to IRE1, PERK is a serine/threonine protein kinase with a ER stress-sensing 
luminal domain [151]. Upon dissociation from GRP78, PERK is activated through 
oligomerization in ER membrane and transautophosphorylation [310]. Activated PERK 
subsequently phosphorylates the  subunit of eukaryotic translational initiation factor 2 
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(eIF2), leading to its inactivation and global translation attenuation [311]. However, 
translation of activating transcription factor 4 (ATF4), a member of the bZIP family of 
transcription factors, is selectively upregulated by eIF2 phosphorylation, and induces the 
expression of genes involved in amino acid biosynthesis and transport, anti-oxidative stress 
response, and apoptosis, such as growth arrest and DNA damage 34 (GADD34) [312], and 
C/EBPα-homologous protein (CHOP or GADD153) [313]. At the late stage of ER stress, 
prolonged CHOP activation can trigger apoptosis through the downregulation of anti-
apoptotic protein B cell lymphoma 2 (BCL2) [313].  
ATF6 ATF6 is another bZIP-containing transcription factor consisting of two isoforms, 
namely ATF6 and ATF6 [151]. In response to ER stress, the dissociation of GRP78 allows 
ATF6 trafficking to the Golgi complex, where ATF6 is cleaved by two proteases, site-1 
protease (S1P) and site-2 protease (S2P) [314]. Like XBP1, only the cleaved form of ATF6 
translocates to the nucleus, where it binds to ERSE in the promoter of UPR genes [151]. 
Known target genes of ATF6 include chaperone protein GRP78, protein disulphide 
isomerase (PDI) and ER degradation-enhancing -mannosidase-like protein 1 (EDEM1) 
[315]. 
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Figure 1.12 A schematic diagram of the classic unfolded protein response (UPR) 
pathway. Adapted from Flamment, M. et al. 2012 [293]. Accumulation of unfolded proteins 
triggers ER stress, which initiates the UPR as an adaptive mechanism. The UPR dissociates 
the molecular chaperone 78-kDa glucose-regulated protein (GRP78) from its binding partners, 
including inositol-requiring protein 1 (IRE1), PKP-like endoplasmic reticulum kinase 
(PERK), and activating transcription factor 6 (ATF6). Unbound GRP78 can facilitate protein 
folding in the ER lumen. Meanwhile, this dissociation activates the master proteins PERK, 
IRE1 and ATF6, which initiate three canonical pathways aiming to attenuate translation and 
to enhance protein folding and degradation.  
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1.4.2 ER stress and lipid metabolism 
ER is the major organelle that involves in lipid metabolism and lipid synthesis [299]. UPR 
activation in response to ER stress stimuli can lead to dysregulation of lipid metabolism and 
ectopic lipid accumulation [182]. It has been reported that ER stress can lead to hepatic 
steatosis with increased triglycerides and cholesterols in vitro and in vivo [299]. These 
changes are associated with the activation of SREBP and can be abolished by overexpression 
of molecular chaperone GRP78 [316]. GRP78 overexpression in the liver of ob/ob mice 
attenuates ER stress and inhibits SREBP1c maturation, which leads to a reduction in the 
expression of SREBP target genes, and as a consequence, liver triglyceride and cholesterol 
contents are reduced and insulin action is improved [294]. 
IRE1 plays a key role in maintaining lipid homeostasis [151]. Genetic ablation of IRE1 in the 
liver results in moderate steatosis in chow fed mice, which is exacerbated after the induction 
of ER stress that accompanied by increased expression of lipogenic transcription regulators 
peroxisome proliferator-activated receptor  (PPAR), CCAAT/enhancer-binding protein  
(C/EBP), ChREBP, and LXR, as well as their targets genes DGAT2, ACC1 and SCD1 
[317]. IRE1 downstream effector named XPB1 is suggested to have an independent role in 
lipogenesis [111]. Site-specific deletion of XBP1 in the liver results in downregulation of 
lipogenic enzymes, such as SCD1 and ACC2, and induces hypocholesterolemia and 
hypotriglyceridemia, suggesting that XBP1 is required for lipid synthesis in the liver [111]. 
Spliced form of XBP1 (sXBP1) has also been reported to interact with the promoter of the 
SREBP1c gene and induce the expression of SREBP1c and FAS [307].  
PERK is essential for lipogenesis in adipocytes and mammary epithelial cells [151]. In PERK 
and eIF2 dependent manner, SREBP maturation is dependent on Insig1 translation 
attenuation while PERK deletion in mammary epithelium inhibits the expression of lipogenic 
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enzymes such as FAS, SCD1 and ATP citrate lyase (ACL) [318]. Subsequently, contents of 
triglyceride and fatty acid are reduced in the PERK deficient mammary gland [318]. Genes 
that are responsible for fatty acid  oxidation including PPARα, CPT1 and ACOX1 are all 
significantly upregulated in the white adipose tissue of ATF4 knockout mice, while the 
expression of key lipogenic proteins SREBP1c, FAS and SCD1 are suppressed during 
enhancement of lipolysis which is measured by elevated glycerol release rate, increased 
hormone-sensitive lipase (HSL) activity as well as upregulated Atgl and Perilipin A 
expression [319]. 
ATF6 is also believed to play an important role in lipid metabolism under certain conditions 
[151]. A study in the liver of ATF6 knockout mice showed induction of ER stress with 
tunicamycin resulted in triglyceride and cholesterol accumulation as well as lipid droplet 
formation which is attributed to impaired fatty acid -oxidation, due to the reduction in 
expression of PPAR, CPT-II and acyl-CoA oxidase 1 (ACOX1); and suppressed lipoprotein 
secretion caused by the decrease in Apolipoprotein B100 (ApoB100) expression [320]. 
Interestingly, de novo lipogenesis (DNL) in the liver of ATF6 knockout mice was 
suppressed and to a degree similar to the control littermates after tunicamycin injection [320]. 
However, ATF6 does not seem to play a role in DNL induced by high-fructose diet [153] or 
activation of PPAR [65]. 
1.5 Autophagy in the liver  
An understanding of autophagy was firstly introduced by Christian de Duve and Wattiaux in 
1957, characterizing a biological phenomenon of autophagy [321] in mammalian cells [322]. 
Auto is derived from Greek meaning ‘self’ and phagy means ‘eating’, the autophagy pathway 
is a ‘self-eating’ catabolic/metabolic mechanism, which is activated to maintain cellular 
homeostasis by protein/lipid degradation and turnover of destroyed cellular organelles [323-
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328]. As the role of autophagy is effective for disposing damaged cell structures caused by 
stresses and recycling cellular debris caused by protein/lipids degradation, the autophagy 
pathway has been implicated in numerous pathological and physiological conditions in 
humans, such as immunity, cancer, metabolic syndrome, T2D, and diseases of heart and liver 
[329]. 
Autophagy in liver is essential for whole-body energy homeostasis, balance of nutrients for 
basic cell functions, the removal of misfolded proteins resulting from genetic mutations or 
pathophysiological stimulations, and the turnover of major subcellular organelles such as 
mitochondria, ER stress, peroxisomes under both normal and pathophysiological conditions 
[328]. Hence, dysfunction of autophagy in the liver is believed to have an important impact 
on liver physiology and liver disease. 
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Figure 1.13 A schematic view of autophagy in numerous pathological and physiological 
conditions. Adapted from Klionsky D. J. 2010 [329]. Autophagy is associated with metabolic 
syndrome including insulin resistance and obesity, T2D and NAFLD. Generally the 
autophagy pathway is implicated in many physiological and pathological conditions, such as 
infections, neurodegenerative diseases, stress-induced ailment, aging, cancer, starvation, 
metabolic syndrome, lipid metabolism, heart disease and liver disease. Failure of autophagy 
function can lead to the cause of these certain conditions. 
1.5.1 Subtypes of the autophagy pathway 
Autophagy is generally described as a term for degradation of cytoplasmic components 
within the lysosome [325]. Degradation of intracellular components is mediated by three 
different subtypes of autophagy, namely 1) macroautophagy, 2) microautophagy and 3) 
chaperone-mediated autophagy, while degradation of extracellular materials is mediated by 
endocytosis in the lysosome system, which is not well understood at this stage [330] (Fig. 
1.14). These three types of autophagy differ in how the cytoplasmic materials are delivered 
into the lysosome [328], and the term ‘macoautophagy’ generally refers to ‘autophagy’ due to 
a bulk sequestration process and degradation of damaged or excess organelles [331]. 
Macroautophagy (autophagy) Autophagy is a non-selective process that involves the 
formation of a double-membraned autophagosome to include protein/lipid targets or 
organelles, which sequentially fuses with lysosome to form an autolysosome before the 
substrates is degraded forming autophagolysosome to function its role in removing or 
recycling cellular debris, proteins and lipids, metabolism of lipid and energy, and 
regeneration [324, 325, 328-335].  
Microautophagy Similar to a general autophagy, it is a non-selective process that shows a 
direct engulfment of cytosolic components into the lysosome through a single-membrane 
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formation of intralumenmal vesicles [324, 325, 328-335]. This is believed to be degraded by 
lysosomal hydrolases in cooperation with the late endosome. 
Chaperone-mediated autophagy Different from the two types of autophagy explained above, 
it is a selective degradation process, in which targeted proteins are recognized by chaperone 
proteins, such as heat shock cognate protein 70 (HSC70) and its co-chaperones including Hip, 
Hop, Bag1, heat shock protein 40 (HSP40) and heat shock protein 90 (HSP90). Delivered to 
the lysosome as a complex to bind to the multiunit lysosomal membrane protein LAMP2A on 
the lysosomal membrane, chaperone-mediated autophagy further leads to substrate 
translocation for degradation by lysosomal protease [328, 330, 336].  
 
Figure 1.15 A schematic view of three subtypes of autophagy. Adapted from Schneider, 
J.L., & Cuervo, A.M. 2014 [330]. Three different modes of autophagy are termed 
macroautophagy, microautophagy and chaperone-mediated autophagy. Macroautophagy 
usually termed autophagy, degrades damaged or excess organelles in certain conditions 
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through a portion of the cytoplasm that is sequestered into a double-membrane 
autophagosome, which then fuses with the lysosome/vacuole. Microautophagy is a process 
for sequestration of cytosolic materials through direct invagination of the lysosomal 
membrane, where chaperone-mediated autophagy involves the translocation of 
unfolded/misfolded substrates across the lysosome membrane. 
1.5.2 Types of selective autophagy 
Autophagy can be a selective process for degradation to remove misfolded/damaged proteins, 
lipid droplets or cellular organelles, such as mitochondria, ER and persoxiome during normal 
or pathophysiological conditions. Hence, there are different types of selective autophagy for 
degradation in relation to this thesis, and these are so called 1) mitophagy, 2) lipophagy and 3) 
ERphagy. 
Mitophagy Selective autophagy occurs to clear damaged or unwanted organelles, including 
mitochondria, to maintain quality control. This process is for selective degradation of 
mitochondria by autophagy, termed mitophagy [337] (Fig. 1.15). Mitophagy is believed to be 
a key process in keeping the cell functioning normally by promoting turnover of 
mitochondria and preventing accumulation of dysfunctional mitochondria which can lead to 
cellular degeneration [338]. It is mediated by autophagy related gene 32 (Atg32) in yeast, 
NIP3-like protein X (NIX), PTEN-induced putative kinase 1 (PINK1) and parkin protein. 
Mitophagy occurrence is not only limited to the damaged mitochondria but also undamaged 
subcellular orangelles [338]. 
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Figure 1.15 A schematic view of mitophagy. Adapted from Ashrafi, G. et al. 2013 [337] & 
Youle, R.K. et al. 2011 [338]. Mitophagy involves sequestration of an entire mitochondrion 
mediated by autophagy related gene 32 (Atg32), NIP3-like protein X (NLX) and PTEN-
induced putative kinase 1 (PINK1) from parkin protein within a double membrane called 
autophagosome, followed by fusion with a lysosome. 
 
Lipophagy Break down of triglyceride and/or cholesterol stored in lipid droplets by a form of 
lysosomal degradation in autophagy is so called lipophagy [327, 339, 340]. Lipophagy is an 
essential selective process which impacts on the cellular energy balance by functioning to 
regulate intracellular lipid stores, that is cellular levels of free lipids including fatty acids (Fig. 
1.16) [339, 340]. It has been linked to important metabolic disorders such as fatty liver, 
NAFLD, obesity, insulin resistance and metabolic syndrome, and thus impaired lipophagy 
can be the cause of these disorders [339].   
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Figure 1.16 A schematic view of lipophagy. Adapted from Liu, K. et al. 2013., Singh, R. et 
al. 2012., &Webb, A.E. et al. 2014 [339-341]. Portions of large lipid droplets are sequestered 
by a double membrane autophagosome either in combination with other cellular parts or as a 
cargo itself. Breakdown of lipid through lipophagy then leads to the cytoplasmic degradation 
producing free fatty acids to sustain mitochonidral β-oxidation, which generates adenosine 
triphosphate (ATP) to maintain cellular energy metabolism. 
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ERphagy A major mechanism for organelle function in homeostatic control is UPR, which is 
a signalling pathway triggering the ER and the biosynthesis pathway [151]. Activation of the 
UPR is suggested to induce the organelle specific binding degradation process of autophagy 
selectively targets the ER, termed ERphagy (Fig. 1.17) [342]. ERphagy generates double-
membrane autophagosomes including ER membranes from the ER, which serves as a 
membrane source for autophagosome formation that further involves of ER engulfment by 
itself through ERphagy [342]. It is believed that ERphagy removes damaged or redundant 
parts including unfolded/misfolded proteins of the ER, and thus it represents an important 
degradative process that regulates homeostatic control. 
 
Figure 1.17 A schematic view of ERphagy. Adapted from Bernales, S. et al. 2007., & 
Bravo-Sagua, R. et al. 2014 [342, 343]. A double-membraned autophagosome is formed with 
involving engulfment of ER by organelle specific selective degradation autophagy, so called 
ERphagy. During this process, autophagosomes selectively interact with damaged portions of 
the ER as a protective mechanism against misfolded/unfolded proteins. 
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1.5.3 Autophagy process and regulation 
Autophagy process Autophagy has been well characterised in yeast and in mammalian cells 
to a lesser extent. The process is mediated by numerous autophagy-related genes (Atgs) and 
associated enzymes. As shown in Fig. 1.18, autophagy initiates the formation of the 
phagophore, which is a fragment of double-membrane sequestered from ER, Golgi apparatus, 
or endosomes [325, 330]. This step requires the invovlement of UNC-51-like kinase 1 (ULK1) 
complex composed of FIP200 also known as RB1CC1, Atg13l and Atg101, and a class III 
phosphatidylinositol 3-kinase (PI3K) complex composed of vacuolar protein sorting 34 
(VPS34), p150, Atg14 and Beclin1 [325]. 
After being sequestered, the isolated membrane undergoes elongation to form autophagy 
vesicles named autophagosomes [325]. This requires two ubiquitin-like systems in parallel, 
Atg5-Atg12 complex including Atg7, Atg10, Atg16L and LC3 complex [325, 330]. LC3 is 
expressed as a full length cytosolic protein cleaved by cysteine protease Atg4 to expose a 
carboxyl glycine, generating LC3I, which is further activated by E1-like activating enzyme 
Atg7 and transferred to E2-like conjugating enzyme Atg3 [344]. In addition to this, LC3I is 
conjugated to phosphatidylethanolamine (PE) via the carboxyl glycine to generate LC3II that 
persists after the fusion of autophagosome and lysosome, while the Atg5-Atg12 complex is 
released into cytosol when the autophagosome is completed [344]. LC3 is suggested to be a 
key marker for monitoring autophagy as biosynthesis and processing of LC3 is increased 
during autophagy [344].  
Cytosolic components, such as protein aggregates, organelles and ribosomes are engulfed 
during phagophore elongation before the enclosed autophagosome. Growing evidence 
suggests phagophore membrane can selectively interact with autophagy targets, even though 
autophagy is considered as a non-selective degradation process. It is proposed that LC3II acts 
as a cargo receptor on the phagophore and recruits an adaptor protein so called nucleoportin 
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p62/sequestosome 1 (p62/SQSTM1), which promotes degradation of poly-ubiquitinated 
protein aggregates  and bind targets to autophagy [345]. Upon completing the formation of 
autophagosome, its outer membrane is fused with the lysosome which may carry lipogenic 
enzyme like SREBP1c and transcriptional factor, such as FoxO1, under certain conditions to 
form an autolysosome [330, 341]. After autophagosomes are fused with lysosomes, the 
autophagosomal contents are degraded by lysosomal acid proteases, resulting in hydrolysis 
products, such as amino acids, which transport back to the cytoplasm, where they can be re-
used for protein synthesis or energy generation [323-325, 330].  
Autophagy regulation Autophagy is responsive to nutrient and energy status, which can be 
monitored by the mammalian target of rapamycin (mTOR) and AMPK respectively [346]. 
mTOR is a serine/threonine kinase that can be activated by a number of stimuli including 
amino acids and hormones to coordinate protein synthesis, cell growth and cell proliferation 
[347]. mTOR acts in two forms of complexes, and these are 1) mTOR complex 1 (mTORC1); 
and  2) mTOR complex 2 (mTORC2). mTORC1 functions to regulate autophagy by 
interacting with the ULK1 complex under nutrient deficiency to allow autophagy induction 
through inactivation of mTORC1, which activates phosphorylation of ULK1 complex [347]. 
It also regulates autophagy indirectly through interaction with transcription factor EB (TFEB), 
which promotes autophagy and lysosome biogenesis, while directly phosphorylated TFEB by 
mTORC1 results in its binding to a 14-3-3 family member (YWHA) for consequent nucleus 
exclusion [58, 347]. mTORC2 consists of the rapamycin-insensitive companion of mTOR 
(RICTOR), GβL, mammalian stress-activated protein kinase interacting protein 1 (mSIN1) 
and Protor ½ that contribute to the regulation of autophagy through the Akt-FoxO axis, where 
FoxO mediates the expression of a number of autophagy genes [58, 341, 347]. 
AMP activated protein kinase (AMPK) is another serine/threonine kinase, consisting of a 
catalytic  subunit which is phosphorylated to activate calcium/calmodulin-dependent kinase 
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kinase  (CAMKK) and serine/threonine kinase 11 (STK11, also liver kinase B1, LKB1). 
AMPK stimulation induces autophagy, a scaffolding  subunit, and a regulatory  subunit,  
which senses energy status through the ratio of ATP to AMP, and is activated when energy 
levels are low [346]. AMPK is required for ULK1 activation and autophagy induction during 
glucose starvation, while AMPK inhibits mTORC1 and relieves mTORC1-mediated 
repression on autophagy [346]. In addition, AMPK indirectly promotes autophagy gene 
expression via activation and nuclear relocalization of the forkhead box protein O3 (FoxO3) 
transcription factor [348]. 
 
Figure 1.18 A schematic view process and regulation of autophagy. Adapted from 
Schneider, J.L. et al. 2014., & Webb, A.E. et al. 2014 [330, 341]. A portion of cytoplasm is 
enclosed by a phagophore with autophagy related proteins and enzymes to form an 
autophagosome by engulfment. Then the outer membrane of the autophagosome fuses with 
the lysosome to form an autophagolysosome, where the internal material is degraded to be 
cleared or recycled. This process of autophagy is regulated by well known signalling 
pathways, such as the mammalian target of rapamycin (mTOR), AMP activated protein 
kinase (AMPK) and AKT-forkhead box protein O (FoxO).  
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1.5.4 Interrelationship between autophagy and lipid metabolism 
Macrolipophagy is termed for interrelationship between the autophagy pathway and lipid 
metabolism [112, 327, 340]. It has been reported that autophagy regulates lipid contents by 
showing increased level of TGs and lipid droplets (LDs) in vitro and in vivo when deficiency 
of autophagy occurs [112]. Decreased activity of autophagy loses function of TGs breakdown 
as TGs and LDs structural proteins are known to co-localize with autophagic comartments, 
whereas LC3 is closely associated with LDs. In reverse, an abnormal increase in intracellular 
lipid impairs autophagic clearance by decreased LD/LAMP1 co-localization, loss of 
autophagic upregulation and reduced association of autophagic vacuoles with LDs in 
response to starvation [340]. These reports suggest that decreased autophagy activity is likely 
to promote lipid accumulation that may further suppress autophagic function, thereby 
increasing lipid retention in liver. Decreased autophagy in the liver may contribute to hepatic 
lipid accumulation that occurs along with an increased metabolic syndrome, wherears the 
ability of increased lipid content to impair autophagy may indicates decreased autophagic 
function due to the lipid accumulation [112].  
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Figure 1.19 A schematic view of interrelationship between autophagy and lipid 
accumulation. Adapted from Singh R, Cuervo A.M., & Czaja M. J. et al. 2009 [112]. During 
feeding, autophagy functions in the basal turnover of lipids from lipid droplets as shown in 
the left panel. Autophagy is increased in response to a short-term increase in lipid availability 
or starvation that leads to a greater breakdown of stored lipids to supply fatty acids for β-
oxidation or other uses (shown in center panel). Lipid accumulation acts to inhibit or decrease 
autophagic functions, therby further promoting lipid accumulation with increased size of LDs 
(right panel). 
1.5.5 Autophagy and Metabolic diseases of the liver 
The role of autophagy in liver is complicated. Earlier, autophagy is described in directly 
controlling lipid catabolism both in vitro and in vivo, and there is evidence to show 
autophagosomes co-localize with lipid droplets and direct them toward lysosomal 
degradation, which is more active during starvation [112]. Additionally, in both wild type and 
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Atg7 knockout mice, high fat feeding reduces lipid containing autophagosomes, along with 
accumulation of enlarged lipid droplets [112]. Knockout of another key autophagy protein, 
VPS34, in the liver, results in reduced glycogen content, accumulated lipid droplets and 
defective mitochondrial fusion [349]. Genetic deletion of hepatic transcription factor EB 
(TFEB) has similar effects on lipid accumulation in the liver after starvation or HF feeding 
[350]. In contrast to these findings, decreased hepatic lipid content has been reported in 
autophagy deficient mice [351], where this effect is shown to enhanced lipid catabolism by 
an increase in FGF21 secretion [351], as well as downregulation of lipogenic enzymes in the 
liver with autophagy deficiency [352]. Also, autophagy coordinates glucose metabolism 
through regulation of gluconeogenesis and glycogen storage [352].  
1.6 Summary, aims and thesis focus 
Liver is a vital organ in our body, having a complex role that functions in relation to 
metabolism of glucose, lipid and protein, immunity, detoxification, restoration and nutrient 
storage (Section 1.1). If disrupted lipid metabolism occurs, and it is likely to cause 
triglyceride/lipid accumulation in excessive amounts in the liver, thus resulting in a fatty liver 
(Section 1.1.1). The fatty liver develops to insulin resistance syndrome which consists of 
obesity, dyslipidaemia, hyperglycaemia and hypertension, major risk factors of T2D (Section 
1.1.3) and NAFLD (Section 1.1.2).  While the causes of insulin resistance are multifactorial, 
over comsumption of dietary fat is one of the major nutrient contributors and results in 
dysregulated lipid metabolism, leading to the accumulation of ectopic lipids and 
intermediates in the liver (1.2.2).  It is believed that the lipid accumulation interferes with 
insulin signalling and that lipid metabolism is regulated by transcription factors named 
PPARα and PPARγ which are also involved in fatty acid metabolism in the liver (Section 
1.3.3).  
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While PPARα and PPARγ regulate lipogenesis and lipid metabolism through fatty acid 
metabolism, it remains unclear how these lipid metabolism regulating transcriptional factors 
are involved in liver either directly or indirectly. The process for cellular debris degradation 
for recycling is the so called autophagy pathway, which is closely associated with lipid 
metabolism in the liver (Section 1.5). However, the role of autophagy in diet-induced 
transcriptional factors named, PPARα and/or PPARγ in coordination to lipid metabolism on 
remains to be investigated. 
Hence, my overall aim for this thesis is to investigate the role of the autophagy pathway in   
PPARα and/or PPARγ induced by its specific pharmacological activator named fenofibrate 
and rosiglitazone rescpectively, in relation to lipid metabolism. Also the possible mechanisms 
involved in PPARα and/or PPARγ induced changes in the hepatic autophagy pathway will be 
investigated (Fig. 1.19). As both lipid regulating transcriptional factors PPARγ and PPARα 
are closely associated with lipogenesis, the first aim is to identify the effect/role of PPARγ on 
autophagy in relation to lipid metabolism during high fat feeding in liver of rats. The second 
aim, in liver of mice during high fat feeding, will investigate the role/effect of PPARα on 
autophagy. Once the possible role or effect of the autophagy pathway is discovered from 
using these two transcriptional factors, I will further evaluate the possible mechanisms 
involved in the associated changes. 
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Figure 1.20 A schematic view of the overall research aims. Detailed description is 
explained in Section 1.6. 
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Chapter 2- Materials and Methods 
2.1 Introduction 
In this Chapter 2, detailed methods and techniques used for presented research studies in the 
following Chapter 3, 4 and 5 are described. Specifically, relevant methods and techniques for 
a particular study are designated in the corresponding Chapters. External collaborators are 
appropriately well acknowledged and their roles are clearly indicated. 
2.2 Animal Studies 
All experimental procedures or protocols were approved by the Animal Ethics Committee of 
RMIT University (#1012 and #1206) in accordance with the National Health and Medical 
Research Council of Australia Guidelines on Animal Experimentation. 
Wistar male rats (between 10-30 weeks of adult age) and male C57BL/6J mice (10 weeks old) 
were purchased from the Animal Resources Centre (Perth, Australia). They were housed at 
22±1°C on a 12-h light/dark cycle in the animal house of the Research Animal Facility at 
RMIT University. Prior to the commencement of actual animal experiments, animals were 
acclimatized at least for one to two weeks during which they had freely access to the normal 
standard chow diet and water ad libitum. 
In collaboration with Professor Aimin Xu’s Laboratory at the Hong Kong University, male 
mice, at the age of 10-16 weeks, of PPARα knockout (PPARα-/-) and FGF21 knockout 
(FGF21
-/-
) in C57BL/6N and C57BL/6J backgrounds respectively, were obtained from 
Jackson Laboratories (Sacramento, CA). The animal experiment of fenofibrate (FB) 
treatment was approved by the Animal Ethics Committee of the University of Hong Kong in 
China. The mice were housed at 23±1°C on a 12-h light/dark cycle with unrestricted access to 
water and standard chow diet. PPARα-/- and FGF21-/- mice were fed with FB (50mg/kg/day) 
or normal chow (CH) for three weeks. After the experiment, the mice were sacrificed by 
cervical dislocation and tissues were collected for further study. The particular liver tissues of 
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PPARα-/- and FGF21-/- mice treated with or without FB (50mg/kg/day) were obtained for 
studies reported in this thesis. 
2.2.1 Diet preparation for the animals 
The normal standard chow (CH), which is a meat free diet for rat and mouse, was purchased 
from Specialty Feeds in Western Australia. CH consists of 12% calories from fat, 23% from 
protein, and 65% from carbohydrate. The digestible energy from CH diet is 3.34kcal per kg.  
The high fat (HF) diet was prepared at the Lipid Biology and Metabolic Disease Laboratory 
of RMIT University and used in two different percentages of fats, 60% and 45%, for rats and 
mice respectively. 60% fat induced HF diet was prepared in-house based on the previous 
publications from our laboratory [246, 353-355] using the recipe reported in Table 2.1, where 
5.40 kcal/kg is the digestible energy. The 45% HF diet was prepared in-house based on the 
previous publications from our group [65, 356] using the recipe reported in Table 2.2, and the 
digestible energy is 4.94kcal/kg.  
Table 2-1 Composition of the 60% high fat (HF) diet for rats 
Prepared Ingredients Amount (g) 
 
Manufacturer 
 
Catalogue No. 
CASEIN 400.0 MPD Dairy Products ACIDCASEIN 
SUCROSE 134.0 Hudson Pacific Corp. #84097 
STARCH 266.0 Hudson Pacific Corp. #S4126 
Mineral Mix (Homemade) 70.0 MP Biomedicals #290545502 
Trace Minerals(ICN) 20.0 MP Biomedicals #296026401 
BRAN 80.0 Hudson Pacific Corp. #BC20KGA 
METHIONINE 4.0 Sigma-Aldrich #M9500 
GELATINE 30.0 Hudson Pacific Corp. #GEPO1 
Choline Bitartrate 7.0 Sigma-Adrich #C1629 
On the Day Add:   
Lard, 
Safflower Oil 
or Tallow 
Safflower 
oil 
74.8 
Stoney Creek Oil 
Products 
SAFFLOWER 
Lard 459.2 Allowrie 
Prime Lard of 
Fonterra#46716002 
AIN Vitamins 20.0 MP Biomedicals #296009801 
  
Total diet weight 1565.0  
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Table 2-2 Composition of the 45% high fat (HF) diet for mice 
Prepared Ingredients Amount (g) 
 
Manufacturer 
 
Catalogue No. 
CASEIN 261.0 MPD Dairy Products ACIDCASEIN 
SUCROSE 230.0 Hudson Pacific Corp. #84097 
STARCH 193.0 Hudson Pacific Corp. #S4126 
Mineral Mix (Homemade) 51.0 MP Biomedicals #290545502 
Trace Minerals(ICN) 14.8 MP Biomedicals #296026401 
BRAN 57.0 Hudson Pacific Corp. #BC20KGA 
METHIONINE 3.4 Sigma-Aldrich #M9500 
GELATINE 23.0 Hudson Pacific Corp. #GEPO1 
Choline Bitartrate 4.6 Sigma-Adrich #C1629 
On the Day Add:   
Lard, 
Safflower Oil 
or Tallow 
Safflower 
oil 
34.0 
Stoney Creek Oil 
Products 
SAFFLOWER 
Lard 250.0 Allowrie 
Prime Lard of 
Fonterra#46716002 
AIN Vitamins 14.8 MP Biomedicals #296009801 
  
Total diet weight 1136.6  
 
2.2.2 Measurement of whole body metabolic parameters  
The whole body metabolic rate was measured at 22ºC using an indirect calorimeter 
(Comprehensive Laboratory Animal Monitoring System, Columbus Instruments, OH, USA) 
on week 2 of each experimental study based on the previous publications from our laboratory 
[65, 356]. The animals were weighed and placed in the metabolic chamber (20 cm × 10 cm × 
12.5 cm) at 6:00 p.m. After overnight acclimation, oxygen consumption (VO2) and 
respiratory exchange rate (RER) were monitored for 24 hours according to manufacturer’s 
instructions. RER is a ratio of VO2 and VCO2. During the experiment, mice had ad libitum 
access to food and water.  
2.2.3 Glucose tolerance test 
Glucose tolerance tests were performed after 3 weeks and 4 weeks after feeding based on the 
previous publications from our laboratory [65, 356, 357]. Blood samples were collected from 
the tail tip for the measurement of blood glucose and insulin levels.  Blood glucose levels 
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were measured using a glucometer (Accu-Chek, Roche). Insulin levels were determined by 
radioimmunoassay (Merck Millipore, #SRI-13K). Animals were fasted for 5-7 hours and 
basal blood glucose and insulin levels were measured at 0 min. Glucose (1.5 g/kg BW or 2.0 
g/kg BW) was administrated to animals by intraperitoneal injection (i.p). The glucose (1.5 
g/kg BW) was used in the mouse model (Chapter 4 & 5), while the other dosage of glucose 
(2.0 g/kg BW) was used in the rat model (Chapter 3). Subsequently, blood glucose levels 
were measured at 15, 30, 60 and 90 min and blood samples were collected at 0, 5, 30, 60 and 
90 min for the measurement of insulin.  
The measurement of insulin is based on a double antibody technique as previously reported 
[65, 356, 357], using 125I-labelled insulin and a specific rat insulin antiserum. 100 µl of 
plasma sample was added to 100 µl of hydrated 125I-insulin, followed by the addition of 100 
µl insulin antibody overnight at 4°C. The next day, 1 ml of cold precipitating reagent was 
added to each tube and incubated at 4°C for 20 mins after vortexing. All samples were then 
centrifuged at 2000x g for 20 mins at 4°C. After centrifugation, the supernatant was 
immediately discarded and the pellet was dried. All samples were counted in a gamma 
scintillator counter (Perkin Elmer, USA) for 1 min. Total count tubes were used as reference. 
The coefficient of variation was less than 10% within and between assays. 
2.2.4 Hyperinsulinemic euglycemic clamp technique 
Hyperinsulinemic euglycemic clamp technique was performed as previously reported in 
publication from our research group [354, 355]. This measurement has been known as the 
gold standard for studies in diabetes drug development and diagnostic evaluation [36]. Often 
this method is to measure insulin sensitivity and resistance. The hyperinsulinemic euglycemic 
clamp requires maintaining a high insulin level by perfusion or infusion with insulin; it is a 
way to quantify how sensitive the tissue is to insulin [36, 353, 354]. Plasma insulin 
concentration was acutely raised and maintained at 100 μU/ml by a continuous infusion of 
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insulin [354]. Meanwhile, plasma glucose concentration was held constant at basal levels by 
a variable glucose infusion [353, 354]. When a steady state was achieved, the glucose 
infusion rate was said to equal glucose uptake by all the tissues in the body and was therefore 
a measure of tissue insulin sensitivity [353, 354].  
The hyperinsulinaemic clamp was performed at an insulin infusion rate of 0.25 U·kg
-1
·h
-1 
to 
elevate circulating insulin levels to a half-maximal physiological concentration [37, 246, 353, 
355, 358] with glucose infused at variable rates (GIR) to maintain euglycaemia. After plasma 
glucose levels reached the designated steady state, a bolus of 2-deoxy-D-[2,6-
3
H] glucose 
(2DG) and D-[U-
14
C] glucose was injected (i.v.) to determine glucose disappearance rate 
(Road) and hepatic glucose output rate (HGO). Under the euglycaemic conditions, HGO was 
calculated as Road – GIR where Road was determined by counting [14C] of the plasma 
collected at 2, 5, 10, 15, 20, 30 and 45 min after the tracer injection, as validated by this 
laboratory [359]. Glucose concentrations during the hyperinsulinaemic clamp in rats were 
determined using a glucose analyser (YSI 2300, YSI Inc., Yellow Springs, OH, USA). 
2.2.5 Animal dissection and Collection of tissue samples 
Rats and mice were fasted for 5-7 hours before tissue collection. Blood samples were 
collected from the tail and centrifuged at 9000 rpm for the isolation of plasma. Liver, 
epididymal fat, subcutaneous fat and quadriceps muscle were harvested and weighted using 
an analytical balance. Liver tissues were kept in 10% neutral buffered formalin (Sigma-
Aldrich, #HT501128-4L) for paraffin-embedding and in OCT compound (Sakura Finetek) for 
frozen sections to examine morphological histology of the tissue. Other tissue samples were 
freeze-clamped and stored at -80C. 
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2.3 Histological Study 
2.3.1 Hematoxylin and Eosin (H&E) Staining  
Liver tissues stored in the 10% neutral buffered formalin were dehydrated using Leica tissue 
processor based on the previous publication from our group [357]. The dehydrated samples 
were embedded by paraffin and cut into 5-μm-thick sections. These sections were put into 
warm water and then transferred to the glass slides. The slides were dried overnight at 37 ºC. 
Before the H&E staining, all of slides were deparaffined by immersing in 2*Xylene (3 min) 
and a gradient of ethanol (2*100% ethanol for 1 min, 90% ethanol for 1 min, 80% ethanol for 
1 min and 70% ethanol for 1min). The slides were washed in tap water for 2 min and then 
stained in Mayer’s haematoxylin (Grale Scientific, #MH-1L) for 2 min. Followed by a 5 dips 
wash in  tap water, the slides were put into Scott's Blueing Solution (Grale HDS, #SCOT-1L) 
for 1 min to blue the haematoxylin. The slides were washed in tap water for 2 min and 
counterstained in 1% aqueous eosin (Grale Scientific Pty. Ltd., #EOA-1L) for 1.5 min. After 
washed in tap water, the slides were dehydrated by immersing in a gradient of ethanol and 
Xylene. Subsequently, the samples were covered by the coverslips using the mounting 
medium (Grale Scientific Pty. Ltd., #3197). Images of the section were taken by Olympus 
microscope equipped with digital cameras.  
2.3.2 Masson’s Trichrome Staining 
The liver samples were processed and deparaffined as described in H&E staining. Bouin's 
Solution (Sigma-Aldrich, # HT10132-1L) was used to mordant the sections overnight and the 
yellow colour was washed off by distilled water. The nuclei were stained blue by immersing 
Weigert's Iron Hematoxylin Solution (Sigma-Aldrich, # HT1079-1SET) for 5 minutes. The 
slides were washed in tap water for 5 min and rinsed in distilled water. Biebrich Scarlet-Acid 
Fuchsin solution (Sigma-Aldrich, #HT15) was used to stain the cytoplasm red (5 min) and 
the slides were rinsed in distilled water. Before the aniline blue stain, the samples were pre-
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treated in the 1:1 mixture of phosphomolybdic acid solution (Sigma-Aldrich, #HT15) and 
phosphotungstic acid solution (Sigma-Aldrich, #HT15) for 10 min. Next, the slides were 
placed in aniline blue solution (Sigma-Aldrich, #B8563) for 5 minutes to stain the collagen 
blue and rinsed briefly in distilled water. Finally, the slides were left in 1% acetic acid 
solution for 3 minutes and dehydrated as described in H&E staining (Section 2.7.1). 
2.4 Measurement of ALT Levels in the Plasma 
The blood samples were centrifuged at 9,000 rpm to obtain the plasma. ALT levels in the 
plasma samples were measured by ALT/SGPT Liqui-UV Kit (Stanbio). Briefly, 20 uL of 
plasma samples were mixed with 200 uL of reagent (mixed R1 and R2 by 5:1 as described in 
manufacturer’s instructions). Immediately, the absorbance at 340 nM was measured by the 
FlexStation microplate reader (Molecular Devices, USA) every minute for 10 minutes to test 
the activity of ALT. 
2.5 Triglyceride extraction and determination for tissue 
To extract triglyceride from a specific tissue, a pre-weighed sample of tissue (30-40 mg of 
liver majorly in my research studies) was homogenised in 4 ml of chloroform/methanol (2:1) 
using a glass pestle tissue grinder based on the previous publications from our group [355, 
356]. After transferring the homogenate to a clean 15 ml tube, the homogeniser was rinsed 
with another 2 ml of chloroform/methanol (2:1) and added to the homogenate. The tubes 
were tightly capped and rotated at room temperature overnight to ensure the complete 
solubilisation of the triglyceride. The next day, 2 ml of 0.6% NaCl was added to the tubes 
followed by centrifugation at 2,000 rpm for 10 min to separate the aqueous from the organic 
phases. The lower chloroform layer contained triglycerides and was carefully transferred into 
a glass vial and dried completely under the nitrogen or air at 45°C. The extract was 
reconstituted in 500 µl absolute ethanol and the triglyceride concentration was determined by 
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a Peridochrom triglyceride GPO-PAP reagent (Roche Diagnostics, Catalogue No. 11730711). 
The Peridochrom triglyceride GPO-PAP is a manufactured kit to determine liver extracts 
from a tissue. According to the manufacturer’s instructions (Roche Diagnostics), 5 µl of each 
samples were mixed with 300 µl of triglyceride reagent and then incubated at 37°C for 10 
min. The absorbance was measured at 485 nm using a POLARstar microplate reader (BMG 
Labtech, Germany). Internal standards (glycerol solution, Sigma-Aldrich, Catalogue 
No.G5516) were included to create a standard curve ranging from 0 to 1.050 µg/well. 
2.6 Cell studies 
2.6.1 General protocol 
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
(v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin-streptomycin-glutamine (PSG) or 1% 
(v/v) penicillin-streptomycin (PS) at 37 °C in 5% CO2 based on the previous publication 
from our laboratory [360]. All above culture reagents were obtained from Invitrogen 
(Melbourne, Australia). The cell culture medium was changed every two or three days. Cell 
passages of 5 to 20 were used for all experiments. Briefly, cells were sub-cultured at 1 in 5 
dilutions when cells reached 70-80% of confluence. Subculture was made by rinsing the cells 
first with 1x phosphate buffered saline (PBS) buffer (0.2 M NaCl, 10 mM Na2HPO4, 3 mM 
KCl, 2 mM KH2PO4, pH 7.4), then adding 1~2 ml of 1x trypsin-EDTA solution (Sigma-
Aldrich, Melbourne, Australia) to detach the cells from the T75 flask (usually within 1 min). 
Cells were then centrifuged at 100 g for 5 mins and re-suspended in ~5 ml of fresh culture 
medium and were transferred with desired amount into a new T75 flask containing fresh 
growth medium. 
2.6.2 Cell storage 
Cells were washed with 1x PBS, trypsinized with 1x trypsin-EDTA solution and incubated at 
37 °C for 1~2 mins. Cells were then rinsing with 5 ml normal culture media per T75 flask 
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and centrifuged at 100 g for 5 mins. Supernatant was aspirated. The remaining cell pellet was 
re-suspended in 0.5 ml of DMEM / 20% FBS / 15% DMSO / 1% PS or PSG to re-suspend 
cells, mixed. Then 1 ml aliquots were prepared in each cryovial. Cryovials were then 
wrapped in a clean paper towel and transferred to a Nalgene® cryo 1°C freezing container 
(Thermo Fisher Scientific, Australia) filled with 100% isopropanol (Sigma-Aldrich, #I9516), 
and stored overnight at -80 °C. The next day, one of the frozen vials was defrosted to test cell 
viability while the rest of vials were placed in liquid nitrogen for long-term storage. 
2.6.3 Counting number of cells 
Cell numbers were counted using hemocytometer shown in Figure 2.1 (Grace Davison 
Discovery Sciences, Australia). In general, 100 µl of well-mixed cells suspension was placed 
into the counting area of a clean hemocytometer and counted under a microscope (10x or 20x 
objectives) and counted (4 x 16 corner squares). Cell concentration was calculated by 
dividing the total number of counted cells by 4 and multiplying by 2, from all 4 corners of the 
hemocytometer. 
 
Figure 2.1 Hemocytometer 
The calculation formula of counting cells using hemocytometer is:  
             ⁄                            ⁄  
Where:  
                                         (                        ) 
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After cells number reached a desired confluence, the cells were seeded into suitable plate for 
further experiments. 
2.7 Ex-vivo studies 
An interest of particular tissue, and for my studies as the liver is focused, liver tissues are 
collected from CH fed male C57BL/6 mice and immediately put into ice-cold Krebs-
Henseleit Buffer (KHB, pH 7.4, pre-gassed with carbogen). Tissues were then rinsed and 
chopped into 1-2 mm explants, followed by 30 min pre-incubation at 37
o
C under continuous 
gassing with carbogen based on the previous publication from our laboratory [361]. Liver 
explants were then incubated in KHB with or without certain treatments of 50 mM 
fenofibrate, 10mM spermidine, tunicamycin, betulin, GW6471 (PPARα antagonist) for 3 
hours. At the end of the experiments, tissues were pelleted and freeze-clamped for further 
analysis. 
2.8 Immunoblotting (Western Blotting) 
Preparation of all reagents and buffers to run immunoblotting (western blotting) is 
summarized in the following Table 2.3 as previously reported from our laboratory [65, 356, 
357, 360-362].  
Table 2-3 Reagents and Buffers for immunoblotting 
Name Included chemical component 
RIPA buffer 65 mM Trizma® base (Tris. Sigma-Aldrich, Catalogue No. T1503), 
150 mM NaCl, 5mM EDTA, 1% Nonide-P 40 Substitute (NP-40. 
Sigma-Aldrich, Catalogue No. 74385), 0.05% sodium-deoxycholate 
(Sigma-Aldrich, Catalogue No. D6750), 0.1% (w/v) sodium dodecyl 
sulphate (SDS. Sigma-Aldrich, Catalogue No. L4390), 10% glycerol 
(Sigma-Aldrich, Catalogue No. 49770), pH 7.5 and stored at 4°C. 
Lysis buffer 10 mM Sodium fluoride (NaF. Sigma-Aldrich, Catalogue 
No.S7920), 1 mM sodium orthovanadate (Na3VO4. Sigma-Aldrich, 
Catalogue No. S6508), 1 mM phenylmethanesulfonyl fluoride 
(dissolved in 100% ethanol. Sigma-Aldrich, Catalogue No. 78830), 
and 10 µl/ml protease/phosphatase inhibitor (Sigma-Aldrich, 
Catalogue No. P5726) in RIPA buffer. 
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4x Laemmli’s buffer 
(100 ml) 
8.2 g SDS, 40ml glycerol, 50 ml 0.5 M Tris, 500 µl 1% 
bromo-phenol blue (Sigma-Aldrich, Catalogue No. 114391) in 
dH2O, pH 6.8 and stored at -20°C. 6.2 mg DL-dithiothreitol (DTT, 
Sigma-Aldrich, Catalogue No. D9779) are added before use. 
10x Running buffer  
(1 L) 
30 g Tris, 144 g glycine (Sigma-Aldrich, Catalogue No. G8898) and 
10 g SDS in dH2O, pH 8.8 and stored at room temperature. 
10x Transfer buffer 
(1L) 
30 g Tris, 144 g glycine in dH2O and stored at room temperature. 
10x TBS (1 L) 24.2 g Tris and 80 g NaCl in dH2O, pH 7.6 and stored at room 
temperature. 
1x TBST  
(1 L) 
100 ml 10x TBS buffer and 500 µl Tween® 20 (Sigma-Aldrich, 
Catalogue No. P9416) in 900 ml dH2O and stored at room 
temperature. 
Blocking buffer 3% (w/v) Bovine serum albumin (BSA. Sigma-Aldrich, Catalogue 
No. A9418) in 1x TBST and stored at 4°C. 
Stripping buffer  
(1L) 
6.25% 1 M Tris-HCl (pH 6.7), 10% (w/v) 20% SDS in dH2O and 
stored at room temperature. 100 mM 2-mercaptoethanol (Sigma-
Aldrich, Catalogue No. M7154) is added before use. 
2.8.1 Homogenization of tissue 
Freeze-clamped tissues were homogenised in ice-cold RIPA lysis buffer listed in Table 2.4 
and solubilised for 2 hours at 4°C. After centrifugation at 15,000 rpm for 10 min at 4°C to 
eliminate debris, the supernatant from each homogenised sample was collected and stored at -
80°C. 
Table 2-4 RIPA Buffer preparation for protein extraction of tissue 
RIPA Buffer Stock Additional chemical to add on the day 
of protein extraction 
Tris 65mM NaF 10mM 
NaCl 150mM Na3VO4  1mM 
EDTA 5mM PMSF 1mM 
NP-40 1% Protease Inhibitor 10ul/ml 
Na-deoxycholate 0.5% Phosphatase Inhibitor 10ul/ml 
SDS 0.10%  
Glycerol 10%  
 
2.8.2 Quantification of protein 
Protein concentrations were determined by a commercial colorimetric BCA protein assay kit 
(Bicinchoninic acid kit, Sigma-Aldrich, Catalogue No.B9643). 5 µl of sample was mixed 
with 200 µl of reagent mix (reagent A:B = 50:1), and incubated at 37°C for 30 min prior to 
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the determination of absorbance by spectrophotometry at 562 nm using a POLARstar 
microplate reader (BMG Labtech, Germany). In each protein assay, a set of solution with 
different concentrations of BSA protein (0-2 µg/ml) was included as standards, which were 
diluted to different concentration. Working reagent was made following the manufacturer’s 
instructions and pipetted to the plate to start the reaction. Protein concentration of the samples 
was calculated from the standard curve. An aliquot of the samples was dissolved in the 4x 
Laemmli buffer to obtain equal amounts of protein in all samples. The samples were heated at 
37 
o
C for 30 minutes or 90 
o
C for 10 minutes to denature, depending on the specific protein 
being assayed. 
2.8.3 SDS-PAGE (Sodium Dodecyl Sulphate-Polyacrilamide Gel Electrophoresis) 
Tris-glycine based acrylamide gels with different percentages of polyacrylamide were 
prepared for separation of proteins according to their molecular weights shown in Table 2.5. 
Polymerization of the gel was facilitated by the addition of 10% APS and TEMED. After 
polymerization of the running gel listed in Table 2.6, additional relevant amount of Ethanol is 
added to remove unnecessarily formed bubbles. Then, after removal of Ethanol, stacking gel 
in Table 2.7 was poured on top of the running gel and polymerized.  
An aliquot of tissue lysate from each sample was diluted with dH2O to the same 
concentration (e.g. 2.5 μg/μl) containing 4x Laemmli’s buffer. The samples were heated at 
37°C for 30 min prior to SDS-PAGE. The denaturized equal amounts of protein (20- 50 μg) 
samples were subjected to SDS-PAGE gel and separated at 120 V in the running buffer (pH 
8.8, 3 g Tris base, 14.4 g glycine and 1 g SDS in 1 L distilled water). A protein ladder (Bio-
Rad Laboratories Inc., Australia; Catalogue No. 161-0374) was loaded as a reference for the 
estimation of molecular sizes. 
Table 2-5 Percentage of polyacrylamide for separation in denaturing gels 
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Polyacrylamide % Effective range of separation (kDa) 
8 25-200 
10 15-100 
12.5 10-70 
15 12-45 
20 4-40 
 
Table 2-6 Different percentage of polyacrylamide composition of the running gel 
 
Ingredient 
Volume for two gels with different polyacrylamide% 
(ml) 
8% 10% 12% 14% 
1.5M Tris Buffer, pH 8.8 5 5 5 5 
30% Acrylamide/Bis-acrylamide 5.3 6.7 8 9.3 
10% SDS 0.2 0.2 0.2 0.2 
dH2O 9.5 8.1 6.8 5.5 
10% APS 0.2 0.2 0.2 0.2 
TEMED 0.02 0.02 0.02 0.02 
 
Table 2-7 Composition of the stacking gel 
Ingredient Volume for two gels (ml) 
0.5M Tris Buffer, pH 6.8 1.25 
30% Acrylamide/Bis-acrylamide 1.7 
10% SDS 0.1 
dH2O 7.0 
10% APS 0.1 
TEMED 0.02 
 
2.8.4 Immunoblotting  
Following the separation of protein by SDS-PAGE, proteins were then transferred from the 
gels to methanol-activated PVDF membranes (Bio-Rad Laboratories Inc., USA) at 90 V for 
90 min. Nonspecific binding was blocked with blocking buffer for 1 hour at room 
temperature. The membranes were then incubated with specific primary antibodies listed in 
Table 2.8 for 2 hours at room temperature or overnight at 4°C. After blocking, the 
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membranes were washed with TBST 6 times, 10 min each time, to remove any unbounded 
antibody. The membranes were subsequently incubated with an appropriate secondary 
antibody (1:3000 dilutions in TBST) in Table 2.7 for 2 hours at room temperature. The 
membranes were washed again with TBST 6 times to remove excess unbounded secondary 
antibody. The bound antibody was detected using a chemiluminescence system with Western 
Lighting Ultra Solution (Perkin Elmer, Catalogue No.NEL113001EA). The membranes were 
exposed in a ChemiDoc (Bio-Rad Laboratories Inc., USA) for images capturing. Quantitative 
densitometry analysis of bands of interest was performed using Image Lab software (version 
4.0. Bio-Rad Laboratories Inc., USA).  
Table 2-8 List of primary and secondary antibodies 
 
Name Supplier Catalogue No. 
Acetyl-CoA Carboxylase Cell Signaling 3662 
Acetyl-CoA Carboxylase (Phospho-Ser79) Cell Signaling 3661 
ACOX1 (H-140) Santa Cruz sc-98499 
Akt Cell Signaling 9272 
Akt (Phospho-Ser473) Cell Signaling 9271 
AMPKα Cell Signaling 2532 
AMPKα (Phosopho-Thr172) Cell Signaling 2535 
ATF4 (D4B8) Cell Signaling 11815 
Atg3 Cell Signaling 3415 
Atg4B Cell Signaling 5299 
Atg5 Cell Signaling 2630 
Atg7 Cell Signaling 2631 
β-Actin Santa Cruz sc-47778 
Beclin1 Cell Signaling 3738 
eIF2α Cell Signaling 9722 
eIF2α (Phospho-Ser51) Cell Signaling 9721 
Fatty Acid Synthase (C20G5) Cell Signaling 3180 
FoxO1 Cell Signaling 9454 
FoxO1 (Phospho-Ser256) Cell Signaling 9461 
FoxO1 (Acetyl;Ac-FKHR (D19)) Santa Cruz sc-49437 
GAPDH Cell Signaling 2118 
GSK3β Cell Signaling 9315 
GSK3β (Phospho-Ser9) Cell Signaling 5558 
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GRP78/Bip Cell Signaling 3183 
IRE1 Abcam ab37073 
IRE1 (Phospho-S724) Abcam ab48187 
LC3 Cell Signaling 12741 
mTOR Cell Signaling 2983 
mTOR (Phospho-Ser2448) Cell Signaling 5536 
p62 Cell Signaling 5114 
P70S6 Kinase Cell Signaling 9202 
pP70S6 Kinase (Phospho-Thr389) Cell Signaling 9234 
PERK Cell Signaling 3192 
PERK (Phospho- Cell Signaling 3179 
SCD1 Cell Signaling 2283 
SREBP1c (K-10) Santa Cruz sc-367 
Tublin-α Cell Signaling 3873 
XBP1 (M-186) Santa Cruz sc-7160 
4EBP1 Cell Signaling 9644 
4EBP1 (Phospho-Thr37/46) Cell Signaling 2855 
Goat Anti Mouse Santa Cruz sc-2005 
Goat Anti Rabbit Santa Cruz sc-2004 
 
2.9 Quantitative real-time PCR 
2.9.1 RNA Isolation from Liver Tissue 
Liver tissues (20-30mg) were homogenised in 1 ml TRIZOL® reagent (Invitrogen, Catalogue 
No.15596026) and centrifuged at 10,000 rpm to remove the undigested tissue based on the 
previous publication from our group [357]. The homogenate was mixed with 200 µl of 
Chloroform (VWR, Catalogue No.22711324) by inverting several times, and incubated at 
room temperature for 5 min. The homogenates were subsequently centrifuged at 13,000 rpm 
for 15 min at 4°C. The upper aqueous phase containing RNA was collected and mixed with 
500 µl of isopropanol (Sigma-Aldrich, Catalogue No.I9516). After another centrifugation at 
13,000 rpm for 20 min at 4°C, the supernatant was removed. The remaining RNA precipitate 
was washed twice with 500 µl 75% ethanol with vortex. The ethanol was removed by 
centrifugation at 13,000 rpm for 5 min at 4°C. The air-dried RNA pellet was dissolved in 100 
µl of DEPC-treated water (Invitrogen, Catalogue No.AM9916) for the measurement of RNA 
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concentration. The samples were diluted to the concentration of 250 ng/µL for reverse 
transcription. 
2.9.2 RNA concentration measurement 
The RNA purity and concentrations were assessed using a NanoDrop Spectrophotometer 
(Eppendorf Thermo Scientific, Australia) at the absorbance of 260 and 280 nm, with DEPC 
water as a blank. The absorption ratio of 260/280 nm is used to assess the purity of RNA 
samples. 
2.9.3 Complimentary DNA synthesis by reverse transcription 
Purified RNA with known concentrations was used to generate the complementary DNA 
(cDNA) using a Reverse Transcription System (Bio-Rad Laboratories Inc., USA) with 
random primers according to the manufacturer’s instructions. The RNA concentration of each 
sample was normalised to 1 µg/8 µl with DEPC water on ice. To remove DNA contamination, 
1 µg of RNA was mixed with 2 µl of DNase I (Invitrogen, Catalogue No.18068-015), and 
incubated at room temperature for 15 min. After the removal of DNA, 1 µl of 25 mM EDTA 
was added and incubated for 10 min at 65°C to inactivate DNase I. 2 µl of purified RNA was 
reverse transcribed using a high-capacity cDNA reverse transcription kit (Life Technologies, 
Catalogue No. 4374967) (2 μl of reverse transcription buffer, 0.8 μl of dNTP mix, 2 μl of 
random primers, 1 μl of reverse transcriptase and 12.2 μl of DEPC water). Reverse 
transcription polymerase chain reaction was carried out using the following steps: 
equilibrated at 25°C for 10 min, 37°C for 2 hr, 85°C for 5 sec, and finally maintained at 4°C. 
The cDNA products from reverse transcription reactions were stored at 4°C to use for real 
time-PCR analysis. 
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2.9.4 RT polymerase chain reaction 
The cDNA samples were analysed for genes of interest by real-time polymerase chain 
reaction (rt-PCR) using the SYBR Green real-time PCR system (Bio-Rad Laboratories Inc., 
USA). A reaction master mixture (1x IQ SYBR Green Supermix (Bio-Rad Laboratories Inc., 
USA; Catalogue No.170-8882), 500 nM forward primers and 500 nM reverse primers, DEPC 
water to a final volume of 24 µl) for each gene of interest was prepared and added to each 1 
µl cDNA sample in a sterile 96-well plate. The plate was placed in a controlled-temperature 
heat block equilibrated at 50°C for 2 min, 95°C for 3 min and 40-50 cycles of 95°C for 15 
seconds, 72°C for 30 seconds. The gene expression from each sample was analysed in 
duplicates and normalised against the ribosomal housekeeper gene 18S (GeneWorks, 
Australia). All reactions were performed on the iQTM 5 Real-time PCR Detection System 
(Bio-Rad Laboratories Inc., USA). The results are expressed as relative gene expression 
using the ΔCt method. Primers used for specific genes are in Table 2.9. 
Table 2-9 Sequences of Primers Used in the Study 
Primer Gene Primer sequence 
18s forward 5’-CGCCGCTAGAGGTGAAATTCT-3’ 
18s reverse 5’-CGAACCTCCGACTTTCGTTCT-3’ 
Atg4B forward 5’-ATTGCTGTGGGGTTTTTCTG-3’ 
Atg4B reverse 5’-AACCCCAGGATTTTCAGAGG-3’ 
Atg5 forward 5’-AACTGAAAGAGAAGCAGAACCA-3’ 
Atg5 reverse 5’-TGTCTCATAACCTTCTGAAAGTGC-3’ 
Atg7 forward 5’-TGCCTATGATGATCTGTGTC-3’ 
Atg7 reverse 5’-CACCAACTGTTATCTTTGTCC-3’ 
Atg12 forward 5’-GGCCTCGGAACAGTTGTTTA-3’ 
Atg12 reverse 5’-CAGCACCGAAATGTCTCTGA-3’ 
Beclin1 forward 5’-GGCCAATAAGATGGGTCTGA-3’ 
Beclin1 reverse 5’-CACTGCCTCCAGTGTCTTCA-3’ 
FoxO1 forward 5’-TTCAATTCGCCACAATCTGTCC-3’ 
FoxO1 reverse 5’-GGGTGATTTTCCGCTCTTGC-3’ 
G6Pase forward 5’-AACGCCTTCTATGTCCTCTTTC-3’ 
G6Pase reverse 5’-5’-GTTGCTGTAGTAGTCGGTGTCC-3’ 
LC3 forward 5’-CGTCCTGGACAAGACCAAGT-3’ 
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LC3 reverse 5’-ATTGCTGTCCCGAATGTCTC-3’ 
PEPCK forward 5’-CCACAGCTGCTGCAGAACA-3’ 
PEPCK reverse 5’-CGAACCTCCGACTTTCGTTCT-3’ 
 
2.10 Statistical Analyses 
Data are presented as mean ± SEM. One-way ANOVA with a Tukey post-hoc and the t-test 
were used for comparison of relevant groups. Differences at p<0.05 were considered to be 
statistically significant. 
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3.1 INTRODUCTION 
As reviewed in Section 1.3, Chapter 1 in details, peroxisome proliferators activated receptors 
(PPARs) belong to a subfamily of nuclear receptors. There are three identified isoforms in the 
PPAR family, namely α, δ (previously known as β), and γ [163]. Since these transcription 
factors play a wide range of important roles in regulating lipid metabolism to influence 
insulin sensitivity, they are considered as attractive drug targets for the treatment of type 2 
diabetes, dyslipidaemia and associated diseases. The functions of PPARs are influenced by 
fatty acids receptors, and the PPARs play an important role in obesity-related metabolic 
diseases such as hyperlipidaemia, insulin resistance and coronary artery disease [67]. Each 
subtype of PPARs has distinct expression patterns and has evolved to sense components of 
different lipoproteins, and regulates lipid homeostasis based on the need of specific tissues.  
PPARγ is predominantly expressed in adipose tissue where it mediates differentiation and 
fatty acid (FA) synthesis [353, 363]. This isoform is the target of the thiazolididione insulin 
sensitising drugs used for the treatment of type 2 diabetes [353]. It has been suggested that 
PPARγ is a key transcriptional factor regulating lipid metabolism, and the effect of PPARγ 
among the PPARs family in lipid metabolism by promoting adipogenesis is consistent with 
previous publication from our group [354]. Importantly, PPARγ has been reported to involve 
in regulation of autophagy which plays a pivotal role in adipogenesis via mediated 
CCAAT/enhancer-binding protein β (C/EBPβ) in transcriptional control [364]. However, an 
understanding of its effect in the liver remains unclear.  
In addition, as reviewed in Section 1.4, ER stress can activate unfolded protein response 
(UPR) signalling pathway [151] to promote lipogenesis [365] which may involve PPARγ 
action. Accumulated misfolded proteins in the ER leading to ER stress promote a self-
clearing catabolic mechanical pathway called autophagy to remove or clear damaged and 
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misfolded proteins and cell organelles [288, 361]. Failure of autophagy regulation has been 
suggested to be a critical component of insulin resistance seen in obesity related to lipid 
metabolism [288]. Although the link between ER stress and autophagy in relation to lipid 
metabolism in the liver has been reported, the PPARγ induced effect on these pathways in the 
liver is not well understood.   
Thus, the purpose of this study was to investigate the effect of PPARγ activator, rosiglitazone 
(RG) on the autophagy pathway during its action in counteracting insulin resistance and lipid 
metabolism. Because the effects of RG on hepatic insulin resistance and lipid metabolism are 
well characterised [353, 355], autophagy and ER stress promoting de novo lipogenesis (DNL) 
in the liver were examined. Possible attempts are made to identify the individual roles of 
those three pathways in the activation of PPARγ by RG at a dose based on the previous 
studies from our group [246, 353, 355]. As rodents fed a HF diet are well recognized, my 
study used the insulin resistant HF model to interrogate these relationships. In my study, rats 
were given chow (CH), HF or high fat treated with rosiglitazone (HF-RG) for 4 weeks, and 
the study examined whether the autophagy and UPR pathways may play a role in these 
effects produced by stimulating PPARγ.   
3.2 MATERIALS AND METHODS 
3.2.1 Animal model 
Wistar male rats (between 10-30 weeks of adult age) were purchased from the Animal 
Resources Centre (Perth, Australia). They were housed at 22±1°C on a 12-h light/dark cycle 
in the animal house of the Research Animal Facility at RMIT University. The animals were 
firstly acclimatized for one to two weeks with free access to the normal standard CH diet and 
water ad libitum. Then, after acclimatization, animals were given three different types of diets 
for 4 weeks. These were CH, 60% HF or HF-RG (15mg/kg/day) and this dose has been 
 111 
 
Chapter 3- Effect of PPARγ activation on Autophagy in relation to Lipid Metabolism and 
Insulin Sensitization 
demonstrated to activate PPARγ under a similar protocol as previously reported [353]. We 
monitored body weight and food intake daily. At the end of the 4 week treatment periods, rats 
were fasted for 5-7 hours before they were sacrificed. After culling, liver tissues were 
collected and freeze clamped immediately for further experiments and analysis. All 
experimental procedures or protocols were approved by the Animal Ethics Committee of 
RMIT University (#1012) in accordance with the National Health and Medical Research 
Council of Australia Guidelines on Animal Experimentation.  
3.2.2 Glucose tolerance test  
After four weeks of CH, HF or HF-RG feeding, a glucose tolerance test (GTT; glucose 
dosage 2.5g/kg/body weight, i.p.) was performed. Detailed description is found in Section 
2.2.3. The levels of blood glucose during the GTT were measured at 0, 15, 30, 60 and 90 
minute time points after the glucose injection. 
3.2.3 Hyperinsulinemic euglycemic clamp technique 
Hyperinsulinemic euglycemic clamp technique was performed as previously reported in 
publications from our research group [354, 355]. The hyperinsulinaemic clamp was 
performed at an insulin infusion rate of 0.25 U·kg
-1
·h
-1 
to elevate circulating insulin levels to 
a half-maximal physiological concentration [37, 246, 353, 355, 358] with glucose infused at 
variable rates (GIR) to maintain euglycaemia. After plasma glucose levels reached the 
designated steady state, a bolus of 2-deoxy-D-[2,6-
3
H] glucose (2DG) and D-[U-
14
C] glucose 
was injected (i.v.) to determine glucose disappearance rate (Rd) and hepatic glucose output 
rate (HGO). Under the euglycaemic conditions, HGO was calculated as Road – GIR where 
Road was determined by counting [
14
C] of the plasma collected at 2, 5, 10, 15, 20, 30 and 45 
min after the tracer injection, as validated by this laboratory [359]. Glucose concentrations 
during the hyperinsulinaemic clamp in rats were determined using a glucose analyser (YSI 
2300, YSI Inc., Yellow Springs, OH, USA). 
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3.2.4 Liver triglycerides 
Detailed description of extraction and measurement of liver triglycerides is described in 
Section 2.5. Liver tissues were homogenized in chloroform/methanol (2:1) solution and 
incubated overnight with continuous mixing of samples. Then 0.6% NaCl was added and the 
samples were centrifuged for phase separation, resulting in the formation of a discrete 
aqueous phase above an organic phase. The aqueous phase, which contains water soluble 
components, was discarded, and the lower organic phase which contained lipid soluble 
components was transferred into glass tubes, and then air-dried at 45
o
C. The dried pellets 
were dissolved in ethanol immediately prior to the assay. Triglyceride levels were measured 
using a Peridochrom triglyceride GPO-PAP kit (Roche Diagnostics). 
3.2.5 Western blots 
Freeze clamped liver tissues of rats and mice were homogenized in ice-cold RIPA lysis buffer 
at pH 7.5 supplemented with inhibitors of protease and phosphatase. Protein levels in 
homogenates were determined by BCA Protein kit. The proteins were then resolved through 
SDS-PAGE. Determination of specific proteins was examined by immunoblotting using 
exact antibodies as indicated in Table 3.1. Detailed description of western blotting is 
described in Section 2.8.  
Table 3-1 List of proteins examined for the pathways of DNL, ER stress and autophagy 
Examined specific proteins for the three pathways in this study of Chapter 3 
 
The 
De novo lipogenesis (DNL) 
pathway 
matured sterol regulatory element binding protein 1 c 
(mSREBP1c) 
Acetyl-CoA carboxylase (ACC) 
Fatty acid synthase (FAS) 
Steroyl-CoA desaturase 1 (SCD1) 
 
 
 
The 
Endoplasmic reticulum (ER) 
Phosphorylation of inositol requiring enzyme 1 (pIRE1) 
inositol requiring enzyme 1 (IRE1) 
Phosphorylation of protein kinase RNA-like endoplasmic 
reticulum kinase (pPERK) 
protein kinase RNA-like endoplasmic reticulum kinase 
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stress 
pathway 
(PERK) 
Spliced X box binding protein 1 (sXBP1) 
Phosphorylation of eukaryotic initiation factor 2 α (peIF2α) 
eukaryotic initiation factor 2 α (eIF2α) 
Immunoglobulin heavy chain-binding protein (GRP78) 
 
 
 
 
The 
Autophagy 
pathway 
Phosphorylation of mammalian target of rapamycin 
(pmTOR) 
mammalian target of rapamycin (mTOR) 
Autophagy related gene 3 (Atg3) 
Autophagy related gene 4B (Atg4B) 
Autophagy related gene 5 (Atg5) 
Autophagy related gene 7 (Atg7) 
Beclin1 
Microtubule associated protein 1A/1B-light chain 3 (LC3) 
Nucleoporin p62 (p62) 
Normalizing control protein α-Tubulin 
 
3.2.6 Statistical Analysis 
Data are presented as mean ± SEM. One-way analysis of variance (ANOVA) was used for 
comparison between relevant groups unless stated otherwise. When significant variations 
were found, the Tukey-Kramer post-hoc multiple comparisons test, and the t-test were 
applied. Differences at p<0.05 were considered to be statistically significant. 
3.3 RESULTS 
3.3.1 PPARγ by RG improved insulin sensitivity and lowered TG levels 
A significant increase of body weight gain was observed in HF fed rats compared to vehicle 
control CH (p<0.05 vs. CH; Fig. 3.1A & B). Compared to HF fed rats, the HF-RG group had 
a significant increase in body weight (p<0.01 vs. HF alone; Fig. 3.1A & B).   
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Figure 3.1 Metabolic changes after HF and HF induced PPARγ by RG treatment (A): 
The body weight changes of rats fed chow (CH), 60% high fat (HF) or 60% high fat treated 
with rosiglitazone (HF-RG, 15mg/kg/day) diet over the 4 weeks. (B): The measurement of 
body weight gain of rats at the end of 4 weeks. Data are expressed as mean ± SEM (n=8). * 
p<0.05, ** p<0.01 compared to CH; †† p<0.01 compared to HF. 
 
We performed glucose tolerance test (GTT) on rats fed CH, HF or HF-RG after 4 weeks of 
feeding. Dietary fat delayed the return of blood glucose to the normal level after the i.p. 
injection of glucose. The incremental area under the curve (iAUC) indicated the regulation of 
blood glucose is impaired significantly in HF (p<0.05 vs. CH, Fig. 3.2A & B). Conversely, 
HF-RG significantly reversed the glucose intolerance in the measurement of GTT (p<0.05 vs. 
HF, Fig 3.2A &B).  
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Figure 3.2 Glucose tolerance test on HF fed rats with or without PPARγ by RG. (A): 
Glucose tolerance test (GTT) was performed in 4 weeks CH, HF or HF treated RG fed rats. 
Glucose tolerance was assessed by (B): The incremental area under the curve of A (iAUC) 
during GTT was measured. Data are expressed as mean ± SEM (n=8), * p<0.05 compared to 
CH; † p<0.05 compared to HF. 
 
To confirm the insulin sensitizing effect of RG in HF fed rats, under the same conditions, we 
performed the hyperinsulinemic euglycemic clamp technique and the data were adapted as 
previously reported in publications from our research group [354, 355]. We measured glucose 
infusion rate during a steady rate and found that the HF required significantly less glucose at 
the whole body insulin sensitivity measurement (p<0.05 vs. CH, Fig. 3.3A), indicating the 
development of insulin resistance. As expected, administration of RG to HF fed rats reversed 
the reduced requirement for glucose infusion (p<0.05 vs. HF, Fig 3.3A). We observed that 
glucose output was effectively suppressed in HF fed rats following treatment with RG (Fig. 
3.3B), indicating sensitized insulin sensitivity to shut off glucose production from the liver.  
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Figure 3.3 Insulin action on HF fed rats with or without PPARγ by RG treatment (A): 
Glucose infusion rate (GIR) which assesses insulin action (insulin sensitivity) in whole body 
as measured by hyperglycemic euglycemic clamp. The data were adapted as previously 
reported in publications from our research group [354, 355]. (B): Hepatic glucose output 
(HGO) which measures hepatic insulin sensitivity based on the ability to suppress glucose 
production from the liver during insulin stimulation. The data were adapted as previously 
reported in publications from our research group [354, 355]. Data are expressed as mean ± 
SEM (n=8), * p<0.05 compared to CH; † p<0.05 compared to HF. 
 
Analysis of TG content in the liver of rats fed with CH, HF or HF-RG showed a significant 
increase in TG lipid accumulation in HF, while the presence of RG in the HF diet 
significantly lowered the TG fat/lipid accumulation in the liver (Fig. 3.4). 
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Figure 3.4 PPARγ by RG lowered lipid accumulation in the liver. Total liver triglycerides 
content measured in rats fed with CH, HF or HF-RG. One-way ANOVA analysis was used to 
compare between the groups. Data are expressed as mean ± SEM (n=8), * p<0.05 compared 
to CH; † p<0.05 compared to HF. 
3.3.2 Effect of HF induced PPARγ by RG on lipogenic enzymes in the liver 
In the liver of rats fed with HF, amount of matured sterol regulatory element binding protein 
1c (mSREBP1c) significantly increased compared to CH fed rats; however, RG treated HF 
fed rats showed no differences when compared to HF fed rats (Fig. 3.5B). Acetyl-CoA 
carboxylase (ACC) was assessed to determine activity of lipogenic enzymes in the liver of 
HF induced PPARγ by RG fed rats. In contrast to mSREBP1c, HF fed rats showed a decrease 
of ACC compared to CH fed rats, and HF-RG showed no differences when compared to HF 
fed rats (Fig. 3.5C). The level of fatty acid synthase (FAS) was increased by RG compared to 
HF fed rats with a trend of increased ACC and stearoyl-CoA desaturase 1 (SCD1) (Fig 3.5D).  
Content of SCD1 was increased in HF-RG compared to CH fed rats while there was no effect 
of HF diet (Fig 3.5E).  
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Figure 3.5 Effect of RG on DNL proteins. DNL signal transduction is determined by 
lipogenic enzymes. (A): Representative images of key proteins in the de novo lipognesis 
(DNL) pathway via western blots. Quantification of representative images for key proteins 
(B): matured sterol regulatory element binding protein 1c (mSREBP1c), (C): acetyl-CoA 
carboxylase 1 (ACC), (D): fatty acid synthase (FAS), and (E): stearoyl-CoA desaturase 1 
(SCD1). One-way ANOVA analysis was used to compare each individual protein levels of 
expression between different groups.  Data are expressed as mean ± SEM (n=8). * p<0.05 
compared to CH; † p<0.05 compared to HF. 
3.3.3 Effect of HF induced PPARγ by RG on ER stress  
There were no significant changes observed in either HF or HF-RG with assessment of the 
activation of two canonical UPR pathways, namely inositol requiring enzyme 1-X-box 
binding protein 1 (IRE1-XBP1) and protein kinase RNA-like endoplasmic reticulum kinase- 
eukaryotic initiation factor 2 α (PERK-eIF2α) (Fig 3.6). There were no significant changes 
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found in the phosphorylation of IRE1 (pIRE1), PERK (pPERK), eIF2α (peIF2α), and 
immunoglobulin heavy chain-binding protein (GRP78) (Fig. 3.6B, C, E & F respectively). 
Conversely, HF-RG demonstrated 1.5 fold enhancement compared to CH or HF fed rats 
respectively, in a downstream effector of IRE1 known as spliced form of X-box binding 
protein 1 (sXBP1; Both p<0.05; Fig. 3.6D).    
      
 
Figure 3.6 Effect of RG on ER stress. ER stress markers were determined. (A): 
Representative images of key protein in the ER stress pathway via western blots. 
Quantification of key proteins were presented in (B): Phosphor/total inositol requiring 
enzyme 1 (pIRE1/IRE1), (C): Phosphor/total protein kinase RNA-like endoplasmic reticulum 
kinase (pPERK/PERK), (D): Spliced form of X-box binding protein 1 (sXBP1), (E): 
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Phosphor/total eukaryotic initiation factor 2 α (peIF2α/eIF2α) and (F): Immunoglobulin 
heavy chain-binding protein (GRP78) respectively in response to PPARγ by RG using 
western blot. One-way ANOVA analysis was used to compare each individual protein levels 
of expression between different groups.  Data are expressed as mean ± SEM (n=8). * p<0.05 
compared to CH; † p<0.05 compared to HF.  
3.3.4 Effect of PPARγ by RG on autophagy  
We investigated whether PPARγ by RG has a role in regulation of autophagy directly. Firstly, 
we observed that HF fed rats enhanced expression of autophagy related genes 7 (Atg7) and 
microtubule-associated protein 1A/1B-light chain (LC3) levels, indicating increased 
autophagy activity (Both p<0.05 vs. CH respectively; Fig. 3.7F & H). However, HF inhibited 
autophagy related genes 3 (Atg3) protein level (p<0.05 vs. CH; Fig 3.7C) indicating 
suppression of autophagy. In addition, there were no significant changes in phosphor/total 
mammalian target of rapamycin (pmTOR/mTOR), autophagy related genes 4B (Atg4B), 
autophagy related gene 5 (Atg5), Beclin1 and nucleoporin p62 (p62) (Fig. 3.7B, D, E, G & I 
respectively), possibly indicating dysregulation of autophagy. As HF dysregulated the 
autophagy pathway, by indicating no clear increase or decrease of its activity, we further 
examined whether HF induced PPARγ by RG has a role in regulation of autophagy. 
Interestingly, PPARγ by RG only increased expression of Atg5 level compared to HF 
(p<0.05 vs. HF, Fig. 3.7E). Additionally, HF-RG decreased Atg3 while increased Atg7, LC3 
and p62 compared to CH (p<0.05 vs. CH respectively, Fig. 3.7B, F & I). There were no 
significant changes found in pmTOR/mTOR, Atg4B and Beclin1 (Fig, 3.7B, D & G), further 
showing PPARγ by RG does not correct HF-induced dysregulation of autophagy.   
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Figure 3.7 RG did not correct HF induced dysregulation of autopahgy. (A): 
Representative images of immunoblots on liver homogenates from CH, HF or HF-RG fed 
rats for relative autophagy proteins. Quantified data were represented in (B): Phosphor/total 
mTOR (pmTOR/mTOR), (C): Protein of autophagy related gene 3 (Atg3), (D): Protein of 
autophagy related gene 4 B (Atg4B), (E): Protein of autophagy related gene 5 (Atg5), (F): 
Protein of autophagy related gene 7 (Atg7), (G): Beclin1, (H): Ratio of microtubule 
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associated protein light chain 3 (LC3) II over I (LC3II/LC3I), (I): Nucleoporin p62 (p62). 
One-way ANOVA analysis was used to compare each individual protein levels of expression 
between different groups.  Data are expressed as mean ± SEM (n=8). * p<0.05 compared to 
CH; † p<0.05 compared to HF.  
3.4 DISCUSSION 
The study reported in this chapter investigated the effect of PPARγ on autophagy in relation 
to lipid metabolism and ER stress in the liver using a HF fed rat model with or without RG 
treatment. The results showed that HF led to TG/lipid accumulation in liver promoting 
hepatic insulin resistance and glucose intolerance; while treatment with RG ameliorated HF 
induced glucose intolerance and the insulin resistance. HF inhibited the lipogenic enzymes 
ACC and FAS. This is consistent with the previous studies showing that HF feeding inhibits 
DNL (measured by 3H-H2O incoopration into TG) and the expression of ACC and FAS in 
the liver [153, 356]. Thus, the accumulation of TG in the liver is due to increased FA influx 
from digested HF as reported [366] .   
RG is well known to promote DNL and adipogenesis in adipose tissue by stimulating PPARγ. 
This is believed to be the mechanism for its effect to increase the body weight as observed in 
this thesis. The results in Fig. 3.5 showed that RG was able to reduce TG content in the liver 
despite increasing the body weight presumably by sequestering HF diet derived FAs in 
enlarged adipose tissue, as demonstrated in an early study. RG as thiazolidinedione classified 
is a well-known drug binding to the PPARγ receptors in fat cells, which contribute to the 
weight gain. As a result of the proliferated fat cells, the lipid content in other tissues including 
liver is re-directed to fat cells by a well-described mechanism of lipid stealing [246]. In 
comparison, RG was unable to promote coordinated increases in all of the measured DNL 
proteins except for ACC.  
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Similarly, the effect of RG on the autophagy pathway was very limited (only significant 
effect shown in autophagy protein, Atg5). Autophagy is a catoblic mechanism regulated by 
multiple autophagy proteins named Atg 5, 7, p62 and LC3. The findings in Fig. 3.7 revealed 
that RG was unable to correct dysregulated HF induced autophagy in the liver despite key 
roles of autophagy in adipogenesis as reported [364]. 
To add, the effect of RG on ER stress was overall ineffective as only changed in sXBP1 
shown. ER stress is caused by an imbalance between the protein folding capacity and the load 
of protein, resulting in the accumulation of misfolded proteins [151] that further induces 
autophagy if uncleared [288]. The results in Fig 3.6 showed that RG had no significant effect 
on ER stress except a clear increase in sXBP1, which did not necessarily indicate the overall 
outcome despite the finding of significant down regulated ER stress genes in the liver of RG 
treated db/db mice [367].  
Overconsumption of dietary fat is one of major factors leading to insulin resistance, which 
has been suggested to originate from TG fats/lipids accumulation in the liver. Acute HF fed 
rats showed hepatic insulin resistance without affecting insulin sensitivity in muscle [368]. 
PPARγ by RG was able to reverse the insulin resistance caused by HF feeding in the absence 
of hepatic steatosis. In the current study, 4 weeks of HF feeding in rats was sufficient to cause 
glucose intolerance, and an additional RG treatment on top of HF feeding was capable of 
restoring glucose intolerance in the liver of rats. 
Ectopic lipids and ER stress are believed to account for the observed insulin resistance in the 
liver. HF increased liver TG while PPARγ by RG lowered the contents of liver TG in the 
absence of DNL regulation. PPARγ by RG is believed to reduce lipid/fats or TG content in 
the liver of rodents [355]. The explanation for this discrepancy is likely due to the different 
pathway or regulation involved in HF mediated lipid synthesis where during HF feeding, 
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fatty acids are directly provided to the liver [65, 356]. In support of this, upregulation of 
lipogenic proteins was not observed clearly in HF fed rats. HF induced PPARγ by RG did not 
show a correlated regulation of DNL. ER stress has been suggested to regulate DNL through 
IRE1 and PERK pathways [111, 318]. No activation of these two UPR transducers was 
observed in HF or HF induced PPARγ by RG. These results consequently suggest PPARγ by 
RG reverses the effect of hepatic insulin resistance caused via ectopic lipids, but with no 
notable regulation of DNL and ER stress.  
Activation of the autophagy pathway is shown by increased autophagy protein expression in 
Atg7 and LC3 [369, 370]. My results showed HF increased expression of autophagy protein 
levels in Atg7 and LC3, decreased in Atg3, while no significant changes were found in other 
autophagy regulating proteins. Additionally, HF induced PPARγ by RG did not show any 
significant changes in the listed autophagy proteins such as Atg7 or LC3 compared to HF. It 
is plausible that HF dysregulates autophagy activity and   PPARγ by RG does not correct HF-
induced dysregulation of autophagy.  However, PPARγ by RG was capable of decreasing 
autophagy proteins in Atg3 and degradation in p62 against vehicle control, CH. These 
possibly suggest that a direct role/effect of PPARγ by RG could be a confounding factor.  
In summary, as shown in Fig. 3.8 this study found that HF can lead to impaired hepatic 
insulin resistance and glucose intolerance via ectopic lipid accumulation, while PPARγ by 
RG reverses these effects. DNL and ER stress did not occur with HF feeding or HF induced 
PPARγ by RG. In addition, autophagy itself is dysregulated by HF, and PPARγ by RG does 
not have a role in correcting the HF-induced dysregulation of autophagy. 
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Figure 3.8 Proposed mechanisms for the effect of HF induced PPARγ by RG. Dietary HF 
promotes TG lipid contents in the liver, likely leading to hepatic insulin resistance. This 
change also induces glucose intolerance in HF. Conversely, PPARγ by RG lowers TG 
content, improving insulin sensitivity and relatively restores glucose intolerance. DNL in HF 
is decreased due to direct influx of FA inhibiting regulation, while HF shows no effect on ER 
stress but dysregulates autophagy activity. HF induced PPARγ by RG does not correct HF-
induced dysregulation of autophagy with no overall effect on ER stress.
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4.1 INTRODUCTION 
Peroxisome proliferator activated receptor α (PPARα) is a subtype of peroxisome proliferator 
activated nuclear receptors (PPARs) that function as transcriptional factors. They are highly 
expressed in tissues with high capacity for fatty acid oxidation, mostly predominantly in liver, 
brown adipose, heart, skeletal muscle and kidney [163]. The role of PPARα activation in 
glucose metabolism and insulin sensitivity is relevantly well known. It is understood that 
altered PPARα has been associated with the pathogenesis of obesity and insulin resistance, 
and its activation may reduce weight gain in rodents [371]. PPARα activation is also believed 
to be critical in regulating insulin sensitivity that may lead to delay of onset of Type II 
diabetes [65]. Pharmacological activation of PPARα is an effective therapeutic approach to 
treat few aspects of metabolic syndrome including hypertriglyceridemia and Type II diabetes 
[372]. PPARα controls and regulates the expression of a large number of genes involved in 
regulating the intermediary metabolism of glucose and lipids, homoeostasis, lipogenesis, 
insulin sensitivity, immune response, cell growth and differentiation [67].  
In liver, both lipid and glucose metabolism is regulated by PPARα. Activated by 
polyunsaturated fatty acids and -3 fatty acids from fish oil [160], PPARα is well recognised 
to be a key regulator of the genes promoting fatty acid oxidation, occurring in peroxisomes, 
mitochondria and microsomes [65, 163]. This is believed to be a mechanism for the lipid-
lowering class of drugs called fibrates, including fenofibrate (FB), the well-known 
pharmacological PPARα activator used in the treatment of dyslipidaemia and associated 
cardiovascular conditions in humans.  In addition, a number of studies indicate that PPARα 
plays much more diverse roles in the pathways of lipid synthesis and protein metabolism [65, 
163]. For example, activation of PPARα increases de novo synthesis of fatty acids in liver [65, 
356] and this simultaneous increase in fatty acid oxidation and synthesis has been suggested 
to increase energy metabolism [356]. Regarding the pathways related to protein metabolism, 
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recent studies showed that PPARα can induce various alterations in unfolded protein 
response (UPR) pathways [65]. The UPR pathways have been reported to interact with 
autophagy (protein degradation mechanism) to control protein homeostasis in vivo and in 
vitro [288, 361, 373].  
Hence, the purpose of the research in this chapter is to investigate the effect of PPARα on the 
autophagy pathway in association with lipid metabolism response to ER stress and DNL in 
the liver. Possible attempts are made to identify the individual roles of the autophagy, ER 
stress and DNL pathways in response to PPARα by FB. This study uses mice that were fed 
chow or chow treated with fenofibrate, high fat or high fat treated with fenofibrate for 3 
weeks, and western blotting is performed with correlated markers of autophagy, ER stress 
and DNL.   
4.2 MATERIALS AND METHODS 
4.2.1 Animal model 
Male C57BL/6J mice (10 weeks old) were purchased from the Animal Resources Centre 
(Perth, Australia). They were housed at 22±1°C on a 12-h light/dark cycle in the animal 
house of the Research Animal Facility at RMIT University. The animals were firstly 
acclimatized for one to two weeks with free access to normal standard chow diet (CH) and 
water ad libitum. After acclimatization, the animals were divided into four different groups 
and given diets of CH, CH treated with fenofibrate (100mg/kg/day; CH-FB), 45% high fat 
diet (HF) or HF treated with fenofibrate (HF-FB) for 3 weeks. We monitored body weight 
and food intake daily. At the end of 3 weeks, mice were fasted for 5-7 hours before they were 
sacrificed. After culling, liver tissues were collected and freeze clamped immediately for 
further experiments and analysis. All experimental procedures or protocols were approved by 
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the Animal Ethics Committee of RMIT University (#1206) in accordance with the National 
Health and Medical Research Council of Australia Guidelines on Animal Experimentation.  
4.2.2 Glucose tolerance test 
After two weeks of CH, CH-FB, HF or HF-FB feeding, a glucose tolerance test (GTT; 
glucose dosage 2.5g/kg/body weight, i.p.) was performed. Detailed description is found in 
Section 2.2.3. The levels of blood glucose during the GTT were measured at 0, 30, 60, 90 and 
120 minutes time point after the glucose injection.  
4.2.3 Liver triglycerides 
Detailed description of extraction and measurement of liver triglycerides is described in 
Section 2.5. Liver tissues were homogenized in chloroform/methanol (2:1) solution and 
incubated overnight with continuous mixing of samples. Then 0.6% NaCl was added and the 
samples were centrifuged for phase separation. This resulted in the formation of a discrete 
aqueous phase above an organic phase. The aqueous phase which contains water soluble 
components was discarded, and the lower organic phase which contains lipid soluble 
components was transferred into glass tubes, and then air-dried at 45
o
C. The dried pellets 
were dissolved in ethanol immediately prior to the assay. Triglyceride levels were measured 
using a Peridochrom triglyceride GPO-PAP kit (Roche Diagnostics). 
4.2.4 Liver histology 
The preparation of liver sections and staining of H&E and Masson’s Trichrome are described 
in Section 2.3.  
4.2.5 Plasma ALT measurement 
Detailed measurement of plasma alanine aminotransferase (ALT) is described in Section 2.4. 
Briefly, the blood samples were centrifuged at 9,000 rpm to obtain the plasma. ALT levels in 
the plasma samples were measured by ALT/SGPT Liqui-UV Kit (Stanbio). When 20 µL of 
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plasma samples were mixed with 200 uL of the reagent, the absorbance was measured 
immediately at 340 nM by the FlexStation microplate reader (Molecular Devices, USA) 
every minute for 10 minutes to test the activity of ALT enzyme. 
4.2.6 Western blots 
Freeze clamped liver tissues of rats and mice were homogenized in ice-cold RIPA lysis buffer 
at pH 7.5 supplemented with inhibitors of protease and phosphatase. Protein levels in 
homogenates were determined by BCA Protein kit. The proteins then were resolved through 
SDS-PAGE. Determination of specific proteins was examined by immunoblotting using 
exact antibodies as indicated in Table 4.1. Detailed description of western blot is described in 
Section 2.8. 
Table 4-1 List of proteins examined for the pathways of DNL, ER stress and autophagy 
Examined specific proteins for the three pathways in this study of Chapter 4 
 
The 
De novo lipogenesis (DNL) 
pathway 
matured sterol regulatory element binding protein 1 c 
(mSREBP1c) 
Acetyl-CoA carboxylase (ACC) 
Fatty acid synthase (FAS) 
Steroyl-CoA desaturase 1 (SCD1) 
The 
Endoplasmic reticulum (ER) 
stress 
pathway 
Phosphorylation of inositol requiring enzyme 1 (pIRE1) 
inositol requiring enzyme 1 (IRE1) 
Phosphorylation of protein kinase RNA-like endoplasmic 
reticulum kinase (pPERK) 
protein kinase RNA-like endoplasmic reticulum kinase 
(PERK) 
Spliced X box binding protein 1 (sXBP1) 
Phosphorylation of eukaryotic initiation factor 2 α (peIF2α) 
eukaryotic initiation factor 2 α (eIF2α) 
Immunoglobulin heavy chain-binding protein (GRP78) 
 
 
 
 
The 
Autophagy 
pathway 
Phosphorylation of mammalian target of rapamycin 
(pmTOR) 
mammalian target of rapamycin (mTOR) 
Autophagy related gene 3 (Atg3) 
Autophagy related gene 4B (Atg4B) 
Autophagy related gene 5 (Atg5) 
Autophagy related gene 7 (Atg7) 
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Beclin1 
Microtubule associated protein 1A/1B-light chain 3 (LC3) 
Nucleoporin p62 (p62) 
Normalizing control protein  
(Housekeeping gene/protein) 
α-Tubulin 
Glyceraldehyde3-phosphate dehydrogenase (GAPDH) 
 
4.2.7 Statistical analyses 
Data are presented as mean ± SEM. One-way analysis of variance (ANOVA) was used for 
comparison between relevant groups unless stated otherwise. When significant variations 
were found, the Tukey-Kramer post-hoc multiple comparisons test, and the t-test were 
applied. Differences at p<0.05 were considered to be statistically significant. 
4.3 RESULTS 
4.3.1 FB treated mice well-maintained body weight, glucose tolerance and insulin 
signalling 
HF increased body weight gain by 10% (p<0.01 vs. CH; Table 4.2), and glucose intolerance 
(p<0.01 vs. CH, Fig.4.1A). FB treated HF fed mice attenuated the diet-induced body weight 
gain (p<0.01 vs. HF, Table 4.2). Additionally, CH-FB showed no significant effects on body 
weight gain, adiposity or caloric intake (Table 4.2). Moreover, there were increased of liver 
weights in FB treated mice irrespective of diet (The result was not included in the thesis as 
this has been based on our previous publication from our group).Those data were adapted 
from the previous publication of our group [356].   
Table 4-2 Metabolic changes of PPARα by FB treated mice in the liver 
      CH  CH-FB      HF   HF-FB  
Body mass (g) 
   Day 0 
   Day 14 
  
27.0±0.3 
28.0±0.4 
  
27.0±0.4 
28.0±0.4 
  
27.1±0.3 
30.0±0.5
*
  
  
26.8±0.4 
27.0±0.6
††
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EPI fat mass (% BW)   1.3±0.1   1.0±0.1   3.3±0.3
**
    1.2±0.1
††‡‡
 
Caloric intake (Kcal/day) 12.0±0.1 12.2±0.1 17.1±0.5
**
 18.0±0.5
††
 
 
Male C57BL/6J mice were fed either a chow (CH) or high fat (HF) for 3 weeks with or 
without the PPARα agonist, fenofibrate (FB, 100 mg/kg/day in the diets). Data are mean ± 
SEM of 8–12 mice per group, * p<0.05, ** p<0.01 vs. CH; † p<0.05, †† p<0.01 vs. HF; ‡ 
p<0.05, ‡‡ p<0.01 vs. CH-FB. These data were adapted from the previous publication of our 
group [356]. 
 
In the HF-FB, glucose tolerance and insulin signalling in the liver were restored to similar 
levels of CH-FB (Fig. 4.1A & C). FB treatment either in CH or HF fed mice also reduced the 
requirement for plasma insulin during GTT (Fig. 4.1B). Consistent with these changes, 
insulin signalling transduction in the liver of FB treated CH or HF fed mice was impaired as 
evidenced by the blunted phosphorylation of Akt and its downstream effector known as 
phosphorylation of GSK3β in response to the stimulation of insulin injection (Fig. 4.1C). 
These data were adapted from the previous publication of our group [356]. 
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Figure 4.1 PPARα by FB corrected glucose intolerance and insulin signal transduction 
in the liver of mice. After 3 weeks of FB treatment either in CH or HF; (A): Glucose 
tolerance test (GTT; 2.5g glucose/kg BW, i.p.) was performed with incremental area under 
the curve (iAUC) for blood glucose level; (B): Plasma insulin levels between 30-60 min of 
GTT. Insulin (2U/kg BW, ip) was injected 20 min before tissue collection to assess hepatic 
insulin signal transduction; (C): Representative images and quantification from immunoblots 
of phosphor/total Akt (pAkt/Akt, Ser473), and phosphor/total GSK3β (pGSK3β/ GSK3β, 
Ser9) respectively. Data are mean ± SEM of 6 to 9 mice per group, * p<0.05; ** p<0.01 vs. 
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CH; † p<0.05; †† p<0.01 vs. HF. Those data were adapted from the previous publication of 
our group [356]. 
4.3.2 PPARα activation by FB does not lower TG contents in the liver but highly 
enhanced ALT levels irrespective of diets 
HF increased TG contents in the liver by 2 fold (p<0.01 vs. CH, Fig. 4.2A), while HF-FB 
was 2 fold higher compared to CH-FB (p<0.01; Fig. 4.2A). FB treated either in CH or HF 
had no effect on total TG contents when compared to corresponding vehicle controls in the 
liver (Fig. 4.2A). These results suggest that there was no correction of hepatic lipid 
accumulation by PPARα using FB. In addition to this, there were no morphological changes 
observed in the liver of mice treated with or without FB (Fig 4.2B).  
In contrast to liver TG contents, FB markedly enhanced the plasma alanine aminotransferase 
(ALT) enzyme levels in the liver irrespective of diets (p<0.05 vs. CH, p<0.01 vs. HF; Fig. 
4.2C), possibly indicating liver injury. Hence, we further examined Masson’s Trichrome 
staining (Fig. 4.2D) for collagen deposition to determine a feature of non-alcoholic 
steatohepatitis (NASH) that distinguishes from simple steatosis. There was no positive 
staining of collagen (in blue colour) detected in FB treated in either CH or HF (Fig 4.2D).  
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Figure 4.2 PPARα activation by FB did not change TG contents but plasma ALT levels. 
(A): Total liver triglycerides content; (B): H&E staining of liver morphology of FB treated 
CH or HF fed mice; (C): Plasma ALT level in FB treated CH or HF fed mice; (D): The 
Masson’s Trichrome staining of liver sections. Data are mean ± SEM of 6 to 9 mice per 
group, 
* p<0.05, ** p<0.01 vs. CH; †† p<0.01 vs. HF; ‡‡ p<0.01 vs. CH-FB. 
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4.3.3 Effect of PPARα by FB on peroxisomal fatty acid oxidation and DNL  
We observed a very large, 12-fold increase, in the level of ACOX1 in FB treated either in CH 
or HF (p<0.01 for all vs. corresponding vehicle controls; Fig. 4.3A), showing the PPARα 
activation by FB in the liver of mice, with this change found irrespective of diet. These data 
are consistent with previous publications from our group [65, 356].  
In response to the PPARα activation by FB, we further examined its effect on regulation of 
DNL by promoting fatty acid synthesis as previously suggested [65, 163, 356]. Both FB 
treated CH and HF enhanced expression levels of mSREBP1c, ACC, FAS and SCD1 
(p<0.01 for all vs. corresponding vehicle controls, Fig. 4.3B). These results indicate that FB 
increased lipogenic enzymes responsible for upregulating DNL in the liver regardless of diets 
given to mice. All of those data were adapted from the previous publication of our group 
[356].  
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Figure 4.3 PPARα by FB increased ACOX1 and hepatic DNL. Representative images 
with quantification via western blots (A): Expression of ACOX1 in the liver of FB treated in 
CH or HF fed mice; (B): Key lipogenic enzymes for fatty acid synthesis in mSREBP1c, ACC, 
FAS, and SCD1 with the respective densitometry. These data were adapted from the previous 
publication of our group [356]. Data are mean ± SEM of 6 to 9 mice per group, ** p<0.01 vs. 
CH; †† p<0.01 vs. HF.  
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4.3.4 Effect of PPARα activation by FB on ER stress in the liver of mice 
We examined the effect of PPARα by FB on ER stress markers of UPR signalling 
transduction in the liver of mice. Interestingly, we detected inhibition of phosphorylation of 
IRE1 in FB treated CH or HF fed mice (p<0.01 vs. corresponding controls; Fig. 4.4B). One 
of another UPR branch recognized as PERK also showed inhibition of phosphorylation of 
PERK with a 50% reduction under PPARα activation by FB (p<0.01 vs. corresponding 
controls; Fig 4.4C). Alternatively, a downstream effector of PERK known as eIF2α branch 
showed enhancement of ER stress expression in FB treated CH or HF fed mice regardless of 
diet (p<0.01 vs. CH, p<0.05 vs. HF; Fig. 4.4E). A downstream effector of IRE1 known as 
spliced form of x-binding protein 1 (sXBP1) showed a trend of a decrease in FB treated mice 
fed CH or HF, but there was not statistically significant (Fig. 4.4D). To add, FB treated CH or 
HF fed mice showed a clear inhibition of GRP78 in the same manner of IRE1, PERK, and 
sXBP1 (p<0.01 for both vs. corresponding vehicle controls; Fig. 4.4F). These data together 
suggest that PPARα by FB has a role in inhibition of the ER stress pathway separate from the 
eIF2α branch. 
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Figure 4.4 PPARα activation by FB inhibited ER stress. (A): Representative images of 
key proteins in the ER stress pathway via western blots. Quantification of each protein was 
shown in expression of (B): Phosphor/total IRE1 (pIREl/IRE1), (C): Phosphor/total PERK 
(pPERK/PERK), (D): Spliced form of XBP1 (sXBP1), (E): Phosphor/total eIF2α 
(peIF2α/eIF2α) and (F): GRP78 with the respective densitometry. Data are mean ± SEM of 6 
to 9 mice per group, ** p<0.01 vs CH; † p<0.05; †† p<0.01 vs HF. 
 
4.3.5 Effect of PPARα by FB on autophagy in the liver of mice 
The levels of autophagy proteins Atg3, Atg4B, Atg5, Atg7 and Beclin1 involvied in 
phagophore membrane elongation were significantly reduced by 50% in the liver of FB 
treated mice regardless of diets (p<0.01 vs. corresponding vehicle controls, Fig. 4.5C, D, E, F 
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& G). Additionally, mTOR signal transduction showed a trend of inhibition but was not 
significant, indicating autophagy induction (Fig. 4.5B). A key process during autophagosome 
formation for autophagy activity is assessed by the conversion of LC3II from LC3I [344]. 
The results showed that PPARα by FB significantly increased LC3II/LC3I ratio in the liver of 
either CH or HF fed mice (~2 fold change; p<0.01 vs. corresponding controls; Fig. 4.5H). 
This suggests an increase in autophagy activity rather than suppression. However, this 
increased activity of autophagy was not supported by accumulation of p62 protein (~1.5 fold 
change; p<0.01 vs. corresponding vehicle controls, Fig. 4.5I) which directs target proteins to 
autophagic degradation as a cargo receptor [344]. Thus, these results suggest that PPARα by 
FB suppresses autophagy in the liver of mice regardless of diet; although dysregulation of 
autophagy was observed by increased level of LC3 protein in FB treated CH or HF fed mice.  
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Figure 4.5 PPARα by FB suppressed hepatic autophagy regardless of diets. Autophagy 
proteins were assessed in the liver of FB treated CH or HF fed mice. (A): Representative 
images of key autophagy proteins examined via western blots. Quantification of these 
specific proteins were shown in the expression of (B): Phosphor/total mTOR 
(pmTOR/mTOR), (C): Atg3, (D): Atg4B, (E): Atg5, (F): Atg7, (G): Beclin1, (H): Ratio of 
LC3II over LC3I (LC3) and (I): p62 with the respective densitometry. Data are mean ± SEM 
of 6 to 9 mice per group, * p<0.05, ** p<0.01 vs. CH; † p<0.05, †† p<0.01 vs. HF. 
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4.4 DISCUSSION 
The research study in this chapter investigated the effect of PPARα by FB on autophagy in 
the liver of FB treated CH or HF fed mice. Several major findings have emerged from this 
study. Firstly, for the first time dietary HF or CH feeding was found to not regulate 
autophagy, ER stress and DNL in the liver. Secondly, PPARα by FB treatment resulted in 
suppression of autophagy irrespective of diet. Finally, the suppression of autophagy may 
occur in parallel to upregulated DNL and inhibited ER stress, rather than in a congruent 
relationship. 
Previously in Chapter 3, the pathways of autophagy, ER stress and DNL were shown with no 
particular regulated effect/role in the liver of PPARγ by RG treated HF fed rats. Interestingly, 
in this Chapter 4, PPARα by FB showed a clear and significant effect/role in autophagy, ER 
stress and DNL, regardless of diet given to the mice. Autophagy was found to be suppressed 
under PPARα activation by FB, while FB alleviated persoxiomal fatty acid oxidation, 
indicating increased PPARα activation by FB as previously suggested [163, 229, 356]. 
Autophagy has been proposed to be triggered by ER stress in assistance of protein clearance 
[289], and recent studies from others have shown hepatic ER stress is associated with 
suppression of autophagy in HF fed and ob/ob mice [288], while disrupted autophagy 
function by genetic ablation of autophagy related proteins can lead to ER stress [288, 374]. 
However, my preliminary study in this chapter showed that autophagy was inactivated in the 
absence of ER stress in the liver after mice were treated with FB added to the diets for a 3-
week period. Collectively, these data suggest hepatic autophagy during PPARα activation by 
FB may result in the suppression of its activity in parallel to ER stress functional regulation. 
This is likely confirmed by the attenuation of ER stress along with suppressed autophagy.       
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Although suppression of autophagy occurred in parallel to ER stress inhibition, DNL itself 
alleviated its regulation under PPARα activation by FB. ER stress has been suggested to 
regulate lipogenesis [111, 365] and autophagy regulates lipid metabolism by degradation of 
lipids through the lipophagy process [112, 340]. Conversely, my results showed upregulated 
DNL in the presence of suppressed autophagy and inhibited ER stress under PPARα 
activation by FB. This would further indicate in parallel activation of DNL against the 
suppressed autophagy with ER stress inhibition.  
Apart from regulating molecular mechanisms, our very interesting results from this study 
show markedly enhanced ALT levels in both FB treated CH and HF. Cytoplasmic protein 
serum ALT is released to the blood circulation upon acute liver injury, occurring in the 
context of apoptotic or necrotic liver injury or other conditions that cause cell leakiness 
without cell death [375]. These data further suggest damage to the liver or indication of liver 
injury is possibly due to autophagy dysfunction under the PPARα activation by FB, even 
though high doses of FB drug may show an effect of toxicity or damage the liver.     
As shown in Chapter 3, dietary HF or carbohydrate feeding was not an important factor in 
regulating the autophagy pathway in the liver. PPARα activation by FB was sufficient to 
suppress autophagy and ER stress while increasing DNL. There was also significantly 
enhanced serum ALT levels, impairing liver function in the absence of hepatic insulin 
resistance but no differences in liver TG contents under PPARα activation by FB. In addition, 
PPARα activation by FB was able to reverse the insulin resistance in HF fed mice. These 
results indicate that the impairment of insulin signal transduction induced by HF feeding is 
restored via PPARα activation by FB but possibly damaging the liver in rodents through 
hepatic autophagy dysfunction. 
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In conclusion, as illustrated in Fig. 4.6 this study provides first evidence showing that PPARα 
activation by FB contributes to the suppression of hepatic autophagy. The results show that 
dysfunction of autophagy is likely due to acute liver injury under PPARα activation by FB in 
parallel to inhibition of ER stress and increased DNL. These findings also provide the 
scientific rationale for targeting the PPARα induced suppression of autophagy for further to 
investigate a closer correlated relationship with associated metabolic disorders.          
 
Figure 4.6 Proposed mechanisms for the effect of PPARα by FB on autophagy in the 
liver of mice. FB increases expression of PPARα action as a pharmacological activator or 
agonist and restores hepatic insulin sensitivity along with conserving glucose tolerance in the 
liver. PPARα activation by FB promotes peroxisomal fatty acid oxidation while upregulates 
DNL, although its action inhibits ER stress. In addition, PPARα activation by FB decreases 
autophagy proteins resulting in suppression of the autophagy pathway. These metabolic 
defects need to be further studied by investigating involved upstream molecular mechanisms.  
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5.1 INTRODUCTION 
Autophagy is a catabolic process to degrade dysfunctional cellular components through the 
lysosome as a quality control mechanism for cell health status. The digested components are 
recycled to synthesise new cellular components or used to maintain the energy for cell 
survival during starvation [328]. As macroautophagy is the main pathway for this process as 
compared to microautophagy or chaperone-mediated autophagy [326], it is simply referred to 
as autophagy in the present study. A number of studies indicated a potentially important role 
of autophagy in multiple cellular processes to co-ordinately regulate cellular metabolism of 
proteins and fuels in the liver. The activity of autophagy can be regulated by the nutrient-
sensitive mechanisms mammalian target of rapamycin (mTOR) and insulin to affect the 
metabolism of fuels and energy. For example, increased autophagy can promote the 
degradation of lipid droplets in the lysosome (a process termed lipophagy) such that fatty 
acids (FAs) are released for further utilization [340]. By clearance of damaged mitochondria 
(termed mitophagy), autophagy is believed to play an important role in maintaining normal 
mitochondrial function for energy metabolism [337].  
Recently, we have found an intrinsic link of increased DNL in the liver to the suppression of 
autophagy during fructose feeding [361]. Interestingly, increased hepatic DNL also occurs by 
the stimulation of PPARα [65, 137, 356]. PPARα is a well-known transcription factor that 
up-regulates the expression of genes that promote FA oxidation and gluconeogenesis in the 
liver during starvation as an adaptive mechanism [163]. Thus, we postulated that activation of 
PPARα may also influence the activity of autophagy in the liver. Indeed, a recent study 
showed that incubation of primary hepatocytes with the PPARα agonist GW7647 induces 
autophagic flux, and short-term administration of GW7647 to mice (up to 48 hrs) increased 
hepatic LC3 levels which were abolished in PPARα-/- mice [376]. However, it is not known 
whether or not the increased autophagy is sustained after chronic activation of PPARα. One 
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important mediator for PPARα induced response revealed from recent studies is fibroblast 
growth factor 21 (FGF21), a hepatokine induced by PPARα activation [207]. An essential 
role of FGF21 in PPARα induced stimulation of FA oxidation and hepatic gluconeogenesis 
has been reasonably well established [206, 207, 215, 377, 378]. A recent study also showed 
an associated up-regulation of hepatic encoding autophagy-related gene 7 (Atg7) with FGF21 
in mice [351]. However, it is yet unclear whether or not PPARα activation is dependent on 
FGF21 expression to influence the effect on autophagy in the liver.    
Hence, the purpose of my main study is to investigate hepatic autophagy in wild-type 
(PPARα+/+) and PPARα knockout (PPARα-/-) mice in response to the chronic administration 
of the PPARα agonist fenofibrate (FB). Then, I further progress to determine whether FGF21 
is required for PPARα to exert its effects on autophagy in the liver using FGF21 knockout 
(FGF21
-/-
) mice. Moreover, possible attempts are made to examine the interactions of 
individual molecular mechanisms with autophagy regulation such as key upstream pathways 
of mTOR, AMPK, Akt/GSK3β, and FoxO1 for changed autophagy during chronic activation 
of PPARα with FB. Dietary requirement is not necessarily examined in this study due to my 
clear observation from the previous preliminary study in Chapter 4 which revealed the effect 
of PPARα by FB irrespective of diet given to mice. 
 
5.2 MATERIALS AND METHODS 
5.2.1 Animal model 
The studies were conducted in male mice starting at an age of 10-12 weeks, including wild-
type (PPARα+/+) and PPARα knockout (PPARα-/-) on the background of C57BL/6N, and 
wild-type (FGF21
+/+
) and FGF21 knockout (FGF21
-/-
) mice on the background of C57BL/6J, 
originally obtained from Jackson Laboratories (Sacramento, CA, US). The mice were housed 
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at 23±1°C in a 12-h light/dark cycle with free access to water and standard rodent diet 
consisting of 70% calories as starch, 10% calories as fat and 20% calories from proteins 
(Specialty Feeds, Australia). After 1-2 weeks of acclimatization, mice were fed the standard 
diet in the absence or presence of the PPARα agonist fenofibrate (FB) for 3 weeks. FB 
(Sigma-Aldrich, Australia) was administered as an additive to diet at a lower dose (50 
mg/kg/day) relative to our previous studies [65, 356] to minimize the possible influence of 
body weight reduction. Body weight and food intake were monitored daily. Blood samples 
were taken from the tail veil in week 3 after 5-7 hours of fasting and mice were culled by 
cervical dislocation. Liver was removed quickly (<5 seconds), weighed on a balance and 
immediately freeze-clamped for storage at -80°C for subsequent analysis. All animal 
experiments were approved by the Animal Ethics Committee of the RMIT University or the 
University of Hong Kong, where animal studies were performed. 
5.2.2 Determination of circulating levels of FGF21 in the liver 
Plasma glucose levels of PPARα+/+ and PPARα-/- mice were determined by glucose assay 
according to the manufacturer’s protocol (Sigma-Aldrich, Australia). The concentrations of 
FGF21 in plasma were measured by an ELISA kit (University of Hong Kong, Hong Kong) 
according to the manufacturer’s introductions [377]. FGF21 assay was based on an affinity-
purified rabbit polyclonal antibody specific to mouse FGF21, and did not cross react with 
other members of the FGF family.  
5.2.3 Glucose tolerance test 
A glucose tolerance test (GTT) was performed in FGF21
+/+
 and FGF21
-/-
 mice. After 5-7 
hours of fasting, mice were injected intraperitoneally with glucose (1.5~2 g/kg of body 
weight). Blood samples were taken from the tail vein and collected for blood glucose level 
measurement at various time points using a glucometer (Acc-Check, Roche Diagnosis; 
Australia).  
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5.2.4 Liver triglycerides 
Detailed description of extraction and measurement of liver triglycerides is described in 
Section 2.5. Liver tissues were homogenized in chloroform/methanol (2:1) solution and 
incubated overnight with continuous mixing of samples. Then 0.6% NaCl was added and the 
samples were centrifuged for phase separation. This resulted in the formation of a discrete 
aqueous phase above an organic phase. The aqueous phase which contains water soluble 
components was discarded, and the lower organic phase which contains lipid soluble 
components was transferred into glass tubes, and then air-dried at 45
o
C. The dried pellets 
were dissolved in ethanol immediately prior to the assay. Triglyceride levels were measured 
using a Peridochrom triglyceride GPO-PAP kit (Roche Diagnosis, Australia). 
5.2.5 Plasma ALT measurement 
The detailed measurement of plasma alanine aminotransferase (ALT) is described in Section 
2.4. Briefly, the blood samples were centrifuged at 9,000 rpm to obtain the plasma. ALT 
levels in the plasma samples were measured by ALT/SGPT Liqui-UV Kit (Stanbio). When 
20 µL of plasma samples were mixed with 200 uL of the reagent, the absorbance was 
measured immediately at 340 nM by the FlexStation microplate reader (Molecular Devices, 
USA) every minute for 10 minutes to test the activity of ALT enzyme. 
5.2.6 Western blots 
Freeze clamped liver tissues of rats and mice were homogenized in ice-cold RIPA lysis buffer 
at pH 7.5 supplemented with inhibitors of protease and phosphatase. Protein levels in 
homogenates were determined by BCA Protein kit. The proteins then were resolved through 
SDS-PAGE. Determination of specific proteins was examined by immunoblotting using 
exact antibodies as indicated in Table 5.1. Detailed description of western blotting is 
described in Section 2.8.  
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Table 5-1 List of proteins examined for the pathways of DNL, ER stress, autophagy, 
mTOR, AMPK, insulin signalling and FoxO1 
Examined specific proteins for the seven pathways in this study of Chapter 5 
 
The 
De novo lipogenesis (DNL) 
pathway 
matured sterol regulatory element binding protein 1 c 
(mSREBP1c) 
Acetyl-CoA carboxylase (ACC) 
Fatty acid synthase (FAS) 
Steroyl-CoA desaturase 1 (SCD1) 
The 
Endoplasmic reticulum (ER) 
stress 
pathway 
Phosphorylation of inositol requiring enzyme 1 (pIRE1) 
inositol requiring enzyme 1 (IRE1) 
Phosphorylation of protein kinase RNA-like endoplasmic 
reticulum kinase (pPERK) 
protein kinase RNA-like endoplasmic reticulum kinase 
(PERK) 
Spliced X box binding protein 1 (sXBP1) 
Phosphorylation of eukaryotic initiation factor 2 α (peIF2α) 
eukaryotic initiation factor 2 α (eIF2α) 
activating transcription factor 4 (ATF4) 
Immunoglobulin heavy chain-binding protein (GRP78) 
The 
Autophagy  
pathway 
Autophagy related gene 3 (Atg3) 
Autophagy related gene 4B (Atg4B) 
Autophagy related gene 5 (Atg5) 
Autophagy related gene 7 (Atg7) 
Beclin1 
Microtubule associated protein 1A/1B-light chain 3 (LC3) 
Nucleoporin p62 (p62) 
The mammalian target of 
rapamycin  
(mTOR) pathway 
Phosphorylation of mammalian target of rapamycin 
(pmTOR) 
mammalian target of rapamycin (mTOR) 
Phosphorylation of serine/threonine kinase (pP70S6K) 
Serine/threonine kinase (P70S6K) 
Phosphorylation of eukaryotic translation initiation factor 
4E binding protein 1 (p4EBP1) 
eukaryotic translation initiation factor 4E binding protein 1 
(4EBP1) 
The forkhead box protein O1 
(FoxO1) pathway 
Phosphorylation of forkhead box protein O1(pFoxO1) 
forkhead box protein O1 (FoxO1) 
Acetylated forkhead box protein O1 (AC-FoxO1) 
Silent mating type information regulation 2 homolog 
1(SIRT1) 
The Akt/ glycogen synthase 
kinase 3β (GSK3β) pathway 
Phosphorylation of Akt(pAkt) 
Akt 
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Phosphorylation of glycogen synthase kinase 3β (pGSK3β) 
glycogen synthase kinase 3β (GSK3β) 
The 5’adenosine 
monophosphate activated 
protein kinase (AMPK) 
pathway 
Phosphorylation of 5’ adenosine monophosphate activated 
protein kinase (pAMPK) 
5’ adenosine monophosphate activated protein kinase 
(AMPK) 
Normalizing control protein  
(Housekeeping gene/protein) 
α-Tubulin 
Glyceraldehyde3-phosphate dehydrogenase (GAPDH) 
 
5.2.7 Statistical analyses 
Data are presented as means ± SEM. One-way analysis of variance (ANOVA) was used for 
comparison between relevant groups unless stated otherwise. When significant variations 
were found, the Tukey-Kramer post-hoc multiple comparisons test, and the t-test were 
applied. Differences at p<0.05 were considered to be statistically significant. 
5.3 RESULTS 
5.3.1 Effect of PPARα by FB on whole-body parameters in PPARα-/- and FGF21-/-mice 
As shown in Table 1, PPARα-/- mice were approximately 16% heavier compared with the 
age-matched PPARα+/+ mice at the start of the experiment (25.5 ± 0.8 vs. 21.5 ± 0.2, n=12, 
p<0.01; Table 5.2). The plasma levels of basal glucose measured towards the end of study 
were significantly lower in PPARα-/- (by 40%; p<0.01 vs. PPARα+/+). Three weeks 
administration of FB did not influence the body weight gain or food intake in either 
PPARα+/+ or PPARα-/- mice at the dose used. Consistent with previous reports of PPARα 
induced hepatomegaly in rodents [65, 353, 356], PPARα+/+ mice treated with FB displayed a 
marked increase in liver weight (by 70%; p<0.01). As expected, FB treatment did not have 
any effect on liver weight in PPARα-/- mice.  
In contrast, FGF21
-/- 
mice were approximately 8% lighter compared with the age-matched 
FGF21
+/+ 
mice at the start of the experiment (21.5 ± 0.2 vs. 25.5 ± 0.8, n=12, p<0.01; Table 
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5.2). As expected, FB treatment markedly increased liver weight by ~80% in FGF21
-/- 
mice 
and the FGF21
+/+ 
mice, indicating a similar degree of response to FB-induced activation on 
PPARα. There was no significant effect on body weight gain, food intake or plasma levels of 
glucose in either FGF21
-/- 
or the FGF21
+/+ 
mice in response to chronic administration of FB.  
Table 5-2 Metabolic responses to chronic activation of PPARα with FB 
 
 PPARα+/+ PPARα+/+FB PPARα-/- PPARα-/-FB 
Body weight (g) 
Basal 
After 
Body weight gain (g) 
 
21.5 ± 0.1 
24.2 ± 0.3 
2.7 ± 0.2 
 
21.5 ± 0.2 
24.4 ± 0.4 
2.9 ± 0.2 
 
26.4 ± 0.9
††
 
28.7 ± 1.1
††
 
2.3 ± 0.2 
 
24.5 ± 1.1 
26.3 ± 1.8 
1.8 ± 0.7 
Food intake (g/day/mouse) 
Basal 
During treatment 
 
3.2 ± 0.1 
3.3 ± 0.2 
 
3.2 ± 0.1 
3.2 ± 0.1 
 
4.1 ± 0.2 
4.8 ± 0.2 
 
5.0 ± 0.2 
5.3 ± 0.2 
Liver weight (g) 0.9 ± 0.0 1.6 ± 0.1
**
 1.1 ± 0.0 1.2 ± 0.1 
Liver weight/Body weight (%) 4.0 ± 0.0 7.0 ± 0.0
**
 4.0 ± 0.0 5.0 ± 0.0 
Plasma glucose level 10.0 ± 0.4 9.3 ± 0.3 6.9 ± 0.2
††
 6.0 ± 0.2
††
 
 FGF21
+/+
 FGF21
+/+
FB FGF21
-/-
 FGF21
-/-
FB 
Body weight (g) 
Basal 
After 
Body weight gain (g) 
 
25.9 ± 1.4 
29.5 ± 1.3 
3.6 ± 0.1 
 
25.1 ± 0.5 
29.5 ± 0.6 
4.4 ± 0.1 
 
21.1 ± 1.1
†
 
24.3 ± 1.2
†
 
3.2 ± 0.1 
 
22.0 ± 1.0
†
 
25.2 ± 1.0
†
 
3.2 ± 0.0 
Food intake (g/day/mouse) 
Basal 
During treatment 
 
4.2 ± 0.2 
4.4 ± 0.2 
 
4.1 ± 0.1 
4.2 ± 0.1 
 
3.8 ± 0.2 
3.9 ± 0.1 
 
4.1 ± 0.2 
4.0 ± 0.2 
Liver weight (g) 1.2 ± 0.0 2.1 ± 0.2
**
 1.1 ± 0.1 2.0 ± 0.1
*
 
Liver weight/Body weight (%) 4.0 ± 0.3 7.2 ± 0.7
*
 4.4 ± 0.2 8.0 ± 0.2
**
 
Blood glucose level 12.2 ± 1.6 10.5 ± 1.2 12.6 ± 1.8 13.2 ± 1.7
††
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The mice were administered fenofibrate (FB, 50 mg/kg/day added in diet) for 3 weeks. Data 
are mean ± SEM of 5–6 mice per group, * p<0.05, ** p<0.01 vs. corresponding vehicle 
control; 
† 
p<0.05, 
††
 p<0.01 vs. corresponding knockout groups.  
5.3.2 PPARα by FB has no change in TG and ALT levels in PPARα-/-and FGF21-/-mice 
FB treated or untreated PPARα+/+, PPARα-/-, FGF21+/+, or FGF21-/- mice showed no changes 
in total liver TG (Fig. 5.1A & B respectively). In addition, plasma ALT enzyme levels in the 
liver of FB treated either in PPARα+/+ or PPARα-/-mice did not change significantly (Fig. 
5.1C), possibly indicating no further liver injury, in contrast to the previous results from the 
study in Chapter 4.  
 
Figure 5.1 No differences in liver TG levels in both FB treated PPARα-/- and FGF21-/- 
mice, while plasma ALT levels did not change under PPARα activation by FB in 
PPARα-/- mice. (A): Total liver triglycerides content in PPARα+/+ and PPARα-/- mice; (B): 
Total liver triglycerides content in FGF21
+/+
 and FGF21
-/- 
mice; (C): Plasma ALT level in FB 
treated PPARα+/+ or PPARα-/- mice. Data are mean ± SEM of 5-6 mice per group, * p<0.05, 
** p<0.01 vs. FB, n.s: not significant. 
 
5.3.3 Effects of FB on hepatic lipid metabolism in PPARα-/- mice  
To confirm the effect of FB on PPARα in the liver, we measured ACOX1, a specific 
downstream effector of PPARα that catalyses the peroxisomal β-oxidation of FAs [160]. As 
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shown in Fig. 5.2A, FB administration increased the content of ACOX1 protein (by ~5-fold 
vs. untreated, p<0.01) in PPARα+/+ mice and showed no such effect in PPARα-/- mice, as 
expected. Consistent to previous results from the study conducted in Chapter 4, my results 
from the current study (Fig. 5.2B) demonstrated that the mature form of SREPB-1c, ACC, 
FAS and SCD1 were all significantly up-regulated (by 2-3 fold, p<0.01 vs. untreated 
PPARα+/+). However, none of these lipogenic proteins were affected by FB treatment in 
PPARα-/- mice (Fig. 5.2B), confirming the dependency of FB on PPARα to induce hepatic 
DNL.  
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Figure 5.2 Effects of FB on hepatic lipid metabolism in PPARα-/- mice. (A): Effects of FB 
on peroxisomal acyl-CoA oxidase 1 (ACOX1), a downstream target of PPARα for 
peroxisomal FA oxidation. (B): Effects of FB on key proteins in the de novo lipogenic 
pathway: matured form of sterol regulatory element-binding protein 1 c (mSREBP1c), acetyl-
COA carboxylase (ACC), fatty acid synthase (FAS) and stearoyl-CoA desaturase 1 (SCD1). 
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Data are mean ± SEM of 5-6 mice per group, * p<0.05; ** p<0.01 vs. corresponding control 
group (vehicle treatment referred to as untreated). 
5.3.4 Effects of FB on hepatic autophagy in PPARα-/- mice  
We characterized changes in multiple proteins in the liver at various steps of autophagy 
during chronic activation of PPARα. As shown in Fig. 5.3, chronic administration of FB 
markedly (by ~ 50%) reduced the level of the autophagy proteins Atg3, Atg4B, Atg5, Atg7 
and Beclin1 in PPARα+/+ mice (all p<0.01 vs. untreated PPARα+/+ mice), suggesting a 
decreased autophagy capacity. Consistent with this, the ratio of LC3II to LC3I (indicative of 
autophagosome formation) was inhibited by 30% whereas p62 protein (indicator of non-
degraded aggregates) was increased by 2 fold, indicating the more acculumated p62 protein 
levels the more likely impaired autophagy at the functional level. In comparison, none of 
these autophagy proteins were altered in PPARα-/-mice during chronic administration of FB, 
further indicating the requirement of PPARα activation for the observed suppression of 
hepatic autophagy. 
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Figure 5.3 Effects of FB on hepatic autophagy in PPARα-/- mice. Effects of FB on key 
proteins in the autophagy pathway; (A): Representative images of key autophagy proteins via 
western blots, and quantified each protein in (B): Autophagy- related protein 3 (Atg3), (C): 
Autophagy-related protein 4B (Atg4B), (D): Autophagy-related protein 5 (Atg5), (E): 
Autophagy-related protein 7 (Atg7), (F): Beclin-1, (G): Microtubule-associated protein light 
chain 3 (LC3) and (H): Polyubiquitin-binding protein p62 (p62) are represented respectively. 
Data are mean ± SEM of 5-6 mice per group, * p<0.05; ** p<0.01 vs. corresponding control 
group (vehicle treatment referred to as untreated); n.s: not significant. 
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5.3.5 Effects of FB on hepatic lipid metabolism in FGF21-/- mice  
We next investigated whether or not the PPARα downstream mediator FGF21 may be 
involved in the observed changes described above by comparing the effects of FB in FGF21
-/- 
mice and FGF21
+/+ 
mice. As expected, FB-induced production of FGF21 was completely 
blocked in FGF21
-/-
 mice (Fig. 5.4A). Despite this, chronic administration of FB induced an 
~8-fold increase in ACOX1 content in FGF21
-/-
 mice compared to untreated FGF21
-/-
 mice 
(p<0.01, Fig. 5.4B), confirming the intact response of PPARα to FB stimulation. There was 
an enhancement of FB-induced increase in ACOX1 in FGF21
-/- 
mice compared to FGF21
+/+ 
mice (p<0.01 vs. treated FGF21
+/+
 mice; Fig. 5.4B). Consistent with the activation of PPARα, 
FB induced up-regulation of the lipogenic proteins SREPB-1c, ACC, FAS and SCD1 in 
FGF21
-/- 
mice was comparable to FGF21
+/+ 
mice (Fig. 5.4C) suggesting PPARα activation by 
FB enhances lipogenic enzymes independent from the expression of FGF21. 
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Figure 5.4 Effects of FB on hepatic lipid metabolism in FGF21
-/- 
mice. (A): Plasma levels 
of FGF21 in response to activation of PPARα with FB in FGF21+/+ and FGF21-/- mice. (B): 
Effects of FB on hepatic lipid metabolism: mSREBP1c, ACC, FAS and SCD1 are presented 
respectively. Data are mean ± SEM of 5-6 mice per group, * p<0.05; ** p<0.01 vs. 
corresponding control group (vehicle treatment referred to as untreated. 
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5.3.6 Effects of FB on hepatic autophagy in FGF21-/- mice  
Interestingly, the autophagy proteins Atg3, Atg4B, Atg5, Atg7 and Beclin1 levels were 
reduced (by ~50% vs. untreated FGF21
-/-
 mice) in the same pattern as observed in FGF21
+/+ 
mice (Fig. 5.5). There was also no significant differences in the effects of FB on the 
LC3II/LC3I ratio or p62 in FGF21
-/- 
compared to control FGF21
+/+ 
mice. These results 
indicate that FGF21 was not required for the suppression of autophagy in the liver by the 
activation of PPARα with FB. 
 
Figure 5.5 Effects of FB on hepatic autophagy in FGF21
-/-
 mice. Effects of FB on key 
proteins in the autophagy pathway; (A): Representative images of key autophagy proteins in 
FB treated FGF21
+/+ 
and FGF21
-/-
 mice, and quantification of these proteins were expressed 
in (B): Atg3, (C): Atg4B, (D): Atg5, (E): Atg7, (F): Beclin-1, (G): LC3 and (H): p62 are 
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presented respectively. Data are mean ± SEM of 5-6 mice per group, * p<0.05; ** p<0.01 vs. 
corresponding control group (vehicle treatment referred to as untreated).  
5.3.7 Effect of FB on hepatic ER stress in relation to PPARα induced inhibition of 
autophagy 
An induction of unfolded protein response (UPR) signalling pathway is suggested to have a 
close relationship with autophagy [111], and as such we examined a potential role of the ER 
stress of UPR signalling transduction in relation to PPARα activation by FB-induced 
suppression of autophagy. Interestingly, we detected inhibition of phosphorylation of IRE1 
(p<0.01 vs. untreated PPARα+/+; Fig. 5.6B) while there was no change in FB treated PPARα-
/- 
mice as expected. UPR branch recognized as PERK showed inhibition of phosphorylation 
of PERK with 50% reduction under PPARα activation by FB in PPARα+/+ mice (Fig. 5.6C). 
However, a downstream effector of IRE1 known as spliced form of XBP1 (sXBP1) exhibited 
no effect in FB treated PPARα+/+ mice and FB treated or untreated PPARα-/- mice (Fig. 5.6D). 
Contrary to these results, a downstream effector of PERK known as eIF2α branch showed 
enhancement of ER stress expression in FB treated PPARα+/+ mice and no significant change 
was observed in FB treated or untreated PPARα-/- mice (p<0.01, Fig. 5.6E). In addition to this, 
a downstream effector of eIF2α named activating transcription factor 4 (ATF4) showed a 
significant reduction in FB treated PPARα+/+ mice but no change was observed in FB treated 
or untreated PPARα-/- mice in the same manner of IRE1 and PERK (p<0.01 vs. untreated 
PPARα+/+; Fig. 5.6F). Also, FB treated PPARα+/+ mice displayed a clear inhibition of GRP78 
in the same manner of IRE1, PERK and ATF4 (p<0.01 vs. untreated PPARα+/+; Fig. 5.6G) 
while no change was found in FB treated PPARα-/- mice. 
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Figure 5.6 Effect of PPARα with FB on hepatic ER stress. (A): Representative images via 
western blots are shown FB treated PPARα+/+ or PPARα-/- mice, and quantification of key ER 
stress proteins were in expression of (B): Phosphor/total IRE1 (p/IRE1), (C): Phosphor/total 
PERK (p/PERK), (D): Spliced form of XBP1 (sXBP1), (E): Phosphor/total eIF2α (p/eIF2α), 
(F): Activating transcription factor 4 (ATF4) and (G): GRP78 with the respective 
densitometry. Data are mean ± SEM of 5-6 mice per group, * p<0.05; ** p<0.01 vs. 
corresponding control group (vehicle treatment referred to as untreated); n.s: not significant. 
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5.3.8 Effect of FB on the mTOR pathway in relation to PPARα induced inhibition of 
autophagy 
As activation of mTOR has been reported to play a key role in inhibiting autophagy activity 
[346, 347, 361], we investigated their potential role in FB-induced inhibition of autophagy. 
FB-treatment of PPARα+/+ mice resulted in a significant reduction in the phosphorylation of 
mTOR and its downstream effectors P70S6K and 4EBP1 (p<0.05; p<0.01 vs. untreated 
PPARα+/+ mice respectively. Fig. 5.7), indicating an inhibition of the mTOR pathway which 
has previously been shown to induce autophagy [347, 361]. In comparison, no significant 
changes in mTOR activation were found in FB treated PPARα-/- mice (Fig. 5.7), indicating 
that FB-induced inhibition of mTOR activity was dependent on the activation of PPARα.  
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Figure 5.7 Effects of PPARα with FB on the mTOR pathway. Effects of activation of 
PPARα with FB on the mTOR pathway; (A): Representative images of key proteins in 
mTOR pathway via western blots, and quantified these proteins were expressed in (B): 
Phosphorylation of mTOR/mTOR (pmTOR/mTOR), (C): Phosphorylation of P70S6 
serine/threonine kinase (pP70S6K/P70S6K) and (D): Eukaryotic translation initiation factor 
4E-biniding protein 1 (4EBP1), downstream effectors of mTOR are presented respectively. 
Data are mean ± SEM of 5-6 mice per group, * p<0.05; ** p<0.01 vs. corresponding control 
group (vehicle treatment referred to as untreated); n.s: not significant. 
 
5.3.9 Effect of FB on insulin signalling pathway in relation to PPARα induced 
inhibition of autophagy 
We next examined the phosphorylation of Akt and GSK3β because autophagy can also be 
inhibited by the stimulation of the insulin signalling pathway [353, 355, 363]. The results 
showed that chronic activation of PPARα with FB significantly inhibited the phosphorylation 
of both Akt and GSK3β (Fig. 5.8). This indicates that the observed suppression of autophagy 
induced by the activation of PPARα with FB was not due to a stimulation of the insulin 
signalling pathway. 
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Figure 5.8 Effects of PPARα with FB on the insulin signalling pathway. Effects on Akt 
and GSK3β in PPARα activation by FB-induced suppression of autophagy; (A): 
Representative images of key proteins in insulin signalling pathways via western blots, and 
quantified these proteins were expressed in (B): Phosphorylation of Akt/total Akt (pAkt/Akt) 
and (C): Phosphorylation of GSK3β/ total GSK3β (pGSK3β/GSK3β) are represented 
respectively. Data are mean ± SEM of 5-6 mice per group, * p<0.05; ** p<0.01 vs. 
corresponding control group without FB treatment; n.s: not significant. 
 
5.3.10 Effect of FB on AMPK in relation to PPARα induced inhibition of autophagy 
Inhibition of mTOR is triggered by activation of AMP activated protein kinase (AMPK) [346] 
in order to induce autophagy. As such, we further investigated an upstream metabolic 
mechanism of AMPK pathway in PPARα induced suppression of autophagy as recent reports 
suggested that the AMPK pathway is highly involved in the autophagy activation [346, 379, 
380]. We observed the suppression of both phosphorylated and total AMPK with a 50% 
reduction in FB treated PPARα+/+ mice (p<0.01; Fig. 5.9A, B & D), while there was no 
significant difference between untreated and treated PPARα-/-mice. However, when AMPK is 
normalized by its phosphorylation against its total, no significant changes were found either 
in PPARα+/+ or PPARα-/- (Fig. 5.9C). Moreover, a downstream marker of AMPK, acetyl 
coenzyme A carboxylase (ACC) phosphorylation, examined against total ACC was 
quantified and found to be significantly reduced in FB treated PPARα+/+ mice (p<0.01; Fig. 
5.9E), although phosphorylation of ACC against a normalising control did not show any 
changes between the corresponding groups (Fig. 5.9F). These data suggest the signalling of 
AMPK inhibition under PPARα induced suppression of autophagy by FB may not be 
involved in this particular metabolic mechanism. 
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Figure 5.9 Effect of FB on AMPK pathway in PPARα-/- mice. (A): Representative images 
of key proteins in the AMPK pathway via western blots, and quantification of these specific 
proteins were expressed in (B): AMPK against α-Tubulin, (C): Phosphorylation of AMPK 
against its total AMPK (pAMPK/AMPK), (D): pAMPK against normalizing control of α-
Tubulin, (E): The downstream of AMPK known as phosphorylation of acetyl-CoA 
carboxylase against its total ACC (pACC/ACC) and (F): pACC against α-Tubulin 
accordingly. Data are mean ± SEM of 5-6 mice per group, * p<0.05; ** p<0.01 vs. 
corresponding control group without FB treatment, n.s: not significant.  
 
5.3.11 Effect of FB on FoxO1 in relation to PPARα induced inhibition of autophagy 
Because chronic activation of PPARα with FB down-regulated multiple autophagy proteins 
(Atg3, Atg4B, Atg5, Atg7 and Beclin1 shown in Fig. 5.3 and Fig. 5.5), we further 
investigated whether this may be regulated at the transcriptional level by examining FoxO1, a 
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critical transcription factor regulating the expression of autophagy proteins [381, 382]. 
Interestingly, the content of FoxO1 was markedly reduced (by ~60%) by the activation of 
PPARα with FB (p<0.01 vs. untreated PPARα+/+ mice, Fig. 5.10B), indicating a reduced 
availability of FoxO1 to mediate the expression of autophagy proteins. It has been reported 
that the phosphorylation and/or acetylation of FoxO1 expels FoxO1 from the nucleus to the 
cytosol for degradation [53, 382]. Indeed, there were increases in both the phosphorylation 
(by ~1.5 fold) and acetylation (by ~2 fold) of FoxO1 in a PPARα-dependent manner (p<0.01 
vs. untreated PPARα+/+ mice; Fig. 5.10C & D respectively). The deacetylation of FoxO1 is 
largely mediated by NAD-dependent deacetylase sirtuin-1 (SIRT1) [383-386]. As shown in 
Fig. 5.10E, SIRT1 was reduced by ~60% during the increased acetylation of FoxO1 by 
chronic activation of PPARα activation with FB (p<0.05 vs. untreated PPARα+/+ mice). 
 
Figure 5.10 Effects of PPARα with FB on FoxO1 and SIRT1. (A): Representative images 
of key proteins in the FoxO1 pathway via western blots, and quantified these proteins were 
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expressed in (B): Total FoxO1 against α-Tubulin, (C): Phosphorylation of FoxO1 (pFoxO1) 
against total FoxO1, (D): Acetylation of FoxO1 (AC-FoxO1) against total FoxO1 and (E): 
Silent mating type information regulation 2 homolog 1 (SIRT1) against α-Tubulin 
respectively. Data are mean ± SEM of 5-6 mice per group, * p<0.05; ** p<0.01 vs. 
corresponding control group without FB treatment, n.s: not significant. 
 
5.4 DISCUSSION 
My study in Chapter 5 investigated the PPARα induced suppression of autophagy and 
possible associated molecular metabolism that interact with this change. Our findings 
revealed that chronic activation of PPARα by FB reduces hepatic autophagy capacity in the 
liver in a manner that is entirely independent of FGF21. PPARα induced suppression of 
autophagy capacity is possibly mediated by a decrease in FoxO1 expression rather than 
through changes in the activity of ER stress, mTOR, AMPK or Akt. These findings suggest a 
need to further investigate the dynamic changes of hepatic autophagy during PPARα 
activation and associated implications for the adaptive response.    
The present study investigated the effect of chronic activation of PPARα on autophagy in the 
liver using the PPARα specific agonist FB. Several novel findings have emerged from this 
study. Firstly, our results clearly demonstrated that chronic administration of FB at a dose 
equivalent to that given to humans inhibited hepatic autophagy. This is in contrast to the 
reported increase in autophagy following acute or short-term stimulation of PPARα [376]. 
Secondly, the present study dissociates the effects of PPARα induced suppression of 
autophagy and associated change in lipogenic proteins from those mediated through the 
endocrine hormone FGF21 [207, 214]. Thirdly, our findings indicate that the suppression of 
autophagy by the chronic activation of PPARα is not due to enhanced ER stresss [111, 361], 
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mTOR [347], Akt [333, 387] and AMPK [346, 380, 388] activity as previoulsy reported. 
However, our data revealed a close link of PPARα induced suppression of autophagy with the 
inhibition of FoxO1, a key transcription factor controlling the expression of autophagy 
proteins. These findings indicate that the autophagy pathway is regulated by PPARα and that 
this may contribute to PPARα–induced responses.  
PPARα is highly expressed in the liver and plays an important role in regulating a wide range 
of metabolic effects. It is activated by elevated plasma levels of FAs during starvation to 
promote FA oxidation [163] by up-regulating the key enzymes in mitochondria and 
peroxisomes including ACOX1 [65, 356]. It also plays an important role in the regulation of 
glucose homeostasis by promoting gluconeogenesis in the liver via stimulating the production 
of FGF21 [351, 377]. We found that 3 weeks administration of FB suppressed both the 
capacity of autophagy (indicated by reduced levels of expression of Atg3, Atg4B, Atg5, Atg7 
and Beclin1) and autophagic activity (indicated by reduced LCII/LCI and an accumulation of 
p62). This effect of FB is clearly mediated by PPARα activation as this effect was completely 
abolished in PPARα-/- mice. In contrast, short-term (24-48 hrs) activation of PPARα in 
primary hepatocytes results in increased autophagy [376]. Therefore, it is possible that 
persistent stimulation of PPARα may result in a down-regulation of multiple autophagy-
related proteins by a negative feedback mechanism, which eventually leads to the suppression 
of autophagy. Clearly further studies are required to investigate whether prolonged 
stimulation of PPARα may also induce a negative feedback mechanism eventually leading to 
the suppression of autophagy.  
To investigate the possible mechanism involved in the effect of chronic activation of PPARα 
on autophagy, we first examined a possible involvement of FGF21 because this hepatokine 
plays a critical role in mediating the metabolic responses initiated by the activation of PPARα 
[206, 207, 214, 215]. However, our study in FGF21
-/- mice demonstrated that PPARα induced 
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suppression of autophagy is entirely independent of FGF21. This is clearly evidenced by the 
intact effects of FB on PPARα activity (indicated by ACOX1) and all measured autophagy 
proteins (Atg3, Atg4B, Atg5, Atg7, Beclin1, LC3 and p62) in FGF21
-/- 
 mice.  
ER stress in organisms from yeast to mammals is reported to induce autophagy [289, 333]. 
My results in this study showed the ER stress pathway was inhibited (indicated by reductions 
in pIRE1, pPERK, ATF4 and GRP78) rather than enhanced in response to PPAR induced 
suppression of autophagy. Thus, it is not likely that activation of ER stress has an association 
in inducing autophagy. Autophagy activity is subjected to the regulation by 
posttranscriptional modifications by mTOR, a kinase which can be stimulated by insulin 
action [57, 325, 326, 328, 347]. In the present study, the mTOR pathway was inhibited 
(indicated by reductions in pmTOR, pP70S6 and p4EBP1) after chronic activation of PPARα, 
rather than activated. Thus, the suppressed autophagy is not attributable to an inhibition of the 
mTOR pathway because this would be expected to increase (rather than decrease) autophagy 
activity [325, 326, 328, 347].  
It is well known that a stimulation of the insulin signalling pathway can activate the mTOR 
pathway [46, 57]. We therefore speculate that the inhibited mTOR pathway by chronic 
activation of PPARα may be due to a reduced activity of the insulin signalling pathway.  
Consistent with this notion, chronic activation of PPARα with FB decreased the activity of 
the insulin signalling pathway (indicated by reduced phosphorylation of Akt and its 
downstream target GSK3β). A recent study from our laboratory has shown a significant 
decrease in plasma levels of insulin (thus reduced stimulation) in mice following a similar 
chronic administration of FB [356]. This may explain the reduced activity of the insulin 
signalling pathway observed in the present study. Taken together, these results indicate that 
the suppressed autophagy by PPARα activation in our study cannot be attributed to the 
described mechanism of an increase in either mTOR activity or insulin stimulation.  
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Conversely, phosphorylation and inhibition of mTOR dependent signalling to stimulate 
autophagy are led by AMPK, a decreased adenosine triphosphate/adenosine monophosphate 
(ATP/AMP) ratio through upstream liver kinase B1 (LKB1) kinase [389]. AMPK is a key 
energy sensor regulating cellular metabolism to maintain energy homeostasis and reported to 
promote the autophagy pathway in response to various cellular stress including glucose 
starvation [346, 380, 388]. We examined AMPK signalling pathway on autophagy in relation 
to the PPARα activation by FB. Unexpectedly, PPARα-induced suppression of autophagy 
occurred by activation of AMPK due to the decreased phosphorylation of AMPK and total 
AMPK inhibition in PPARα+/+ mice, with no significant difference observed in PPARα-/- 
mice. These results together with the decreased ACC phosphorylation suggest that our 
observed findings in PPARα induced suppression of autophagy are mediated by the AMPK 
signalling pathway.     
Autophagy is also regulated by FoxO1, a master transcription controlling the expression of 
multiple autophagy proteins such as Atg7, LC3 and p62 [381]. FoxO1 exerts its transcription 
activity in the nucleus and once phosphorylated or acetylated it is expelled out of the nucleus 
to the cytosol undergoing degradation [360, 381, 382]. Thus, the level of FoxO1 is indicative 
of its overall activity. Interestingly, we found the level of FoxO1 was markedly reduced 
following chronic activation of PPARα with FB. Consistent with this, the phosphorylation 
and acetylation of FoxO1 were both significantly increased. These data suggest that the 
suppressed autophagy during chronic activation of PPARα is possibly due to the inhibition of 
FoxO1. This interpretation is supported by our recent finding showing FoxO1-mediated gene 
expression is inhibited when FoxO1 level is decreased by duel increases in acetylation and 
phosphorylation [360]. As SIRT1 plays a critical role in the deacetylation of FoxO1 [390] 
and the expression of SIRT1 is reduced upon FB treatment, we postulate that the acetylation 
of FoxO1 is probably prompted as a result of decrease in SIRT1. However, the reason for the 
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increased phosphorylation of FoxO1 (indicated by an increased activity of Akt via its 
phosphorylation) in the present study requires further investigation.    
Overall, as explained in Fig. 5.8 the present study clearly demonstrated that chronic 
activation of PPARα suppresses autophagy in the liver independent of FGF21. This may be 
through a decrease in FoxO1 content. Recent studies have suggested a potential role of 
autophagy in both FA synthesis [361] and utilization [112] in the liver. In line with these 
reports, PPARα-induced suppression of autophagy was found to be associated with up-
regulation of the peroxisomal FA oxidation (indicated by ACOX1) and lipogenic enzymes 
(indicated by SREBP-1c, ACC, FAS and SCD1). Thus, the suppression of autophagy by 
chronic PPARα activation may play an important role in regulating FA metabolism in the 
liver. 
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Figure 5.11 Proposed mechanism of the suppression of hepatic autophagy induced by 
persistent PPARα activation with FB. Chronic activation of PPARα with FB suppresses 
autophagy in the liver. This effect is independent of the effect of PPARα on FGF21 but 
associated with an upregulation of DNL and inhibited ER stress. Activation of PPARα 
induces dual effects on FoxO1 to increase its acetylation (possibly via SIRT1 reduction) and 
phosphorylation (by an unknown mechanism), leading to a degradation of FoxO1. 
Importantly, the reduced content of FoxO1 leads to suppression of the autophagy pathway 
rather than through inhibited ER stress, mTOR, AMPK or Akt signalling pathways.   
  
 
 
 
 
CHAPTER 6 
General Discussion 
 
 
 
 
 
 175 
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This chapter will summarize the overall findings of the thesis, discuss the limitations of the 
studies and also provide future directions for the investigation of PPARγ induced autophagy 
and PPARα induced suppression of autophagy in relation to liver metabolism. 
6.1 SUMMARY AND IMPLICATIONS OF MAJOR FINDINGS 
As reviewed in Chapter 1, fatty liver is one of serious health issues which is believed to be 
still growing at an alarming rate worldwide. Environmental factors such as sedentary lifestyle 
with lack of exercise and overconsumption of dietary fats are believed to be fundamental 
contributors to lipid accumulation in liver, causing fatty liver or alternatively termed hepatic 
steatosis. These are believed to disturb metabolic homeostasis and eventually progress to 
NAFLD and T2D. Lipid metabolism regulating transcription factors named PPARα and 
PPARγ were also reviewed in Chapter 1 to explain their specific role in association with the 
protein degrading autophagy pathway in hepatic lipid metabolism. Involvement of those 
nuclear receptors in autophagy may suggest a unique mechanism contributing in regulation of 
lipid metabolism in the liver. 
 
The overall aim for this thesis was to investigate the role of macroautophagy (referred as 
autophagy in my studies) in relation to lipid metabolism in the liver mediated by activation of 
PPARα and PPARγ. As described in Chapter 1, autophagy is a catabolic mechanism which is 
closely associated with regulating lipid metabolism in the liver. As for this, autophagy 
dysfunction is known to lead lipid accumulation causing fatty liver that possibly promotes to 
hepatic insulin resistance [327]. To regulate lipid metabolism, key transcriptional factors, 
such as PPARγ and PPARα are well understood. PPARγ is mainly expressed in adipose 
tissue [164, 165], and the autophagy pathway in PPARγ induced changes in adipose tissue 
has been described as to be induced for the activation [259, 391]. However, it was not clear 
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whether autophagy may play a similar role in lipid metabolism in the liver as reported in the 
adipose tissue. If so, the relationship with the sensitising effect of PPARγ activation on 
insulin action in relation to autophagy in the liver was unclear.  Thus, to address this 
particular question my study was carried out in Chapter 3.    
 
PPARγ and Autophagy Chapter 3 demonostrated the effect/role of HF induced PPARγ by 
RG in liver of rats. It was clearly observed that HF fed rats induced insulin resistance while 
PPARγ by RG treatment on top of HF feeding reversed the effect, showing improved insulin 
action or sensitivity under PPARγ by RG through performing GTT and hyperinsulinemic 
euglycemic clamp technique. Ectopic lipid accumulation is another factor, like dietary fat to 
cause insulin resistance in liver, and as shown in my results hepatic TG content was lowered 
in PPARγ by RG treated HF fed rats but as expected HF fed rats alleviated TG content in the 
liver. These results are consistent with previous publications from our group. Those results 
promisingly suggest that PPARγ by RG has an effect on stimulating insulin action in absence 
of lipid accumulation in the liver, although adipogenesis effect of PPARγ by RG carries out 
for causing fatty acid re-distribution [164, 165, 178, 236, 248] at the same time. 
After observation of the metabolic effects including insulin action and hepatic TG content in 
HF induced PPARγ by RG, its role on autophagy in association with lipid metabolism were 
further explored. Autophagy is a molecular mechanism which has a close association with 
lipid metabolism in the liver, as for this autophagy dysfunction is known to lead lipid 
accumulation causing fatty liver that possibly promotes to hepatic insulin resistance [327]. 
There were no overall effects of dietary fat feeding, such as HF on autophagy in the liver of 
rats due to dysregulated activity of autophagy proteins in the absence of TG content in liver. 
Moreover, PPARγ by RG on top of HF fed rats showed no overall correction of the 
dyregulated multiple autophagy proteins which further indicating that there were no 
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significant corrections to investigate its role in the autophagy pathway despite effect of 
PPARγ by RG on lipid metabolism in the liver.  
In addition to this, PPARγ by RG showed no  overall increase of lipogenic enzymes while HF 
fed rats also showed irregulated activity of lipogenic enzymes due to lipid mibilisation fatty 
acids influx into the liver [392]. Interestingly, ER has been suggested to be responsible for 
the inhibition of insulin signalling while closely associated with ectopic lipids due to the 
upregulation of lipogenesis by UPR [111, 307]. My results in PPARγ by RG treated HF fed 
rats showed no significant changes on ER stress in the UPR pathway as different from the 
previously reported [183] while the de novo lipogensis (DNL) showed no overall effect in 
this model despite that DNL has been suggested to be abolished in HF in the presence of 
hepatic steatosis [356]. 
As shown in Fig 6.1, from this study I might conclude that there were no overall effect of 
autophagy, ER stress and DNL in PPARγ by RG induced liver of rats despite the increased 
insulin sensitivity. It is cleary required to speculate why these effects were shown in details 
and to understand the study with depth of knowledge, future studies are needed as described 
in Section 6.2.  
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Figure 6.1 A schematic overview of major findings in study of Chapter 3. Detailed 
description is explained in Section 6.1. 
The nuclear receptor PPARα activated by starvation or its specific ligand known as fibrates 
has been reported to be involved in a number of cellular processes, such as lipid and 
lipoprotein metabolism, apoptosis and autophagy responses in liver. As explained, autophagy 
is the self-eating protein degradation pathway, which is well involved in lipid metabolism. 
Interestingly, activated PPARα by the short period time of fasting has been reported to induce 
the autophagy activation in the liver of mice [376]. Hence, as discussed in Chapter 4 I 
invetistigated whether the effect of autophagy in PPARα induced changes by its 
pharmacological activation known as fenofibrate at high dosage (100mg/kg/body weight) in 
relation to lipid metabolism in the liver of mice.  
 
PPARα and Autophagy In Chapter 4, I have demonstrated PPARα activation by fenofibrate 
(FB) treatment in CH or HF fed mice at high dosage (100mg/kg/body weight). This was 
previously established and performed from our group, also the data observed in this study 
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were consistent from the previous publication of our group [356]. To explain, FB is well 
recognized pharmacological drug as a PPARα agonist for promoting PPARα activation [163], 
and perosixomal acyl-CoA oxidase 1 (ACOX1) is a key downstream target of PPARα 
activation. In my study, FB as a pharmacological activator or agonist of PPARα increased 
expression of PPARα action and restores hepatic insulin resistance along with conserving 
glucose tolerance in the liver as reported previously [356]. PPARα activation by FB 
promoted peroxisomal fatty acid oxidation while upregulates DNL, although its action 
inhibits ER stress. PPARα activation by FB suggested inhibition of ER stress regardless of 
diet given to the mice apart from eIF2α branch in UPR pathway rather than enhancement as 
previously reported from our group [65, 356, 361]. In relation to PPARα activation by FB 
stimulating DNL in the liver, an induction of unfolded protein response (UPR) signalling 
pathway is suggested to be involved [111]. More importantly, PPARα activation by FB 
decreased autophagy proteins resulting in suppression of the autophagy pathway in 
irrespective of diet as drawn in Fig. 6.2. 
It is believed that these metabolic defects need to be further studied by investigating involved 
upstream molecular mechanisms and further study was investigated in Chapter 5.  
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Figure 6.2 A schematic overview of major findings in study of Chapter 4. Detailed 
description is explained in Section 6.1. 
The further study carried out from Chapter 4 in the Chapter 5 investigated the role of PPARα 
induced suppression of autophagy by administrating the PPARα specific agonist, FB, and the 
possible mechanisms involved in such changes in the liver of PPARα+/+ and PPARα-/- mice.  
PPARα induced suppression of autophagy and possible mechanisms Interestingly in the 
Chapter 5, my results clearly demonstrated that activation of PPARα by FB inhibited, rather 
than stimulated, the autophagy pathway in the liver. Moreover, the PPARα activation by FB 
was entirely abolished in PPARα-/- mice, confirming the role of PPARα in the suppression of 
autophagy. In addition, as the endocrine hormone FGF21 is reported to be a mediator for the 
pleiotropic actions of PPARα and is induced directly by PPARα in liver [207, 214], my study 
in FGF21
-/-
 mice revealed that the PPARα induced suppression of autophagy is independent 
of the FGF21 downstream pathway. My findings suggest a possible role of the autophagy 
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pathway in mediating the metabolic effects induced by PPARα by FB, and its potential 
implications to provide new insights into the associated metabolic changes. 
Both starvation and specific fibrates activate PPARα [163] to stimulate the autophagy 
pathway in the liver [376]. I have induced PPARα activation by FB as a pharmacological 
approach rather than use of nutrient deficient status of starvation. PPARα is highly expressed 
in the liver and activation of this nuclear receptor is known not only to increase its activation 
in the liver but also its downstream protein ACOX1 [65, 163, 356]. Furthermore, PPARα 
activation by FB in the liver is reported to enhance FA oxidation [65, 356]. From our results 
the PPARα activation by FB in the liver is clearly highlighted by ACOX1, and furthermore 
its effect on FA synthesis is greatly enhanced under PPARα activation in PPARα-/- mice. 
Additionally, these data confirm that FB is required for PPARα to mediate these effects.  
In recent years, autophagy has been a highlighted as a catabolic mechanical process of self-
degradation by which cellular components of cells are degraded to maintain essential activity 
and viability in response to starvation or nutrient deficiency [325]. Metabolic studies have 
reported that the PPARα activation plays an essential role in the up-regulation of autophagy. 
In contrast to this, our data revealed that PPARα activation by FB clearly suppressed 
autophagy in the liver of mice. Yet, a specific effect of PPARα induced suppression of 
autophagy with a possible molecular mechanism is still unknown. My study investigated a 
molecular signalling mechanism which may be involved in PPARα induced suppression of 
hepatic autophagy.   
Numerous signalling components and mechanism are involved in the regulation of autophagy 
and cellular growth with mTOR, a key factor regulating the balance between cellular growth 
and autophagy in response to cellular physiological conditions and environmental stress [347]. 
mTOR plays a role in autophagy induction when nutrient starvation occurs but also by 
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reducing, growth factor signalling, while mTORC1 is a key mediator of growth factor 
signalling to autophagy [347, 361]. Therefore, we examined whether or not mTOR may be 
involved in PPARα induced suppression of autophagy. From our results, we found that 
suppression of autophagy clearly occurred with sufficient inhibition in the mTOR pathway. 
Although significant inhibition of mTOR is observed with reduced downstream expression of 
70S6 Kinases and 4EBP1, the PPARα induced suppression of autophagy still remained. This 
novel finding may indicate that mTOR inhibition of autophagy is an independent signalling 
pathway in the PPARα induced suppression of autophagy.  
As neither mTOR nor AMPK signalling pathways have a close relation to PPARα induced 
suppression of autophagy, I further progressed to investigate whether the change of 
autophagy is attributable to insulin signalling pathway as has been suggested [332]. 
Autophagy is regulated by mTOR through the action of phosphatidylinositol (PtdIns)-3-
kinases which indirectly activate protein kinase B also known as Akt [393]. Akt negatively 
regulates the activity of its downstream effector, glycogen synthase kinase 3 β (GSK3β), in 
the process of activating mTOR. From our observations of Akt/GSK3β signalling pathways, 
our data suggest that both Akt and its downstream effector, GSK3β are inactivated within 
phosphorylation while total Akt or GSK3β show no significant difference between the 
corresponding groups. From these results we further proceeded to examine on the 
transcriptional factor, FoxO1 which is phosphorylated by Akt and retained as an inactive 
form in the cytosol [393].  
It is suggested that FoxO1 transcriptional factor blocks cell cycle and cell growth when 
entering the nucleus. Using obtained data from our group we propose that the FoxO1 is 
deactivated in order to suppress autophagy under PPARα activation by FB. As autophagy is 
suppressed the possible mechanism pathway of mTOR is inhibited, opposing irs signalling 
function in relation to activation of the autophagy pathway, insulin signalling pathway 
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targeting of Akt/GSK3β including phosphorylation of FoxO1 is observed. In contrast to 
current reports [394, 395], my data revealed that insulin signalling pathway involvement is 
significantly abolished in the PPARα mediated suppression of autophagy. Here, I investigated 
total content of its FoxO1 is suppressed under PPARα induced suppression of autophagy. As 
shown in Fig. 6.3, these led to my findings to show that FB is required for PPARα action to 
induce a reduction of FoxO1 content in order to suppress the autophagy pathway. In addition 
to this, the acetylation of FoxO1 is likely to be prompted via deacetylation of SIRT1, which 
possibly promotes decrease of total FoxO1 content. 
 
Figure 6.3 A schematic overview of major findings in Chapter 5. Detailed description is 
explained in Section 6.1. 
As displayed in Fig. 6.4, overall the reduced PPARα activation and inhibited regulation of 
autophagy, which is instigated by dual effects of FoxO1 in acetylation and deacetylation via 
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reduced SIRT1, reveal an essential mechanism and a new insight into the regulatory role of 
PPARα and suggest a causal relationship to metabolic pathologies including metabolic 
syndromes such as obesity and insulin resistance. Taken together, our data indicate a possible 
role of the autophagy pathway in mediating the metabolic effects induced by PPARα 
activation rather than PPARγ activation by RG. It is definitely required to speculate further 
studies in PPARγ induced changes in hepatic autophagy. Nonetheless, my findings may have 
potential implications for the use of PPARα activators for the treatment of dyslipidaemia and 
provide new insights into the metabolic changes during starvation. 
 
Figure 6.4 A schematic view of major findings and overall aim. Detailed description is 
discussed in Section 6.1. 
6.2 FUTURE DIRECTIONS 
Chapter 3: PPARγ and Autophagy 
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In Chapter 3, I found that HF can lead to impaired hepatic insulin resistance and glucose 
intolerance via ectopic lipid accumulation, while PPARγ by RG reverses these effects. DNL 
and ER stress did not occur with HF feeding or HF induced PPARγ by RG. In addition, 
autophagy itself is dysregulated by HF, and PPARγ by RG does not have a role in correcting 
the HF-induced dysregulation of autophagy. A further research is needed to identify the tissue 
responsible for the dysregulation of autophagy. This may carried out by investigating 
different type of tissue. As PPARγ expression is predominantly activated in adipose tissue, it 
would be promising to demonstrate the effect of autophagy in PPARγ induced changes in 
adipose tissue. Measurement of accumulated fat content would be required if the adipose 
tissue is targeted in comparion between the liver as the tissue. Also, cell culture with different 
cell-lines can be used to assess the effect of autophagy in PPARγ induced changes. For 
example, 3T3L1 or HepG2 cells can be used to mimic fat and hepatocytes respectively in the 
liver. Rosiglitazone can be added to these cell lines to see PPARγ activation. The mRNA 
expression of PPARγ including autophagy related genes will be measured by quantitative 
RT-PCR or alternatively by western blotting with protein level expression.  
Chapter 4: PPARα and Autophagy  
This study in Chapter 4 provides first evidence showing that PPARα activation by FB 
contributes to the suppression of hepatic autophagy. The results show that dysfunction of 
autophagy is likely due to acute liver injury under PPARα activation by FB in parallel to 
inhibition of ER stress and increased DNL. These findings also provide the scientific 
rationale for targeting the PPARα induced suppression of autophagy for further to investigate 
a closer correlated relationship with associated metabolic disorders. In order to investigate the 
mechanism involved, as previously reported from our group [361] it can be demonstrated by 
the specific intervation research studies. In vivo, treating the mice with PPARα agonists 
including fenofibrate and Wy14643 to alleviate the activation of PPARα can be examined 
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and at the same time with PPARα antagonist to show the reversal effect. Also, using 
autophagy inducers, such as rapamycin, spermidine and reservatrol, and ER stress inducer or 
inhibitor known as tunicamycin or TUDCA respectively, can be investigated to discover the 
relationship between these two particular pathways in PPARα induced changes in the liver.  
Chapter 5: PPARα induced suppression of autophagy and possible mechanisms 
As shown in Chapters 5, PPARα by chronic feeding of FB has prolonged effects on 
autophagy via reduced FoxO1 content in liver metabolism including obesity, insulin 
resistance, lipid metabolism and ER stress. In order to investigate the underlying mechanisms 
of these effects of the PPARα induced suppression of autophagy, further research can be 
considered as the proposed studies as follows. It is clearly required to demonostrate the 
molecular studies including cell culturing. As the present study is mainly focused in the 
specific liver tissue, it will be advantaged if primary cultured hepatocytes which are fresly 
isolated from the liver of PPARα-/- mice as well as the wildtype for the comparison are used 
as a methodology. Primary cultered hepatocytes can be plated to investigate the PPARα 
dependent autophagy activation via FoxO1 alteration at posttranscriptional level. In addition 
to this, FGF21
-/-
 mice can be further explored under starvation or fasting condition along with 
PPARα-/- mice group for comparison in the effect of PPARα induced autophagy. 
Alternatively, using autophagy specific protein knockout mouse type in vivo is also believed 
to be essential. These suggestions for future studies are believed to confirm the story of 
current research study within full understanding.   
Limitation and the overall future plans 
In my thesis, there are few limitations observed during the studies of research. For this, I have 
drawn the limitations observed in each Chapter and suggested for future strategies to manage 
the limitation of the research. Also, overall future plan of my research in this thesis is 
discussed.  
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Chapter 3 The limitations in this Chapter 3 were observed in using animal specie as a rat 
model with HF feeding when comparing with rosiglitazone drug effect. To establish a 
comparable model, it would represent very solid and conclusive results of PPARγ activation 
when not only administering rosiglitazone but also PPARγ agonist/antagonist in CH fed rat. 
Additionally, correspond with animal model used in Chapter 4 and 5 would be essential to 
investigate the role of autophagy in the change of PPARγ activation.  
Chapter 4 In this chapter, the limitations were detected in several sections. When PPARα 
agonist or antagonist was used to test its clear action, it would represent very solid and 
conclusive results of PPARα activation. I have attempted to use this approach in the study 
using liver tissues as ex-vivo study. I have used the antagonist of PPARα, named GW6471 to 
provide the clear activation of PPARα in response to autophagy in the liver. However, a clear 
result to show the effect of GW6471 in ex-vivo was not detected. The data were not presented 
or given in this thesis, as the results were not conclusive. 
Chapter 5 It is well known that FGF21 is an endocrine hormone or so called hepatokine 
mostly secreted in the liver via PPARα, where this PPARα is known to activate via a well-
known ligand named fibrates. The expression of FGF21 is up-regulated along with Atg5 
during starvation and recently it has been revealed that FB increases cardiac autophagy via 
FGF21/SIRT1.  The well use of FGF21 recombinant or its agonist/antagonist to show a clear 
effect in the model in relation to PPARα induced suppressed autophagy would be essential in 
this thesis which that became the limitation in this Chapter. Additionally, the transcriptional 
activity of FoxO1 is inactivated once translocated from the nucleus to the cytosol for 
degradation which is promoted by its phosphorylation and acetylation. The decreased FoxO1 
content was associated with increases in its phosphorylation (pFoxO1/FoxO1) and acetylation 
(AcFoxO1/FoxO1) without altering its mRNA expression. Regarding the acetylation of 
FoxO1, our recent studies have revealed a link to the suppression of deacetylases. Reduced 
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level of SIRT1 and HDAC4 phosphorylation suggest that the acetylation of FoxO1 by 
chronic activation of PPARα may be due to the suppression of these deacetylases.  
Overall f uture plan The reduced autophagy revealed in the present thesis may explain, at 
least in part, why chronic activation of PPARα with Wy-14,643 or FB in our recent studies 
fails to reduce hepatic steatosis in high fat fed mice despite increased FA oxidation. Overall, 
our findings indicate a need to further investigate the dynamic changes of hepatic autophagy 
during PPARα activation and associated implications for lipid metabolism.   
 
6.3 SUMMARY AND CONCLUSION 
Overall, the research in this thesis provides new insight into the effects of autophagy and 
PPARs induced changes in the liver on the pathogenesis of the metabolic syndrome including 
insulin resistance and lipid accumulation. The obtained data demonstrate the crucial role of 
autophagy in the progression from simple hepatic steatosis or so called fatty liver to 
metabolic diseases. Furthermore, the results from this thesis indicate that the nuclear 
receptors PPARγ and PPARα have moderate effects on liver metabolism including adiposity 
and insulin resistance in rats and mice, repectively. These data provide a solid base for further 
investigation of the dynamic changes of hepatic autophagy during PPARγ or PPARα 
activation and associated implications for lipid metabolism.   
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